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ABSTRACT 
Research performed over the last decade has highlighted the role of HDAC inhibitors 
(HDACi) as modulators of transcriptional activity and as a potential new class of 
therapeutic agents against many types of malignacies including breast cancer. These 
drugs inhibit histone deacetylases, leading to derepression of transcription of various 
genes that are important for cell cycle arrest and cell death. Trichostatin A (TSA) is 
one of the best established HDAC inhibitors and has been shown to exhibit potent 
differentiating and anti-proliferative properties. My data demonstrated that treatment 
of the MCF-7 breast cancer cell line with TSA causes G2/M phase cell cycle arrest. I 
characterised the novel F-Box protein called FBXL20 and identified it as an 
important target of TSA. This protein is part of a novel E3 ligase complex as it binds 
Skpl, CUL-l and ROC-1 and forms a classical SCF complex that is responsible for 
ubiquitination and targeting proteins for degradation by the 26S proteasome. I further 
studied the differences between FBXL20 in human cells and its isoform in rat cells. 
My data showed that FBXL20 is localised in the cytoplasm concentrated around the 
nucleus and plays a role in the TSA-induced effects in MCF-7 cells, through 
regulating the pro-apoptotic protein Bim. Silencing FBXL20 abolished the G2/M 
arrest caused by TSA treatment. Although FBXL20 is a similar protein to Skp2 they 
are regulated by different proteins and exert different functions. These findings 
provide novel data to demonstrate that known and novel HDACi induce G2/M arrest 
followed by cell death and that this arrest is dependent on the novel FBXL20 protein 
in breast cancer cells. Using these newly defined properties of HDACi, I screened a 
panel of potential HDACi and identified at least one to be more potent than SAHA, 
which is currently used in the clinical setting, and showed that it is able to inhibit 
proliferation, cause cell cycle arrest and cell death of breast cancer cells. 
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1.1 Cancer 
Cancer is one of the leading causes of death in the UK. Every year, around 
280,000 people are diagnosed with cancer. Overall, it is estimated that more than 
one in three people will develop some forms of cancer during their lifetime and 
about 25% will die from it. From 1993 to 2002, the incidence rate for cancer has 
increased by 3% in females and has not change a lot in males. 
Although cancer affects people of all ages, the risk increases with age. It most 
commonly occurs in people aged 65 or over, while a small percent occurs in 
children. In UK, the risk of cancer diagnosed in a child less than 15 years of age is 
1 in 500 individuals. Between 1975 and 1990 childhood cancers increased 19%. 
Of course, apart from people, cancer may affect animals and plants (Statistics 
obtained from the Cancer Research UK Website). There are more than 200 
different types of cancer, but the most common ones are breast, prostate, lung and 
colorectal cancer (Fig. 1.1). 
15 
CC10"c ZY 
Oadoc 
U. 
f4 K. 1 Non Mogin Lyrpfwn'Q 44 
M ßi 3VV Aula 
Ouop? -Ae. -- 7. S42 
Pým 1 CL 7. I: 2 
Lc, rx "".: &In? 
Ova -v & tS9 
K, a &64S 
dfn wd ChC" . *1 4S43 
J: 4. lOS 
r" `A, pit MMd u '. j 
cjb'r p4! 
Lary 
UQ"c 
o1U. CC[ 
""ten.. I ' s. Warr 
». s" 
- e;. ees 
e+. 9LJ 
 -.. 
Jo 386 
m"a,. "a 
Ni ber of oft cab" 
Figure 1.1 New cancer cases in 2005 (Cancer Research UK website) 
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There are many references that attempt to define cancer but perhaps the simplest 
one is `a group of diseases characterized by uncontrolled growth and spread of 
abnormal cells'. If the spread is not controlled, it can result in death (American 
Cancer Society website). 
1.2 Breast cancer 
Breast cancer is one of the most commonly diagnosed malignancies and one of 
the main causes of cancer death among women (Ferlay, 2007). Breast cancer can 
occur in sporadic and hereditary forms. In hereditary forms, a mutation in a 
specific gene predisposes individuals to cancer. However, unlike typical genetic 
diseases in which mutations in a single gene is responsible for the disease, it is 
rather the mutations in several genes that lead to carcinogenesis. Hereditary breast 
cancer is suspected when there is a strong family history of breast cancer. 
Hereditary breast cancer accounts for as much as 10% of breast cancer cases 
16 
(Lynch et al., 2008). In the 1990s, research into the genetic basis of familial breast 
cancer led to the identification of the 'high risk' breast cancer susceptibility genes 
BRCAJ (Miki et al., 1994) and BRCA2 (Wooster et al., 1995). In the case of 
sporadic forms, mutations in somatic cells accumulate and result in 
transformation of a normal cell to one with malignant potential. Hereditary factors 
do not seem to contribute to these types of cancer. The vast majority of new cases 
are sporadic tumours, occurring in women usually over 50 years of age. 
Studies have identified a number of risk factors associated with breast cancer. 
They include family history, individual history of breast diseases, age, late 
menopause, early menarche, excess ionizing radiation exposure, not having 
children and hormone replacement therapy. 
Breast cancer is heterogeneous in its clinical, genetic, and biochemical profile. 
Overall there are more than 50,000 deaths from breast cancer every year in the 
United States alone. Breast cancer accounts for 30% of all female cancers 
diagnosed in the UK and in 2002 41,000 women were diagnosed with breast 
cancer. A woman's risk of developing breast cancer by the age of 65 is less than 
6% but the overall lifetime risk is 11% (Statistics obtained from the Cancer 
Research UK Website). Due to screening, improved treatment options and the 
intensive research over the past decades, there has been a 15% fall in mortality 
from breast cancer in the UK. 
The most important regulators of breast cancer growth are the oestrogens, the 
most abundant of which is 170 estradiol. Oestrogens are steroid hormones 
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synthesised mainly by the ovary and placenta. They act through the nuclear 
oestrogen receptors ERa and ERß that control gene expression by recruiting 
transcriptional co-factors (Paruthiyil et al., 2004; Sommer and Fuqua, 2001). 
Although these receptors are very similar, they exert different functions. ERa has 
a proliferative role and changes in its expression and activity can cause 
deregulation of various cellular processes, eventually leading to cancer (Sommer 
and Fuqua, 2001). In contrast to ERa, ERB has anti-proliferative properties. Both 
receptors play distinct roles in breast development (Paruthiyil et al., 2004). ERa 
knockout mice have primitive mammary development (Couse and Korach, 1999), 
whereas ERP knockout mice develop normal mammary glands (Krege et al., 
1998). Therefore, only ERa is required for growth and differentiation of the 
mouse mammary gland. Studies indicate that ERP may function as a tumour 
suppressor and its loss promotes breast carcinogenesis (Jarvinen et al., 2000; 
Roger et al., 2001; Skliris et al., 2001); however, the exact role of ERP remains 
unknown. 
Oestrogens and the oestrogen receptors are important in the regulation of many 
physiological conditions such as the growth and function of the female 
reproductive organs, determination of the mineral density of bones and 
maintenance of the cardiovascular and central nervous system. Nuclear, 
cytoplasmic (Pietras and Szego, 1977) and the more recently discovered 
membrane-localised oestrogen receptors (Razandi et al., 1999) exhibit distinct 
protein interactions, signalling mechanisms and cellular functions which are 
implicated in the initiation and development of breast cancer (Aranda and 
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Pascual, 2001). The connection between oestrogens and cancer was established 
more than 100 years ago by George Beatson. 
High levels of oestrogen and its metabolites are associated with both the initiation 
and progression of breast cancer. Oestrogens can induce the formation of reactive 
oxygen and nitrogen species and through different cellular signalling pathways 
can lead to genotoxic damage, cell apoptosis, or cell growth (Roy et al., 2007). 
However, no study has yet definitively demonstrated that oestrogen metabolites 
contribute to human breast cancer. 
Breast cancer treatment 
Systemic treatment for breast cancer can be given after (adjuvant) or before 
(neoadjuvant) locoregional treatment. Adjuvant therapy has been shown to 
improve survival and reduce the risk of recurrent breast cancer and is now the 
standard of care in the treatment of early stage breast cancer. With neo-adjuvant 
therapy, about 50-70% of the patients will have enough tumour regression that 
mastectomy will be avoided. The choice of adjuvant treatment depends on the risk 
of relapse, oestrogen receptor status, patient performance status and acceptability 
of treatment. The current treatment for breast cancer involves multimodality 
therapy including surgery, chemotherapy, radiotherapy, endocrine treatment and 
molecular therapy (Smith and Chua, 2006). 
Over the past twenty years, the most common endocrine therapy used for the 
treatment of breast cancer is tamoxifen (Howell and Dowsett, 1997), which is a 
member of the selective oestrogen receptor modulators (SERMs) (they can 
19 
function as both agonists and antagonists) (Ali and Coombes, 2002). Tamoxifen is 
an anti-oestrogen that blocks the binding of oestrogen to its receptor. ERa is 
therefore a well-established predictive marker of hormone sensitivity in breast 
cancer as only ER(a)-positive tumours can be treated with tamoxifen (Hayes, 
2004). In contrast to normal breast cells, most breast cancer cells overexpress 
ERa and are hormone-dependent and thus when oestrogen is removed, tumours 
shrink. Tamoxifen has antagonistic functions but also agonistic actions on the 
endometrium and bone. It also causes an increase risk of thromboembolism. 
Another disadvantage of this treatment is that after a period of time, patients 
become resistant to tamoxifen. Tamoxifen is effective in both pre- and 
postmenopausal women in all age groups and has been shown to be more 
effective when given after chemotherapy rather than concurrently (Smith and 
Chua, 2006a; Smith and Chua, 2006b; Smith and Chua, 2006c; Smith and Chua, 
2006d). Breast cancer patients who become resistant to tamoxifen are sometimes 
responsive to ICI182,780 (also called faslodex), which is a pure anti-oestrogen. In 
contrast to tamoxifen, it has no agonistic activities as it degrades the ER protein 
and can therefore target ER dependent tumours that are resistant to endocrine 
therapy (Horwitz and McGuire, 1980). Research is now focused in understanding 
the mechanisms that underlie endocrine resistance and the discovery of novel 
agents for the treatment of breast cancer. 
Various clinical trials have shown that aromatase inhibitors are also suitable for 
the treatment of breast cancer (Buzdar et al., 2007). These agents act by inhibiting 
oestrogen synthesis and include the non-steroidal anastrozole and letrozole and 
the steroidal compound exemestane. They are effective only in post-menopausal 
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women and have been shown to improve disease free and metastatic free survival 
when compared to tamoxifen alone (ATAC trial) (Forbes et al., 2008). Nowadays, 
patients are switched to an aromatase inhibitor after two or three years of 
tamoxifen, as it has been shown that sequential treatment with tamoxifen followed 
by an aromatase inhibitor improves long term survival and reduces the risk of 
recurrent breast cancer (Dutta and Pant, 2007). 
When chemotherapy is used as an adjuvant treatment, younger women tend to 
have the greatest benefit, particularly when they are lymph node positive and ER 
negative. The side effects usually include hair loss, fatigue, lethargy, oral 
mucositis, haematological toxicity and ovarian suppression with potential loss of 
fertility. The most common chemotherapeutic agents used currently are the 
anthracyclines doxorubicin and epirubicin. These drugs have been shown to be 
more effective than the traditionally used cyclophosphamide, methotrexate and 
fluorouracil (CMF) chemotherapy combination (Smith and Chua, 2006). 
Furthermore, evidence indicates that the addition of the newer class of 
chemotherapeutic agents, the taxanes, (paclitaxel and docetaxel) may improve 
survival in high risk patients. Clinical trials are ongoing to establish the most 
effective chemotherapy combination for use in early stage breast cancer. Many of 
these drugs have already proven efficacy in women with metastatic breast cancer 
(Friedrichs et al., 2002). 
Presence of growth factor receptors has been correlated with poor disease-free 
survival and resistance to endocrine therapy and chemotherapy and therefore 
inhibitors of growth factor activity have attracted increasing interest in the 
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treatment of breast cancer (Spigel and Burstein, 2002). Anti-receptor antibodies 
and tyrosine kinase inhibitors are some of the strategies used to develop drugs to 
target the epidermal growth factor receptor (EGFR) and the related ErbB2IHER- 
2/neu. One of these inhibitors is the recently discovered Herceptin or trastuzumab 
(Slamon et al., 2001). Herceptin is a novel humanized monoclonal antibody that is 
directed against the external domain of the HER2 receptor. HER2 is over- 
expressed in 20% of breast cancers (Stern, 2000). Results have shown that this 
inhibitor reduces the risk of recurrence by about 50% when given with or after 
chemotherapy for a year in women across all ages with early stage breast cancer 
(Engel and Kaklamani, 2007). Clinical trials have also shown that herceptin 
improves survival when given in combination with paclitaxel or docetaxel in 
patients with metastatic disease (Azambuja et al., 2008). However, there is an 
increased risk of cardiotoxicity when given with the anthracyclines; hence 
Herceptin is given after chemotherapy and not concurrently (Sengupta et al., 
2008). Furthermore, because Herceptin only targets one protein, it is limited in the 
range of patients it can reach. 
Recent studies reveal that the novel tyrosine kinase inhibitor lapatinib may also 
play a role in the treatment of breast cancer. It targets both the epidermal growth 
factor receptor (EGFR) and HER2 receptor and has recently been approved by the 
US Food and Drug Administration (FDA) (Bilancia et al., 2007). Lapatinib 
prevents tumour growth by inhibiting intracellular tyrosine kinase activity and in 
contrast to other EGFR tyrosine kinase inhibitors, such as erlotinib and gefitinib, 
it binds the inactive form of the receptor and therefore dissociates at a slower rate 
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from the receptor resulting in a greater duration of effect on the target site (Wood 
et al., 2004). 
1.3 Cell cycle 
The growth and development of organisms is based on a fundamental process 
known as the `cell cycle', in which cells reproduce by duplicating their contents 
and dividing into two daughter cells. A complex set of cellular events have to be 
coordinated with one another during this process, so that normal cell growth is 
maintained. Loss of regulation of the cell cycle can result in unrestrained cell 
division leading to proliferative diseases such as cancer. The cell cycle consists of 
four phases. The first phase, Gl phase, is the most variable of the cycle phases and 
is the period in which future commitment to division, differentiation or death is 
made. It is a growth period during which RNA and proteins are synthesized. 
Following the Gl phase is the S phase, where synthesis of DNA occurs. During 
this phase the total content of DNA increases from the diploid value of 2N to the 
fully replicated value of 4N. The period from the end of S phase until mitosis is 
another gap phase like Gl called the G2 phase. During this period, the cell ensures 
that DNA replication is complete before it enters mitosis. During M phase, the 
replicated chromosomes segregate into separate nuclei by mitosis and the cell 
splits into two daughter cells (Schafer, 1998); Alberts et al., 1994). 
Cell cycle regulation 
Tight regulation is needed for the series of events during the cell cycle. The cell 
cycle transitions, entry and exit from S and M phases, are the major points of 
regulation. With regard to cellular transformation, the two most important 
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transitions are the transition through the restriction point (R) and the transition 
from a quiescent state (Go) to an actively dividing state. When a cell enters the Go 
phase, it cannot enter the S phase and can remain there for a long period of time 
before starting to proliferate again. Reentry into the cell cycle from Go is triggered 
by extracellular growth factors. The restriction point is the point beyond which 
the cells are no longer dependent on growth factors but continued growth factor 
stimulation is required for cells to reach this point. If cells progress through the 
restriction point they can complete the cell cycle. Many proto-oncogenes (genes 
that when mutated or over-expressed lead to cancer) deregulate the Go-G1 
transition, while many tumour suppressor genes (genes that protect cells by 
inhibiting tumour cell growth) regulate passage through the restriction point 
(Lewin et al., 2000; Vermeulen et al., 2003). 
Other points of regulation of the cell cycle are the checkpoints, which occur in the 
different cell cycle phases. In each checkpoint the cells ensure that the initiation 
of one event in the cell cycle depends on the successful completion of an earlier 
event. The Gl/S checkpoint ensures that damaged DNA is not replicated. The S 
phase checkpoint prevents the replication of damaged DNA that has not been 
repaired in Gl phase or DNA that was damaged early at S phase. The G2 
checkpoint prevents damaged DNA being segregated into daughter cells and also 
it allows repair of DNA that was damaged in late S phase. The M checkpoint 
controls mitotic spindle and metaphase-anaphase transition (Skorski, 2002). 
The cell cycle is regulated by a complex of two types of proteins the cyclin- 
dependent protein kinases (CDK) and the cyclins. CDKs phosphorylate target 
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proteins on serines and threonines. They are inactive on their own because their 
catalytic sites, which bind ATP and substrate, are blocked by their C-terminal 
tails. When cyclins bind CDKs, a conformational change is induced that allows 
access to the catalytic site and activation of CDK kinase activity. There are two 
classes of cyclins: the mitotic cyclins, which bind to CDK molecules during the 
G2 phase and are required for entry into mitosis and the Gl cyclins which bind to 
CDK molecules during the Gl phase and are required for entry into the S phase. 
Each of the different cyclins is activated at different cell cycle phases. Cyclin E- 
A-B levels and activity are highest in late G1, G2 and M respectively (Schafer, 
1998; Vermeulen et al. 2003). Cyclin D rises early in mid-GI and remains 
constant thereafter (Baldin et al., 1993). CDK4 and CDK6 in combination with 
cyclin D are responsible for cell progression through Gl phase, CDK2 and cyclin 
E are responsible for progression from Gl phase to S phase, CDK2 and cyclin A 
for progression through S phase, and a complex of CDKI (cdc2) and cyclin B for 
mitosis (Fig. 1.2) (Vermeulen et al., 2003). 
Finally, the cyclin-CDK complexes are in turn controlled by another family of 
regulatory proteins known as the cycle-dependent kinase inhibitors (CKIs). The 
most well known inhibitors of the cell cycle are the CKIs which regulate the G1 
checkpoint. One group made up of members of the inhibitor of cyclin-dependent 
kinase 4 (INK4) family, which associate with CDK4 and CDK6, therefore 
preventing binding of the D-type cyclins. CKIs include p15INK4b, p16INK4a, p18 
INK4c, p19 4d (Guan et al., 1994). The other CKIs, called Cip/Kip, family 
members of which are the proteins p21cp1, p27Kip1, p57K'p2, bind to cyclin-CDK 
complexes, rather than the CDK alone. Interactions between cyclins, CKIs and 
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CDKs regulate the checkpoints of the cell cycle (Barnes and Gillett, 1998, 
Schafer, 1998). 
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Figure 1.2 Cell cycle profile and regulators 
1.4 Cell death and senescence 
It has been increasingly noted that chemotherapeutic agents induce apoptosis or 
other forms of cell death such as necrosis and autophagy, but they also cause 
irreversible cell cycle arrest called senescence. 
Senescence is the process where cells stop dividing after a finite number of 
division cycles (about 50). During this terminal growth arrest, cells cannot divide 
even if stimulated by mitogens, but they remain metabolically and synthetically 
active. Senescent cells show changes in morphology, such as enlarged, flattened 
cell shape and increased granularity (Roninson, 2003). The rate of senescence in 
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some cells depends on the cell's environment, such as the concentration of growth 
factors in the medium (Alberts et al, 1994). Cancer cells can be induced to 
undergo senescence by treatment with radiation, chemotherapy (Chang et al., 
1999) or genetic modifications (Tominaga et at., 2002). Understanding how 
senescence is regulated makes possible the design of new therapeutic agents that 
have less side effects and are more efficient than current cancer therapy. It has 
been reported that the proteins p53 and p21c'p', which regulate senescence in 
normal cells, are important for treatment-induced senescence of cancer cells 
(Chang et al., 1999). In fact, senescence is considered to be a physiologically 
significant tumour suppression mechanism. 
Mitotic catastrophe is a form of cell death occurring in mitosis. It has been 
proposed that it results due to cellular damage and the deficiency of cell cycle 
checkpoints. It is controlled by many proteins that are important for the cell cycle 
such as cyclin B1, polo-like kinases (PLK) and Aurora kinases but it is also 
controlled by p53, other checkpoint proteins, caspases and members of the Bcl-2 
family of cell death regulators (Castedo et al., 2004). Mitotic catastrophe, like 
apoptosis, results in cell death by caspase-dependent and caspase-independent 
mechanisms (Mansilla et al., 2006). Mitotic catastrophe is usually assayed by 
visualization of multinucleated cells. 
Autophagy is a protein degradation system in which proteins and organelles in a 
cell are sequestered then transported to lysosomes, before being digested by 
lysosomal hydrolases. In normal cells, unnecessary proteins and damaged 
organelles are removed by autophagy so that homeostasis is maintained and 
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therefore autophagy functions to protect cells. However, it is still unknown if 
autophagy in cancer cells plays the same role. In order to detect autophagic cell 
death, electron microscopy is usually used to visualize the autophagosomes in 
cells. The autophagosome-associated protein microtubule-associated protein 1 
light chain 3 (LC3) is also used as a marker of autophagy. When autophagy is 
induced, LC3 is localised in the autophagosome membrane, whereas when it is 
not activated it is localised homogeneously in the cytoplasm. In contrast to 
apoptosis where the phagosome eats the dying cell, cells undergoing autophagy 
digest themselves by formation of autophagosomes (Kondo and Kondo, 2006). 
Various anticancer therapies like the histone deacetylase (HDAC) inhibitors 
Butyrate and SAHA have been demonstrated to induce autophagy in different 
cancer cells (Shao et al., 2004). 
Necrosis (derived from the Greek "nekros" for dead) is a form of cell death 
characterized by swelling of cell organelles, random DNA degradation and loss of 
membrane integrity. Necrosis has been know to occur during the accidental cell 
death caused by physical or chemical agents; so it results from events outside the 
cell and leads to the release of the cellular components and an inflammatory tissue 
response (Zong et al., 2004). Many insults induce apoptosis at lower doses and 
necrosis at higher doses (Majno and Joris, 1995). Chemotherapeutic agents, such 
as alkylating DNA-damaging agents, have been shown to cause necrosis instead 
of apoptosis in cancer cells (Zong and Thompson, 2006). 
Apoptosis is a genetically programmed mechanism for cell death that is known to 
play a role in both normal breast epithelial cell development and breast 
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carcinogenesis (Kinloch et al., 1999; Song and Steller, 1999). Characteristics of 
apoptotic cell death include chromatin condensation, membrane blebbing, 
breakdown of cytoplasmic and nuclear skeletons, DNA fragmentation, and 
formation of "apoptotic bodies", which are phagocytozed by neighboring cells 
(Fig. 1.3) (Kerr, 2002; Kerr et al., 1972). Apoptosis is a highly regulated process, 
being controlled by various ligands and signalling pathways (Kinloch et al., 1999; 
Song and Steller, 1999). A trigger for apoptosis can be an external signals e. g. 
nutrient deprivation, accumulation of toxic metabolites, hypoxia or excessive 
formation of reactive oxygen species (Barber, 2000). Nowadays, detection of 
apoptosis can be done by many methods including Annexin V staining and 
caspase activation assays. 
Inappropriate control of cell death has been implicated in the pathogenesis of 
diseases ranking from neurodegenerative disorders to tumour development 
Deregulation of apoptosis is associated with diseases including cancer, AIDS, 
various neurodegenerative diseases, etc. (Thompson, 1995). Inhibition of 
apoptosis in tumour cells is thought to play a critical role in breast cancer 
pathogenesis as well as resistance to chemotherapy. In the adult human breast, 
multiple endocrine and paracrine signals keep the balance between epithelial cell 
proliferation and apoptotic cell death during pregnancy, lactation and the 
menstrual cycle. 
Two major apoptotic pathways exist and they are: the extrinsic death receptor and 
the intrinsic mitochondria-initiated pathways. The former is activated by 
interaction of cell surface death receptors with their ligands. The mitochondrial 
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apoptotic pathway involves the permeabilisation of the outer mitochondrial 
membrane and subsequent release of several pro-apoptotic factors into the 
cytosol. Both of these two major systems lead to the activation of the executioners 
of apoptosis named caspases. Caspases form a family of cysteine proteases that 
exist within the cell as inactive proenzymes which are cleaved to form active 
enzymes that then induce apoptosis (Thornberry and Lazebnik, 1998). However, 
it has been reported that it is possible for caspase-independent apoptosis to occur 
(Broker et a1., 2005). 
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Figure 1.3 Apoptosis versus necrosis (Goodlett and Horn, 2001) 
1.5 Bim 
The bcl-2 protein family is known to regulate cell death. One group of this family 
includes anti-apoptotic proteins such as Bcl-2, Bcl-XL, MCLI which are required 
for cell survival and the other group, includes pro-apoptotic proteins such as 
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Bax/Bak-like proteins and BH3-only proteins. Bcl-2 proteins have four homology 
domains: BH-1, BH-2, BH-3 and BH-4 that are characteristics of this family of 
proteins (Gross et al., 1999). Not all members contain all of these domains, as 
there are pro-apoptotic proteins that only contain one. An important member of 
this type of pro-apoptotic Bcl-2 family is Bim (Bcl-2 interacting mediator of cell 
death). It is a member of the BH3-only proteins as it only contains the BH-3 
domain. There are three Bim isoforms: Bima (the largest), Bims and Bims. Bim 
causes release of cytochrome c from mitochondria into the cytosol, which then 
leads to apoptosis. Cell death is regulated through interaction between pro- 
survival and pro-apoptotic members of the Bcl-2 family of proteins (Coultas and 
Strasser, 2003). In order for the 1313-only proteins such as Bim to initiate 
apoptosis they have to bind the pro-survival Bcl-2 family members. This binding 
occurs between the helix formed by the BH3 region of the BH3-only proteins and 
the hydrophobic cleft formed on the surface of the pro-survival proteins by the 
combination of their BH1, BH2 and BH3 regions (Fesik, 2000). 
BimL and Bimj are expressed in normal cells, but they cannot induce apoptosis 
because of their binding to the dynein motor complex via an interaction with 
dynein light chain (DLC)1 (Song et al., 1999). Bims does not have the domain that 
binds DLC1 and therefore it is a much more potent inducer of apoptosis 
(Puthalakath et al., 2001). The MAP kinase related stress activated c-Jun NH2- 
terminal kinase (INK) induces apoptosis through phosphorylation of Bim in this 
DLC1 binding domain and enhances its pro-apoptotic activity (Lei et al., 2002). 
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The most abundant of all Bim isoforms, BimEr, is degraded by the ubiquitin- 
dependent proteasome pathway following phosphorylation by the extracellular 
signal-regulated kinase (ERK1/2) pathway (Ley et al., 2003). The exon 3 of 
BIMa, contains the ERKI/2 phosphorylation sites and provides an ERKl/2 
docking domain, which is not only important for its proteasomal degradation but 
also impairs its binding to Bax, thereby inhibiting its pro-apoptotic activity (Ley 
et al, 2003). When ERK1/2 is inactivated, these regions encoded by exon 3 are 
crucial for the stabilisation and activation of Bim. Furthermore, although it was 
previously thought that the E3 ubiquitin ligase c-Cbl is required for the ERKI/2 
dependent degradation of Bim, it has now been proved that this is not necessarily 
true as BimEL degradation has also been demonstrated to be c-Cbl independent 
(Wiggins et al., 2007). However, the E3 ligase responsible for its degradation 
remains unknown. 
Inhibition of the P13 kinase pathway and subsequent inactivation of Akt leads to 
the dephosphorylation and nuclear translocation of the Forkhead transcription 
factor FOXO3a (Greer and Brunet, 2005). FOXO3a regulates Bim at the 
transcription level and thereby controls its mRNA expression (Sunters et al., 
2003). This regulation has been demonstrated to control apoptosis in paclitaxel- 
treated breast cancer cells (Sunters et al., 2003). 
1.6 Epigenetics 
Genetic as well as epigenetic events play a key role in carcinogenesis and cancer 
progression. Epigenetic is a term used to describe changes in gene expression that 
are not due to changes in the DNA sequence and are inheritable from one 
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generation to the next (Bird, 2002). Unlike genetic changes, epigenetic alterations 
are reversible. Some of the epigenetic events include: acetylation, methylation, 
ubiquitination, phosphorylation, sumoylation and glycosylation. 
Methylation occurs on DNA and histones. DNA methylation is used for long- 
term silencing of gene expression. DNA is methylated in the 5' position of the 
cytosine ring, most commonly located in CpG islands within the promoter regions 
of genes, and is mediated by enzymes called DNA methyltransferases (Takai and 
Jones, 2002; Yoo and Jones, 2006). Lack of DNA methylation activates gene 
expression (Fujita et al., 1999). The methylation pattern is established during 
development. Methylation can maintain differential gene expression patterns in a 
developmental-stage specific and in a tissue-specific manner. Genome-wide 
decrease in methylation leads to chromosomal instability and carcinogenesis (Yoo 
and Jones, 2006). Histone methylation occurs on lysine and arginine residues by 
specific enzymes called histone lysine methyltransferases and protein arginine 
methyltransferases respectively (Yoo and Jones, 2006). 
Acetylation is a chemical modification involving the transfer of an acetyl group 
from the acetyl co-enzyme to the c-amino group of lysines in target proteins (Lin 
et al. ) 2006). Acetylation can occur 
in histones as well as other proteins and can 
have many effects. Histone acetylation affects histone structure by destabilizing 
nucleosomes leading to their dissociation or by inhibiting their stacking into the 
solenoid structure. Therefore acetylation leads to a less compact structure that 
allows access of transcription factors and other molecules such, as RNA 
polymerase to the DNA and thus stimulate transcription of genes (Cress and Seto, 
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2000). Acetylation of a protein affects protein stability as acetylation and 
ubiquitination occur on lysine residues and so there are cross-talks between these 
two modifications (Caron et al., 2005). The stability of many known proteins, 
such as p53 and p73, has been shown to increase after lysine acetylation. The 
same lysines in these proteins are subject to ubiquitination and acetylation, 
therefore when acetylation occurs ubiquitination is prevented and stability of 
these proteins is increased (Caron et al., 2005; Ito et al., 2002; Jin et al., 2004). In 
other cases acetylation is needed to stimulate degradation, such as in the case of 
the Hypoxia-induced factor 1 (Hif-1), where its degradation occurs after binding 
to pVHL which then mediates its ubiquitination. Acetylation of one of the 
subunits of Hif-1. Hif-la, enhances its binding to pVHL and therefore its 
degradation (Lee et al., 2004). More complex and indirect processes connecting 
ubiquitination and acetylation other than just through competition have also been 
reported (Caron et al., 2005). 
In addition, acetylation plays a role in protein-protein interactions and localization 
(Minucci and Pelicci, 2006). For example, acetylation of the transcription factor 
signal transducer and activator of transcription 3 (STAT3) induces its 
dimerization and translocation into the nucleus (Yuan et al., 2005) (Minucci and 
Pelicci, 2006). 
Phosphorylation is one of the most common protein modifications that occur in 
animal cells. It was originally discovered in the mid-1950s and is important for 
the regulation of many cellular processes such as protein-protein interactions, 
protein degradation, and enzyme activity inhibition and also for the biological 
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thermodynamics of energy-requiring reactions. Phosphorylation is mediated 
through the addition of phosphate to a molecule. Reversible phosphorylation 
results in conformational changes in the structure of many enzymes and receptors, 
causing them to become activated or deactivated. The enzymes that phosphorylate 
proteins are termed kinases and those that remove phosphates are termed 
phosphatases. The common amino acids phosphorylated in animal cells are serine, 
threonine and tyrosine (Pawson, 2005) the most common of which are serines and 
threonines. Tyrosine phosphorylation occurs less frequently but is very important 
for many cellular functions in eukaryotes and bacteria (Grangeasse, 2007). An 
important epigenetic event is the phosphorylation of histone H3 at Ser10, which is 
implicated in both transcriptional and mitotic regulation. 
Ubiquitination, is the process by which ubiquitin is attached through Lys48 to 
target proteins. Ubiquitination regulates target proteins in many ways. The most 
common use of ubiquitination is for targeting proteins for degradation as it will be 
discussed later on. However, besides this, ubiquitination also plays a role in 
protein-protein interaction, transcription, intracellular trafficking and activation of 
protein kinases (Pines and Lindon, 2005). Moreover, mono-ubiquitination has 
also been shown to regulate histones, the endocytosis of membrane receptors and 
retroviral budding from the plasma membrane (Hicke, 2001). 
Sumoylation is the modification where small ubiquitin-like modifier (SUMO) 
proteins covalently attach to their targets. SUMO is a small protein that 
mechanistically acts similar to ubiquitin but they do not always have similar 
sequence similarity and also they exert different functions. Both ubiquitin and 
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SUMO bind lycine residues of substrates. SUMO competes with ubiquitin for the 
conjugation of the same protein on the same time and thus proteins can be 
stabilized from ubiquitin-dependent proteasomal degradation (Ulrich, 2005). 
Sumoylation plays many important roles, such as in regulating protein stability 
and function, DNA damage repair, cell cycle regulation, nucleo-cytoplasmic 
trafficking, transcriptional regulation, apoptosis, maintaining genome stability and 
thus participates in maintaining cellular homeostasis (Kim et al., 2006). 
Glycosylation is a highly conserved post-translational modification. Three types 
of glycosylation occur: N-linked glycosylation of asparagine residues of proteins 
within the consensus sequence Asn-Xaa-Ser/Thr, 0-linked glycosylation of serine 
or threonine, and glycosylphosphatidyl inositol derivatization of the carboxyl- 
terminal carboxyl groups. N-glycosylation is very important as it has been to 
shown to be crucial for viability. It plays a role in cell cycle regulation, protein 
folding and stability and cell-matrix and cell-cell interactions (Kukuruzinska and 
Lennon, 1998). H1 histone and core histones have also been shown to be 
glycosylated. This modification probably plays a role in the regulation of cell 
proliferation and protein-DNA interactions, but further studies need to be done to 
examine its role and significance. 
1.7 HDACs 
Genomic DNA is wrapped around 8 histones to form nucleosomes, which is the 
fundamental unit of chromatin. Chromatin contains five types of histones: H1, 
H2A, H2B, H3, and H4. The nucleosome consists of an octamer of four core 
histones i. e. two H2A/H2B dimmers and an H3/H4 tetramer, surrounded by 
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146bp of DNA (Yoo and Jones, 2006). Hi histone lies on the outer portion of the 
nucleosome and occurs in chromatin in about half the amount of the other types of 
chromatin. There is also the H5 histone that has similar functions to H1 (Marks et 
al., 2000). The amino-terminal and the carboxyl-terminal tails of histones 
protrude out of the nucleosomes and are subject to post-translational 
modifications that regulate gene expression. Studies on the impact of these 
modifications in cellular processes are fast growing areas of research. Such a 
modification is the acetylation of histones by histone acetyltransferases (HATs) 
and deacetylation by histone deacetylases (HDACs). Acetylation is correlated 
with an open chromatin structure, allowing transcription factors to access the 
promoters of target genes, therefore activating transcription (Nelson et al., 2007). 
Acetylation is involved in the regulation of DNA replication, repair and 
recombination (Masumoto et al., 2005; Yang and Seto, 2007). Disordered HAT or 
HDAC activity has been linked to cancer. The fact that acetylation plays a very 
important role in the regulation of gene expression has lead to the extensive study 
of HDACs in relation to cancer (Vigushin and Coombes, 2002). 
HATs acetylate histones leading to an open chromatin structure where 
transcription factors can easily reach the DNA and as a result transcriptional 
activity is induced. There are four families of HATs. The prototype family related 
to the yeast GCN5 includes human GCN5 and P/CAF (p300/CREB binding 
protein associating factor). The second family includes CREB binding protein 
(CBP) and p300 which mainly function as co-activators for many transcription 
factors. The third family includes the TAF250 protein which is part of the TFIID 
transcription factor complex that binds the TATA box and finally the fourth 
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family, including SRC-1 and ACTR, function as co-activators for ligand-activated 
nuclear receptors. Other splice variants or related proteins exist that have HAT 
activity (Kouzarides, 1999). 
HDACs deacetylate histones leading to a very compact chromatin structure 
where transcription factors and other regulatory complexes cannot access the 
DNA, thereby gene transcription is repressed. HDACs usually interact as 
constituents of large protein complexes that downregulate genes through 
association with co-repressors (NcoR, SMRT), transcription factors (ER, p53, 
Mad/Max), cell cycle specific regulators (Rb, E2F), but they can also bind their 
target directly (Cress and Seto, 2000) (Fig. 5). For example, a decade ago the non- 
histone tumour suppressor p53 protein was shown to be acetylated by the 
recruitment of coactivators/HATs, a process very crucial for p53 function and 
activation of transcription of target genes (Gu and Roeder, 1997; Barleu et al., 
2001). Another example is the thyroid hormone receptor that activates 
transcription, upon binding of a ligand, by associating with the p300/PCAF 
histone acetyltransferases (Cress and Seto 2000). The proteins NCoR (Horlein et 
al., 1995; Kurokawa et a1., 1995; Zamir et al., 1996), SMRT (Chen and Evans, 
1995), Sin3 and histone deacetylases (Alland et al., 1997; Heinzel et al., 1997) are 
part of this complex which is usually referred to as the Sin3 complex. Many 
proteins interact with HDACs directly or through other yet unidentified proteins 
(Brehm et al., 1998; Chen et al., 1999; Luo et al., 1998; Yang et al., 1996). 
Dependent on sequence similarity and cofactor dependency, HDACs are grouped 
into two families: the classical HDAC family and the Sirtuin family of NAD+- 
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dependent HDACs. Members of the classical HDAC family are divided in three 
classes. Class I HDACs include HDAC1,2,3,8 and resemble the RPD3 
trascriptional regulator in yeast, class II include 4,5,6,7,9,10 HDACS and 
resemble the yeast HDA1 deacetylase and class IV includes HDAC11. Classes I, 
II, IV have a similar sequence and are dependent on Zinc for their deacetylase 
activity. Class I is expressed in most cell types, while class II expression is more 
restricted. For this reason class II HDACS are thought to be involved in 
developmental processes and differentiation (de Ruijter et al., 2003). The newly 
discovered HDAC 11 has conserved regions in the catalytic core region shared by 
both class I and II HDACs (Gao et al., 2002). Most HDACs contain a nuclear 
localisation signal (NLS) that targets them to the nucleus where most their 
substrates locate. Other HDACs can be cytosolic depending on other regulatory 
domains (de Ruijter et al., 2003). For example HDAC3 has both a NLS and a 
nuclear export signal (NES) suggesting that it can be also located in the cytoplasm 
(Yang et al., 2002). In most studies, HDAC3 is localized in the nucleus but this 
can be cell type specific. Class II HDACs shuttle between nucleus and cytoplasm 
depending on the signals they receive, while HDAC1 and HDAC2 are always in 
the nucleus as they lack a NES (Bertos et al., 2001). 
Functional HDACs are never found as single polypeptides but, with the exception 
of HDAC8, they form parts of multiprotein complexes along with other chromatin 
modifying enzymes or specific co-regulators. Both class I and class II HDACs 
play roles as transcriptional co-repressors by forming complexes with other DNA 
binding proteins and target the promoters of genes (Kumar et al., 2005). Although 
class I and 11 HDACs have a very similar catalytic site, they have differences in 
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the entrance region of the active site and the outer charge transfer relay system 
(Finnin et al., 1999; Hildmann et al., 2006; Nielsen et al., 2005; Somoza et al., 
2004; Vannini et al., 2004). Many class II HDACs are subject to posttranslational 
modifications such as sumoylation as it has been shown with HDAC4 where it is 
sumoylated at lysine 559 (Kirsh et al., 2002). HDAC 7 has been shown to act as a 
mitochondrial protein playing a role in apoptosis, as it translocates from the 
mitochondrial membrane to the cytoplasm in response to apoptotic signals (Bakin 
and Jung, 2004). Class II HDACs are able to bind directly and inactivate some 
transcription factors leading to their transcriptional repression, therefore HDAC 
biological function are not strictly dependent on their enzymatic activity 
(Gallinari et al., 2007). 
The class III HDAC family called the sirtuin family includes seven members 
SIRT1-7. There are no sequence similarities amongst members and they require 
NAD+ as the cofactor important for their enzymatic activity (Nelson et al., 2007). 
It was recently shown that the mutational status of HDACs is very important in 
future pharmacogenetic treatment of cancer patients. Frameshift mutations in 
HDAC2 causing its loss of expression were seen in sporadic carcinomas with 
microsatellite instability and in cancer patients with hereditary non polyposis 
colorectal cancer syndrome. This loss of HDAC2 expression leads to tumours 
being less sensitive to the anti-cancer effects of HDACi (Ropero et al., 2006). 
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HDAC inhibitors (HDACi) 
It has become apparent that imbalances of histone acetylation play a significant 
role in cancer development and progression. Cancer cells target chromatin- 
remodeling pathways in order to disrupt transcriptional regulation. Research 
performed over the last decade has highlighted the role of HDACi as modulators 
of transcriptional activity and as a potential new class of therapeutic agents. 
HDAC inhibitors have been shown to inhibit proliferation, cause cell cycle arrest, 
promote differentiation, induce mitotic cell death, senescence and reactive oxygen 
species-induced cell death (Fig. 1.4,1.5) (Johnstone et al., 2002; Narlikar et al., 
2002). Part of the reason why HDACi have anti-cancer properties is that they 
suppress cancer cell migration, invasion, metastasis in vitro (Dyer et al., 2002, 
Eyupoglu et al., 2005; Kim et at., 2004; McGarry et at., 2004) and in vivo 
(Coradini et al., 2004; Tang et al., 2004) and also suppress angiogenesis (Kwon et 
at., 2002a; Sasakawa et al., 2003; Zgouras et al., 2004; Zgouras et at., 2003). 
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Figure 1.4 Effects of HDACi 
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Low concentrations of HDACi usually induce GI arrest while higher 
concentrations induce both Gl and G2/M arrest. Gi arrest is predominantly caused 
by the increase in the expression of the p21c'p' cell cycle inhibitor (Richon et al., 
2000). However, cells without p2lc'pl have been seen to arrest in response to 
HDACi treatment by the induction of the p15INK4b cell cycle inhibitor (Hitomi et 
al., 2003). HDACi have been shown to activate intrinsic apoptotic pathways 
which are mediated by the mitochondria, by inducing the expression of pro- 
apoptotic proteins such as Bad, Bim, caspase 3, Apaf-1 and repress the expression 
of anti-apoptotic proteins like Bcl-2, XIAP and Bcl-XL (Liu et al., 2006). They 
also activate extrinsic apoptotic pathways initiated by death receptors like Fas 
(Kwon et al., 2002b) and TRAIL (Nebbioso et al., 2005) by upregulating their 
expression. Compounds such as MS-275, TSA, vorinostat and butyrate induced 
cell death by generation of reactive oxygen species (ROS) (Rosato et al., 2003; 
Ruefli et al., 2001; Ungerstedt et al., 2005; Xu et al., 2006). Also, HDACi disrupt 
the structure and function of centromeres which eventually leads to mitotic cell 
death. Nevertheless, the mechanisms by which these inhibitors exert their actions 
remain elusive. Twenty % of the known genes are affected by HDACi but not all 
of them are upregulated by treatment. The ratio of upregulated to downregulated 
is close to 1: 1 (Xu et al., 2007). Recent studies have shown that the expression of 
around 7-1O% of genes is altered in response to 48 hour treatment with TSA, MS- 
275, vorinostat or depsipeptide in leukaemia, colon bladder kidney, prostate, 
multiple myeloma, and breast cancer cell lines (Chambers et al., 2003; Glaser et 
al., 2003; Mitsiades et al., 2004; Peart et al., 2005; Sasakawa et al., 2005). Some 
of these changes are caused by direct effects of the inhibitor on specific gene 
promoters while other effects are secondary. Of course, a different mumber of 
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genes have variations in their expression when using a different concentration of 
drugs and for a different length of time. 
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Figure 1.5 HDACi inhibit HDACs that target the chromatin or other proteins 
directly, leading to cell cycle arrest, apoptosis etc. 
Noteworthy, HDACi not only influence transcription but also other processes, 
such as DNA repair. In a few cell lines, HDACi inhibit DNA repair leading to 
increased DNA damage, which can then lead to tumour cells being more 
radiotherapy and chemotherapy sensitive (Bolden et al., 2006, Munshi et al., 
2006). An important advantage of HDACi as therapeutic agents is that they 
preferentially target transformed rather than normal cells. Evidence suggests that 
this might be due to the induction of thioredoxin by HDACi in normal cells, but 
not in transformed (Ungerstedt et at., 2005). Thioredoxin is a ubiquitous 
oxidoreductase enzyme that acts as an antioxidant by facilitating the reduction of 
other proteins. Another advantage of using HDACi as a treatment is that in 
contrast to anti-estrogens, HDACi can act in both ER positive and negative cells. 
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A number of HDACi have been developed, several of which are in clinical trials. 
HDACi are classified into four categories: hydroxamic acids, short-chain fatty 
acids, benzamide derivatives, and cyclic peptides. The very potent hydroxamic 
acids include compounds such as the well known Trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA) and LAQ-824. They inhibit Class I and 
II HDACs (Lin et al., 2006). Crystallographic studies have shown that HDACs 
have a tubular catalytic site containing a zinc atom at its base and the hydroxamic 
moiety of these inhibitors bind this zinc and fit into this structure (Marks et al., 
2000). Short-chain fatty acids are well tolerated by patients and clinical trials are 
carried out to evaluate them. Their disadvantage is that they have a short plasma 
half-life due to the rapid rate of metabolism and their non-specific mode of action, 
as well as the high doses needed for therapeutic effects. Agents like this are 
Valproate, Butyrate and Phenylbutyrate. On the other hand, benzamides inhibit 
HDACs at pM concentrations. These agents include MS-274 and CI-944 which 
are currently under clinical evaluation. Lastly, cyclic peptides, like depsipeptide 
and apicidin A, are the most structurally complex class of HDACi. Depsipeptide 
was pulled out from clinical trials due to its cardiovascular toxicity (Lin et al., 
2006). 
Very few HDACi developed can only inhibit a specific HDAC. For example, 
tubacin selectivily inhibits HDAC6 but does not inhibit proliferation and causes 
accumulation of acetylated a-tubulin. Also, the novel compounds SK7041 and 
SK7068 target only HDAC1 and 2 and have been shown to inhibit the 
proliferation of cancer cell lines (Haggarty et al., 2003; Kim et al., 2003a). The 
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anti-proliferative effects of selective HDACi towards cancer cells, remains 
undetermined. 
HDACi have been demonstrated to induce apoptotic and autophagic cell death in 
vitro and in vivo (Hess-Stumpp, 2005; Minucci and Pelicci, 2006; Shao et al., 
2004). Induction of autophagic cell death has clear clinical implications in treating 
cancers with apoptotic defects. Butyrate, a short fatty-acid HDACi, and the 
hydroxamic acid SAHA, induced caspase-3 activation and apoptosis through the 
mitochondria/cytochrome C-mediated apoptotic pathway in many cancer cell 
lines. However, cell death was also induced without caspases and resembled the 
features of autophagic cell death. Therefore, HDAC inhibitors can induce both 
mitochondria-mediated apoptosis and caspase-independent autophagic cell death 
(Shao et al., 2004). 
While the primary action of HDACi is attributed to histone remodelling, other 
targets are also responsible for their anti-tumour properties. For example, 
treatment with HDACi leads to the dephosphorylation of Akt (also called protein 
kinase B/PKB) resulting in its inactivation. This occurs through the dissociation 
of protein phosphatase 1 (PP1) from HDACs, leading to an increased association 
of PP1 with Akt. Akt enhances cellular survival through the phosphorylation- 
dependent inhibition of several proapoptotic proteins (Datta et al., 1999; 
Woodgett, 2005). Mutation of negative regulators of Akt and the deregulated 
expression or activation of Akt has been demonstrated in several cancers 
(Samuels et al., 2005). 
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It is important to mention that HDACi can also cause non-desired effects in 
cancer cells since they are also able to induce proliferation and differentiation and 
abrogate apoptosis (Minucci and Pelicci, 2006). An example is the retinoblastoma 
protein (Rb) that recruits HDACs to E2F transcription factor target genes, thereby 
controlling the Gl to S transition. HDACi should therefore induce Rb targets but 
only a subset of these is dependent on HDAC recruitment. RB regulation of cell 
cycle would therefore continue to be unaffected by HDACi and can therefore 
induce proliferation of cancer cells (Siddiqui et al., 2003). 
Clinical potential of HDAC inhibitors 
HDACi are being heralded as the first anti-cancer drugs targeting the epigenome. 
They have entered clinical trials for both blood cancers and solid tumours. 
Generally, HDACi have a favourable outcome in clinic trials so far. SAHA is now 
approved by the Food and Drug Administation (FDA) for the treatment of 
cutaneous T-cell lymphoma and can be administrated to patients intravenously or 
orally and is well tolerated by patients (Kelly et al., 2005; Kelly et al., 2003). It 
has also been proven to inhibit the growth of pancreatic cancer cells causing G2/M 
arrest, differentiation and apoptosis (Kumagai et al., 2007). Similarly depsipeptide 
is advancing in clinical trials but it has not shown much activity in solid tumours. 
On the other hand cutaneous T-cell lymphoma has again been proven to be 
responsive to depsipeptide (Piekarz et al., 2001). The reason why this cancer is 
responsive both to SAHA and depsipeptide remains unclear. FK-228 or 
romidepsin has been reported to induce apoptosis in colon cancer, chronic 
myelogenous leukemia, and non small cell lung carcinoma. It is well tolerated and 
has a similar toxicity profile as SAHA. As it is not a hydroxamic acid as SAHA it 
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is a more selective inhibitor of the class I HDACs (Choudhary and Wang, 2007; 
Radhakrishnan et al., 2007; Yu et al., 2007). In addition, the benzamide MS-275 
has been shown to induce apoptosis in B-chronic lymhocytic leukaemia cells, 
prostate cancer cells and Jurkat lymphoblastic cells and is used in clinical trials in 
combination with other agents (Lucas et al., 2004; Maggio et al., 2004; Pan et al., 
2007; Qian et al., 2007). It is however anticipated that inhibitors targeted against 
specific HDACs may potentially have a greater therapeutic effect than all these 
non-specific drugs. 
Furthermore, it appears that HDACi will have better clinical efficacy when used 
in combination with other drugs. There are many ongoing phase II trials in which 
this is investigated. Combination of HDACi with other chemotherapeutic agents 
has shown to reduce side effects and morbidity in patients. For example, 
depsipeptide in combination with the nitrogen mustard derivative melphalan, has 
been reported to be more cytotoxic in multiple myeloma cells (Khan et al., 2004). 
Also, clinical trials are now testing the combined effect of anthracyclines with an 
HDAC inhibitor in leukaemia. The novel hydroxamic acid Belinostat has been 
reported to have additive or synergistic activity when combined with carboplatin 
and paclitaxel in ovarian cancer models (Karagiannis and El-Osta, 2006). 
Inhibition of HDACs with compounds like valproic acid has been reported to 
enhance the anti-proliferative action of anti-oestrogens in breast cancer cells and 
block tamoxifen-induced proliferation of uterine cells (Hodges-Gallagher et al., 
2007). 
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Pre-incubation of cancer cell lines with TSA or SAHA increases the cell death 
efficiency induced by the DNA cross-linking agent cisplatin, the DNA 
intercalator doxorubicin and the topoisomerase II inhibitor VD-16. This is 
probably caused because HDACi make the DNA more accessible for the other 
DNA binding drugs. However, this in not true for all the DNA binding drugs 
since cyclophosphamide induced cell death was not increased by pre-incubation 
with SAHA (Kim et al., 2003a; Zhang et al., 2004). It has also been proved that 
HDACi sensitize cells to ionizing radiation. 
Suberic bishydroxamate (SBHA) has proved to be effective on inducing apoptosis 
on a panel of human melanoma cell lines but not in melanocytes and fibroblasts. 
It induced caspase-dependent apoptosis and down-regulated anti-apoptotic Bcl-2 
family proteins, Bcl-XL and Mcl-1, while inducing the expression of pro- 
apoptotic Bim, Ba; and Bak. Bim was particularly important in the SBHA 
induced apoptosis (Zhang et al., 2004). 
Besides cancer, HDACi are also used for the treatment of other diseases. For 
example, some HDACi can reduce graft-versus-host disease in patients that have 
had bone marrow transplantation by the suppression of pro-inflammatory 
cytokines. HDACis affect proteins such as STAT1, STAT3 and NFkB that 
regulate immune cell function (Leng et al., 2006). Moreover, they activate latent 
viruses like HIV. When the virus is in latent stage activation by HDACi causes it 
to be more susceptible to treatment with targeted anti-viral-therapy. The 
combination of valproic acid and highly active retroviral therapy caused resting 
cell infection declined significantly in 3 out of 4 patients (Ylisastigui et al., 2004). 
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HDACi have also been useful for the treatment of strokes and other 
neurodegenerative diseases as they increase the expression of neuroprotective 
proteins, like Hsp70 and Bcl-2, in the ischemic brain. Valproic acid has been 
found to be a very efficient anti-epileptic drug. Although, it is well tolerated by 
patients, it can cause birth defects, like neural tube defects, during early 
pregnancy (Nau et al., 1991). HDACi have also proved to be important for the 
therapy of Huntington's disease (Sadri-Vakili and Cha, 2006). 
However, some HDAC inhibitors have very toxic side effects at high doses and 
therefore, are of limited therapeutic use. Other HDACi, such as butyrate and 
phenylbutyrate, degrade rapidly, therefore patients will require high dose 
administration (Warrell et al., 1998). Another disadvantage of these compounds is 
that they are not specific. They not only inhibit HDACs but they also inhibit other 
processes like the phosphorylation and methylation of proteins as well as DNA 
(Newmark and Young, 1995). 
1.8 Trichostatin A 
The natural product Trichostatin A (Fig. 1.6), was first isolated from the culture 
broth of Streptomyces hygroscopicus as an antifungal antibiotic active against 
Trichophyton species. Now it has been shown to exhibit potent differentiating and 
anti-proliferative properties (Vigushin and Coombes, 2002). TSA consists of a Zn 
motif that has a chelating function, a conjugated, aliphatic chain that acts as a 
linker and finally a polar cap group. All these motifs interact with the enzyme 
pocket. The HDAC catalytic domain consists of a tube like pocket and Zn is 
located at the bottom of this. X-ray crystallographic analysis of the bacterial 
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HDAC histone deacetylase- like protein (HDLP) has revealed how inhibitors like 
TSA mediate enzyme inhibition. A distinct protein-ligand interaction occurs 
where TSA is docked into the active site pocket of HDLP following energy 
minimization (Lin et al., 2006). 
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Figure 1.6 Chemical structure of trichostatin A (Vigushin et al. 2002) 
TSA induces different types of cell death, differentiation and cell cycle arrest 
(Yoshida et al., 1990). In cancer cells, TSA induces apoptosis, whereas in normal 
cells it arrests cell cycle progression. Generally, TSA has been shown to induce 
the expression of the p21c'pl cell cycle inhibitor, increase the acetylation of H4 
and cause arrest in Gl/S and G? JM in many cancer cell lines (Kim et al., 1999; Li 
et al., 2006; Rokhlin et al., 2006; Sowa et al., 1999; Yamashita et al., 2003). 
Studies have also shown that TSA inhibits the growth of non-small-cell lung 
cancer cells (Mukhopadhyay et al., 2006) and small-cell lung cancer cells (Platta 
et al., 2007). 
In the A2780 ovarian cells TSA caused differentiation and inhibited cell 
proliferation by inducing p21c'p', reducing the phosphorylation of the cell cycle 
regulator retinoblastoma protein (Rb), decreasing Idl expression (Inhibitor of 
differentiation 1), while not affecting Id2levels (Strait et al., 2002). Furthermore, 
TSA not only has been demonstrated to induce caspase-dependent apoptosis but it 
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is also able to induce caspase-independent apoptosis in human gastric cancer cells 
through regulating apoptosis-related genes, such as Bcl-2, Bax and surviving (Wu 
et al., 2007). TSA has also been seen to inactivate the mitotic spindle checkpoint, 
suggesting that it can increase the cell death caused by microtubule-disrupting 
agents like the taxanes (Dowling et al., 2005). 
TSA treatment also modulates the radiation-induced DNA damage repair process 
in human squamous carcinoma cells SQ-20B. This was partly due to TSA induced 
suppression of the BRCAI gene expression, suggesting that BRCA1 is one of the 
molecular targets of TSA (Zhang et at., 2007). Recently, it was shown that TSA 
also inhibits the telomerase activity in brain cancer cell lines and may therefore be 
used as a telomerase inhibitor in cancer therapy (Khaw et al., 2007). 
TSA has also proved to inhibit angiogenesis. TSA treatment reduced the 
expression of VEGF-D in U251MG glioblastoma cells suggesting that HDACi 
modulate the expression of VEGF family members, and therefore may inhibit 
angiogenesis (Sawa et al., 2002). Also, combination of TSA and alpha-interferon 
(IFNalpha) therapy reduced tumour angiogenesis in neuroblastoma-bearing 
transgenic mice (Kuljaca et al., 2007). 
TSA increases the agonist activity of anti-estrogens, by a mechanism dependent 
on the reduction of ERa expression (Margueron et al., 2003). ERa positive cell 
lines are more sensitive than ERa negative cell lines to the antiproliferative 
effects of TSA. This was shown to be due to the fact that in ER+ breast cancer 
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cells the p21C'" gene was expressed at higher levels and it was more sensitive to 
TSA regulation (Margueron et al., 2003). 
Recently, TSA has been shown to sensitize ERa-negative (MDA-MB-231 and 
Hs578T), endocrine resistant breast cancer cells to tamoxifen possibly by 
upregulating ERP activity (Dang et al., 2004). Studies in our lab have also shown 
that TSA represses the transcription of ERa and cyclin Dl in the MCF-7 breast 
cancer cells and induces ubiquitin-dependent proteasome degradation of cyclin 
D1 in both ERa- positive and ERa-negative cell lines. Cyclin D1 is known to 
activate ERa, independent of CDK and estrogen binding, and therefore can 
stimulate cancer cell growth. The inhibition of this effect by TSA provides a 
potential tool in overcoming resistance to endocrine therapy (Alao et al., 2004). 
TSA is also thought to provide an important treatment of cancer by combining its 
activity with other chemotherapeutic agents or radiation. Studies are now being 
done on the link of TSA and radiation, some of them reporting that TSA enhances 
the radiosensitivity in some human cancer cell lines (Akimoto, 2004). 
Besides the fact that TSA is toxic, another disadvantage is its high 
biotransformation. Research on the biotransformation pathways of TSA in rat 
hepatocytes and human liver microsomes showed that TSA undergoes a high 
phase I biotransformation. The hydroxamic acid was converted to its 
corresponding metabolites after only 20min of exposure therefore causing a very 
short exposure to the pharmacologically active parent compound. This has 
important consequences for its potential development as an anti-cancer drug, as 
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exposure to a complex mixture of metabolites is usually not desired (Elaut et al., 
2002). 
Clearly, an understanding of the mechanism of action of HDAC inhibitors like 
TSA is very important for their potential use as cancer therapeutic agents. 
However, although there is a high volume of research going on regarding TSA, 
targets of this drug are still unknown. In this study I characterized the regulation 
and function of an important target of TSA. 
1.9 F-Box proteins 
At present little is known about the genes encoding F-Box proteins and their 
functions. F-box proteins contain an approximately 50 amino acid domain called 
F-box that functions as a site of protein-protein interaction. The name F-Box 
proteins was quoted by Bai et al. in 1996, (Bai et al., 1996) because it was first 
identified in cyclin F. F-Box proteins are present in all eukaryotes; 11 members of 
the F-Box family have been found in budding yeast, 22 in Drosophila, 326 
predicted in Caenorhabditis elegans, and 38 in humans but none known in 
prokaryotes. The interestingly high number of F-Box proteins in C. elegans 
makes it the fourth most common protein domain in C. elegans. The F-Box 
domain is usually found in the N-terminal region of proteins. A small number of 
studies have been carried out to analyze the subcellular localisation of F-Box 
proteins and showed F-box proteins to be distributed both in the cytoplasm and 
nucleus. No information is available on their expression patterns and tissue 
specificities. Furthermore, mutating the F-Box domain has been shown not to be 
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important for determining their localisation in the cell (Kipreos and Pagano, 
2000). 
F-box proteins are also characterised by their carboxyl-terminal motifs capable of 
protein-protein interaction; the most common motifs being WD repeats and 
leucine-rich repeats (LRRs). They are also shown to contain other secondary 
motifs, eg. cyclin domains, zing fingers, the diversity of which suggests that F- 
Box motifs must have been transferred into existing proteins many times during 
evolution (Ilyin et al., 2002). The F-box proteins containing LRRs are named 
FBXL, those with WD40 repeats are denoted FBXW and those with no or another 
motif are called FBXO. F-Box proteins have been shown to play an important role 
in the ubiquitin-mediated degradation of many cellular proteins. 
1.10 Ubiguitin-dependent proteasomal degradation pathway 
The ubiquitin-dependent proteasomal degradation pathway (Fig. 1.7) plays a very 
important role in the post-translational regulation of proteins. It involves the 
generation of a polyubiquitin chain covalently conjugated to the protein substrate 
followed by degradation of the conjugated protein by the 26S proteasome. 
Ubiquitin is a 76-amino acid globular protein that its covalent conjugation to other 
proteins - ubiquitination - is essential for their degradation. This process 
involves the action of three enzymes: the ubiquitin activating enzyme El, the 
ubiquitin-conjugating enzyme E2 and the ubiquitin ligase E3 (Ciechanover et al., 
2000; Weissman, 2001). 
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In detail, free ubiquitin is activated by the El enzyme to form a thiol- ester bond 
between glycine 76 and cysteine in an ATP-dependent reaction. The ubiquitin 
molecule is then transferred to the active cysteine of one of several E2 enzymes. 
There are approximately 13 E2s in vertebrates and yeast. Then, E3 enzymes 
facilitate the transfer of ubiquitin from E2s onto a lysine residue on specific 
substrate proteins or onto Lys-48 of a substrate bound multi-ubiquitin chain. 
Following 26S proteasomal degradation, free ubiquitin is released back into the 
cellular ubiquitin pool. In certain instances, the E3 may itself be tagged with 
ubiquitin and targeted for degradation. The 26S proteasome is an abundant 5'- 
triphosphate-dependent protease complex consisting of a cylindrical 20S core 
particle flanked by two 19S regulatory particles regulating substrate access on 
both ends of the 20S core (Ciechanover et al., 2000; Jackson et al., 2000; 
Weissman, 2001). Furthermore, proteasomes are present in eukaryotic cells both 
in the cytoplasm and nucleus and are more active and abundant in transformed 
compared to non-transformed cell lines. 
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Figure 1.7 Ubiquitin-dependent proteasome degradation pathway 
Although some proteins are quite unstable and this degradation by the ubiquitin- 
proteasome system occurs most of the time, some proteins are only degraded at a 
particular time, in response to a particular event or at particular locations. For 
example, the anaphase promoting complex (APC/C) E3 ligase gets 
phosphorylated and activated upon entry into mitosis. The APC/C mediated 
degradation of the cyclin BI protein is spatially controlled as proteolysis seems to 
occur in the mitotic spindle. Other times a protein has to be modified by processes 
like glycosylation or phosphorylation, in order for the E3 ligase to recognise it 
and target it for proteolysis. Controlling when proteins are degraded is important 
for enhancing the specificity and timing of ubiquitin-proteasome degradation 
(Pines and Lindon, 2005). 
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The ubiquitin-dependent proteasome degradation pathway regulates a number of 
cellular processes. For example, it regulates the differences in expression of 
cyclins and CKIs throughout the cell cycle. It is crucial to maintain functioning 
degradation pathways as any deregulation of for example an SCF complex might 
play a role in carcinogenesis. The cellular role of cyclins and CKIs and their E3 
ligases is correlated with aspects of breast cancer (Ohta and Fukuda, 2004). One 
of the cullin genes, CUL-4A has been implicated in breast cancer as it was 
reported to be amplified and overexpressed in primary breast cancers (Chen et al., 
1998). 
Inhibition of the 26S proteasome results in cell cycle arrest and apoptosis. 
Therefore dysregulation of this system may result in carcinogenesis and drug 
resistance, making the proteasome a novel target in cancer therapy. Indeed 
clinical trials are on going with the proteasome inhibitor Bortezomib. Bortezomib 
is a boronic acid dipeptide that is quite specific for the proteasome. It was 
approved by the FDA for the treatment of advanced multiple myeloma in patients 
who had relapsed after at least two prior treatments and were resistant to the 
previous treatment (Rajkumar et al., 2005). It has been reported to activate c-Jun 
N-terminal kinase activation and inhibit nuclear factor-kappa B leading to 
apoptosis (Mitsiades et al., 2002a; Mitsiades et al., 2002b). 
E3 ligases 
E3 ligases are the most varied proteins of the pathway. They are responsible for 
the direct substrate recognition and are classified into Ring-H2-finger domain, 
HECT domain and U-box domain families (Ang and Wade Harper, 2005). These 
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three families differ in the way they transfer ubiquitin to their substrates. With E3 
ligases containing the HECT domain, ubiquitin is first transferred to the HECT E3 
ligase and then to the substrate whereas the RING E3 ligases transfer ubiquitin 
directly from the E2 enzymes onto the target proteins (Ho et al., 2006). U-box E3 
ligases mediate polyubiquitination in the presence of enzymes El and E2. In the 
absence of E3 U-box proteins they catalyse polyubiquitination by targeting lysine 
residues of ubiquitin other than lysine 48, which is utilized by HECT and RING 
finger E3 enzymes (Hatakeyama et al., 2001). 
The best characterized of the RING E3 ligase is the SCF ubiquitin ligase which is 
composed of S-phase kinase associated protein 1 (Skpl) (Bai et al., 1996; Zhang 
et al., 1995), Cdc53/CUL-1 (Lisztwan et al., 1998; Lyapina et al., 1998), the 
Rocl/Rbxl ring finger protein (Kamura et al., 1999; Ohta et al., 1999; Tan et al., 
1999) and one of many F-Box proteins. Other domains may also be part of the 
SCF complex but are probably not important for its ubiquitinating activity. 
Cdc53/CUL-1 binds Skpl through its N-terminal domain while the C-terminal of 
cullin binds Rocl/Rbxl. CUL-1 is a member of the cullin family (containing 
CUL-I-CUL-5 and Apc2), and their function is to recruit E2 enzyme into the E3 
ubiquitin ligase complex and they also organize and activate the ubiquitin ligase 
complex. Some cullins, like CUL-3, has been shown to control the stability of 
cyclin E. Rocl/Rbxl is essential for the ubiquitinating activity of the SCF 
complex. It also associates CUL-1 with the E2 enzyme. The role of F-Box 
proteins is to ensure specific substrate recognition and many of the F-Box 
subunits facilitate the ubiquitination of various substrates. The F-Box binds Skp1, 
which is the subunit facilitating ubiquitination by spatially orientating the SCF 
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subunits and the substrate proteins (Ang and Wade Harper, 2005). Substrate 
recognition by F-Box proteins is usually dependent upon certain modifications of 
the substrate proteins like phosphorylation or glycosylation (Feldman et al., 1997; 
Nash et at., 2001; Orlicky et at., 2003; Skowyra et at., 1997). Phosphorylation 
also allows regulation of the degradation of the substrate when SCF complexes 
are active throughout the cell cycle. The SCF complex itself can also be subject to 
post-translational modifications. The winged-helix B domain of the cullin subunit 
can undergo neddylation, in which the ubiquitin-like Nedd8-a protein binds a 
lysine residue on a substrate protein (Lammer et al., 1998). 
E3 ligases can also be important to determine a person's predisposition to cancer. 
The N-terminal RING finger domain of BRCAI has a ubiquitin ligase activity 
when bound to the RING finger protein BARD 1. This ubiquitin ligase activity of 
BRCA1-BARDI can be abolished by mutations in this RING finger domain of 
BRCA1 found in many familial breast cancers. Analysis of those mutations are 
important for the determination of the effect they have on biological function of 
BRCA1 and its role as a tumour suppressor as well as to predict an individuals 
predispotion to cancer (Hashizume et al., 2001; Ohta and Fukuda, 2004). 
Mutations have also been found in the BRAD1 gene in breast and ovarian cancer 
patients (Thai et al., 1998). In recent years, a series of studies have focused on 
elucidating ubiquitination-related mechanisms in carcinogenesis. 
Another, very well studied E3 ligase is the anaphase promoting 
complex/cyclosome or APC/C. Like SCF it is also a member of the Ring-H2- 
finger-containg E3 ubiquitin-ligase family but whereas SCF is functional 
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throughout the cell cycle, APC/C functions during mitosis and G1 phase. APC/C 
mediates the ubiquitin dependent degradation of mitotic cyclins and anaphase 
inhibitors. It also contains a similar ring finger protein to Roc 1 /Rbx 1 named 
Apc II (Ohta et a1., 1999). 
The importance of determining the functions of F-Box proteins and their 
involvement in cancer is very well illustrated by the F-Box protein Fbw7, which 
has been shown to catalyse the ubiquitination of the oncogene c-Myc, cyclin E, c- 
jun and Notch. Fbw7 was originally shown to be linked to the degradation of 
Notch/LIN-12 in C elegans. Its frequent loss in cancer cells is linked to the 
activation of c-Myc, a transcription factor regulating proliferation, differentiation 
and apoptosis (Welcker et al., 2004; Yada et al., 2004). c-Myc degradation by 
Fbw7 occurs by phosphorylation by GSK3ß at Thr-58 (Ang and Wade Harper, 
2005). Its knockdown in U2OS osteosarcoma cells has been shown to increase 
cell size, consistent with its ability to regulate c-myc levels in the nucleolus 
(Welcker et al., 2004). Therefore, Fbw7 acts as a tumour suppressor gene. Fbw7 
knockout mice die at approximately 10 days of gestation with many defects in 
heart, vascular and haematopoietic development. Furthermore, colon cancer cell 
lines lacking Fbw7 have increased levels of cyclin E, overexpression of which 
leads to genomic instability (Ang and Wade Harper, 2005). 
Another well-characterised F-Box protein is the Skp2 (Fbll). It is an important 
regulator of cell proliferation and has C-terminal leucine-rich repeats that are 
important for protein-protein interactions. Skp2 also binds Skpl forming an E3 
ligase complex mediating the ubiquitination of cyclin E and the CDK inhibitor 
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p27x; p' (Carrano et al., 1999; Sutterluty et al., 1999; Zhang et al., 1995). Skp2 
recognises p27K'pl in a phosphorylation-dependent manner (Carrano et al., 1999). 
It also binds the cyclin A-CDK2 complex making it very important for S phase 
entry. 
The cell regulates the activity of Skp2 primarily by regulating its levels 
throughout the cell cycle. Its levels vary during the cell cycle, being first 
detectable at the GI-S transition point, accumulating at S and G2 and decreasing at 
mitosis (Ang and Wade Harper, 2005). Levels of Skp2 are being regulated by the 
ubiquitin-mediated protein degradation pathway. It is degraded by the anaphase- 
promoting complex (APCCDH1)(Wei et al., 2004). Moreover, Skp2 is subject to 
degradation through autoubiquitination which is known to be negatively regulated 
by the cdc kinase subunit I (Cksl). Cksl binds Skp2 and plays a very important 
role in the ubiquitination of p27K'p'. Upon phosphorylation of threonine-187, 
p27K'pl binds to Cksl and Skp2, both of which are being degraded by APC`dnl 
(Wang et al., 2004). 
Skp2 has been shown to exert oncogenic potential in breast epithelial cells and is 
overexpressed in many breast carcinomas (Signoretti et al., 2002). It has also been 
shown to ubiquitinate and lead to the degradation of the Forkhead transcription 
factor FOXO1, an action dependent upon AKT phosphorylation at Ser-256. Skp2 
abolishes the inhibitory role of FOXO1 in proliferation and survival, showing 
again the importance of Skp2 in tumorigenesis (Huang et al., 2005). Skp2 also 
influences c-Myc stability and has been shown to play a role in promoting c-Myc 
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transcriptional activation but also overexpression of Skp2 promotes c-Myc 
ubiquitination (Kim et al., 2003b). 
Some F-Box proteins have functions not directly related to the SCF complexes. 
For example, in budding yeast, three F-Box proteins were bound to Skpl but they 
were not part of an SCF complex. Skpl here plays a critical structural role in the 
CBF-3 protein complex assembly by activating the Ctfl 3 F-Box protein. CBF-3 is 
composed of p110 (NdclO), p64 (Cep3), p58 (Ctfl3) and Skpl and plays a role in 
the kinetochore. The mechanism of activation is independent of SCF. Skpl's 
associated F-box protein interacts with other proteins in a way reminiscent of the 
SCF (Bouck and Bloom, 2005; Kitagawa et al., 1999). 
Furthermore, some F-box proteins function independently of their F-box motif or 
their interaction with Skpl. Some times, an F-Box protein associates with Skpl 
and the SCF complex to regulate its own degradation or even others (Hermand, 
2006). For example, the APC inhibitor Rcal/Emil prevents premature cyclin 
degradation. The F-box of Rcal is not important for its inhibitory effect on the 
APC, but along with its interaction with components of the SCF, is required for an 
unknown function at the Gl -S transition (Zielke et al., 2006). 
Noteworthy is the existence of the F-Box protein Fbx2 that has been proved to 
bind Skpl but not the other parts of the complex, cullin-1 and ROC-1. This 
protein bound to Skpl is thought to form a novel heterodimeric complex and may 
form a non traditional complex that has a different function (Nelson et al., 2007). 
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Previous research in our laboratory has shown that Skp2 is involved in the 
degradation of cyclin D1 in the MCF-7 breast cancer cell line. Interest in finding 
proteins related to Skp2 that may be involved in cyclin D1 regulation, led to the 
identification of the novel FBXL20 F-Box protein. Like Skp2, the FBXL20 
protein has an F-box domain and C-terminal LRR repeats. FBXL20 has been 
shown to interact with Skpl suggesting a possible role for FBXL20 in the 
ubiquitin dependent proteasomal degradation of target proteins. In contrast to 
Skp2, FBXL20 was found to localise in the cytoplasm of rat liver epithelial cells 
and its expression increased in growth-arrested cells, indicating that although both 
proteins bind Skpl and are structurally related, they probably have different 
cellular functions (Ilyin et al., 1999). 
Recently, a very similar protein to FBXL20, FBL2 was shown to have a 
geranylgeranylation site, CAAX (CVIL), in the very end of the coding sequence 
that is important for binding the hepatitis C virus (HCV) nonstructural protein 5A 
(NS5A). The binding of NS5A to FBL2 doesn't require the F-Box. Experimental 
observations like, siRNA-mediated knockdown of FBL2 in Huh7-HP cells 
reduced HCV RNA by 65%, lead to the conclusion that geranylgeranylated FBL2 
binding to NS5A plays an important role in HCV RNA replication (Wang et al., 
2005a). 
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1.11 The Forkhead box Ml transcription factor (FoxMl) 
FoxMl is part of the mammalian Forkhead box transcription factor family that 
includes at least 50 proteins (Costa, 2005). This family is characterized by a 
winged-helix DNA-binding motif. FoxMl is the only Forkhead transcription 
factor shown to exhibit proliferation-dependent expression and it is one of the 
most important regulators of the Gl/S and G2/M transitions. The levels of FoxMl 
increase at the onset of S-phase and persist until the end of mitosis (Laoukili et 
al., 2005). The G1/S transition is controlled by FoxMl by decreasing the nuclear 
levels of the cyclin- dependent kinase inhibitors p2l. 'PI and p27K'p1. Inhibition of 
these two CDK inhibitors has been linked to a FoxMl-induced transcriptional 
increase in the expression of Skp2 and Cksl (Wang et al., 2005b). At the Gi/S 
phase FoxMl also increases the levels of the Cdc25A phosphatase which 
activates Cdk2-cyclin E activity. 
For progression through the G2/M transition FoxMl has been shown to be 
important for the transcription of a number of proteins including, cyclin B1, 
Cdc25B, Polo-like kinase 1 (PLK1), survivin, Aurora B kinase, the centromere 
protein A (CENPA) and CENPB (Wang et al., 2005b). Cdc25B and Cdc25C 
phosphatases dephosphorylate and activate Cdkl leading to activation of the 
cyclin B1-Cdkl complex and progression through the G2/M phase of the cell 
cycle. PLK1 phosphorylates and activates these phosphatases. PLK1 is also very 
important for centrosome duplication and along with Aurora B kinase facilitate 
attachment of spindle microtubules to the kinetochore complex on the 
centrosomes (Meraldi et al., 2004). Aurora B kinase is important for cytokinesis 
and chromosome segregation (Meraldi et a1., 2004). Furthermore, FoxMl is very 
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important for chromosome stability. FoxMl depleted cells show a high degree of 
polyploidy, abnormal chromosome segregation and a significantly reduced G2/M 
progression (Laoukili et al., 2005). 
Additionally, translocation of FoxMl to the nucleus, just before entry into the 
G2/M phase, requires the activity of the c-raf/MEK/MAPK pathway (Ma et al., 
2005). Furthermore, the activity of FoxMl regulated genes is suppressed when 
the RAF/MEK/MAPK pathway is inhibited by the specific MEK-1 inhibitor 
U0126. In cells treated with U0126, synchronized S-phase cells become arrested 
in the following G2 phase with a concomitant decrease in cyclin B-CDK1 kinase 
activity (Roberts et al., 2002; Wright et al., 1999). All these reports have 
demonstrated that there is a link between the RAF/MEK/MAPK pathway and 
FoxMI in regulating G2/M transition (Ma et al., 2005). 
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PROJECT AIMS 
This project aims to lead to a better understanding of the mechanism of action of 
HDACi, using the well known hydroxamic acid TSA as a model of HDACi. This 
will be done by examining the role of TSA on one of its novel targets, the protein 
FBXL20, in the MCF-7 breast cancer cell line. Since FBXL20 has not been 
characterized in human cells this project will firstly aim to chracterize this protein 
in breast cancer cells. The effect of this protein on the TSA-induced inhibition of 
proliferation and the induction of cell cycle arrest and cell death will then be 
examined. Lastly this work also aims to identify a novel HDACi that is more 
potent but less toxic than the HDACi SAHA, currently used in the clinical setting. 
Using the structure of SAHA, novel HDACi will be developed and analysed for 
their ability to inhibit HDACS and the proliferation of breast cancer cells. 
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CHAPTER II 
MATERIALS AND METHODS 
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Data bank analyses 
The NCBI databases and blast programmes were used for DNA and protein 
sequence analysis. 
Cell culture 
The MCF-7 breast cancer cell line was used for the experiments. They were 
maintained in Dulbecco's modified eagle medium (DMEM) (Life Technologies 
GibcoBRL, Paisley, UK) supplemented with 10% foetal calf serum and L- 
Glutamine-Penicillin-Streptomycin solution (2mM L-glutamine, 100U/ml 
penicillin and 100µg/ml streptomycin). Cultures were maintained at 37°C, in 10% 
CO2 humidified atmosphere. For oestrogen depleted conditions, cells were grown 
in phenol red-free DMEM supplemented with 5% (v/v) dextran-coated charcoal- 
stripped fetal calf serum, 2mmol/L L-glutamine, 100units/mL penicillin, and 
IOOpg/m1 streptomycin. 
Cell line maintenance 
Cells were split 1: 5 twice a week. Media was aspirated and cells were washed 
once in PBS followed by washing once with trypsin. After cells were detached by 
the addition of trypsin, they were resuspended in the appropriate media and 
seeded into new plates. Cells were cultured for approximately 35 passages before 
discarding. 
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Chemicals 
Cycloheximide (Sigma-Aldrich, Dorset, UK) was dissolved in DMSO and stored 
at -20°C at a concentration of 10mg/µl. TSA (Sigma-Aldrich, Dorset, UK) was 
dissolved in ethanol at 10mM concentration and stored at -20°C. SBHA (Sigma- 
Aldrich, Dorset, UK) was dissolved in DMSO at 10mM concentration and stored 
at -20°C. SARA and the novel HDAC inhibitors (provided by Prof. Marson) 
were dissolved in DMSO at 10mM concentration and stored at -20°C. 
PCR 
PCR amplification was performed using a Taq DNA polymerase Kit (West 
Sussex, Qiagen). Reaction solutions contained DNA template (1µg), 0.5µM of 
forward primer, 0.5µM reverse primer, lx PCR buffer, lx Q solution, 0.2nM 
dNTP, 0.5U Taq polymerase and ddH2O to a final volume of 50µ1. cDNA was 
denatured at 94°C for 3min, followed by 22-35 cycles of annealing and a final 
10min extension at 72°C. PCR reactions were carried out using a DNAEngine 
Peltier Thermal Cycler (BIO-RAD) using the following programme: A initial 
denaturation step for 3min at 94°C, followed by 22-35 cycles of denaturation for 
I min at 94 T. annealing for 1 min at 50-68°C depending on the oligonucleotides 
utilised, extension at 72°C for lmin/kb DNA followed by a final extension for 
10min at 72 T. 
The FailSafe PCR PreMix Selection Kit and defined oligonucleotide primers were 
used to amplify the complete FBXL20 cDNA. The kit contains a FailSafe PCR 
enzyme mix containing a 3' to 5' proofreading DNA polymerase and a set of 
twelve reaction premixes containing a buffered salt solution with all four dNTPs 
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and various amounts of MgCl2 and FailSafe PCR enhancer (with betaine). PCR 
mix contained: 25[d of each FailSafe PCR 2X Premix, O. 511 of FBXL20 forward 
primer (100pmol/µl), O. 5µ1 FBXL20 reverse primer (100pmol/µl), DNA template 
and ddH2O in a 50µl final volume. 35 cycles were performed and the annealing 
temperature was 5 8°C. For a control reaction, DNA was substituted with the 
equivalent amount of ddH2O. After amplification, PCR products were separated 
and visualized on an ethidium bromide-stained 1% agarose gel, using a 100bp 
molecular marker. 
Primer Sequence Gene Annealing 
Temp °C 
FBL20RF2-F 5'-catgaggagggacgtgaacg-3' FBXL20 58°C 
FBL20RF-R 5'-aaggttgaccacctccattg-3' FBXL20 58°C 
FBL2-R 5'-tggcatctgtgatgttggag-3' FBXL20 58°C 
FBL2-F 5'-tgagtgagggatgtccactg-3' FBXL20 58°C 
FBL2BamH1 5'-ccggatcctaggatggatgcagc-3' FBXL20 58°C 
FBL2xhoI 5'-ccgctcgagaggagggacgtgaac-3' FBXL20 58 °C 
GAPDH-F 5'-tcccatcaccatcttcca-3' GAPDH 23 °C 
GAPDH-R 5'-catcacgccacagtttcc-3' GAPDH 23 °C 
ACTIN-F 5'-tctggcaccacaccttctacaatgagctgcg-3' Actin 23 °C 
ACTIN-R 5'-cgtcatactcctgcttgctgatccacatctgc-3' Actin 23 °C 
Table 2.1 Primers used for PCR and RT-PCR in human cell lines. 
It is sometimes necessary to re-amplify the PCR product by a second step PCR. 
This form of PCR is described as `Semi-Nested' or `Nested PCR' depending on 
whether either primer or both primers are substituted in the second reaction. All 
reactions were carried out using the same conditions as for normal PCR except 
that 2µl of the first step PCR was used as the template. 
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Production of recombinant vector 
FBXL20 cDNA (1200bp) (GenBank accession number: B0007557) was amplified 
from human breast carcinoma MCF-7 cDNA using the forward primer FBL2xhol 
and the reverse FBL2BamH1 that contain restriction sites. PCR products were 
digested and cloned into the XhoI and BamHI sites of the PSG5 vector (4.7kb) 
containing a Flag-tag. Genes cloned into the multiple cloning sites of vectors will 
be expressed as fusions to the C-terminus of Flag if they are in the same reading 
frame as the Flag epitope and there are no intervening stop codons. 
Digestion 
The FBXL20 cDNA and vector DNA were digested with the appropriate 
restriction enzymes in a 2Oµ1 reaction mixture containing up to 5µg DNA, 2µl IOx 
Buffer, 1.0µI (10units) of BamHI and XhoI enzymes, and ddH2O. Incubation for 
1-3h at the appropriate temperature was followed in incubators or PCR cyclers 
with heated leads to minimize evaporation of the sample. Aliquots of each sample 
where then mixed with 5x agarose gel loading buffer containing bromophenol 
blue and run on agarose gels to ensure complete digestion and verify the sizes of 
the fragments. 
Calf intestine alkaline phosphatase treatment 
In order to prevent self-ligation of vector plasmids with compatible sticky ends, 
calf intestine alkalike phosphatase treatment (CIAP) treatment was carried out as 
follows: after restriction enzyme digestion and DNA purification, linearised 
plasmids were eluted in 2Oµ1 of sterile distilled water. 16µl of the elutant, was 
mixed with 20 units of CIAP (Fermentas) and 2 t1 of the lOx dephosphorylation 
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buffer supplied by the manufacturer in a 2Oµ1 reaction mixture. The mixture was 
incubated for 2h at 37°C, followed by agarose gel electrophoresis and DNA 
purification as described above. 
Agarose gel electrophoresis 
One % (w/v) agarose gels were made up with lx Tris-acetate buffer (40mM Tris- 
acetate, 1mM EDTA, pH 8.0) and 1µg of ethidium bromide. Samples were 
electrophoresed by applying a constant current (100V) through the gel. Separated 
DNA fragments were visualised using a UV transilluminator. Where required, the 
DNA fragment from the gel was cut out using a razor blade for subsequent 
purification. 
DNA extraction from agarose gel 
DNA restriction fragments separated on agarose gels were purified using the 
QlAquick Gel Extraction Kit (Qiagen), according to the manufacturer's 
instructions. After agarose separation DNA was viewed with a long wavelength 
ultraviolet emission (UV) transilluminator and the required band cut out using a 
scalpel and transferred to an eppendorf tube. The gel fragment was dissolved by 
adding 3 volumes (per weight of gel slice) of QG buffer (QlAquick spin kit, 
Qiagen) and incubating at 50°C for 10min. The sample was then transferred to a 
QlAquick spin column and microcentrifuged for Imin, after which the DNA in 
the column was washed with 0.75m1 of PE buffer (QlAquick spin kit, Qiagen). 
Residual wash buffer was removed by centrifugation for Imin at full speed. DNA 
was eluted in a microcentrifuge tube by adding 30µl of ddH2O and centrifugation 
for 1 min. 
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Ligation 
Ligation of FBXL20 with the PSG5 vector was performed using T4 DNA ligase. 
This enzyme catalyses the formation of a phosphodiester bond between 
juxtaposed 5' phosphate and 3' hydroxyl termini in duplex DNA or RNA. Vector 
is treated with alkaline phosphatase to remove 5' terminal phosphates so to 
prevent vector from self-ligating. The ligation reaction included 1.0µl lOx T4 
DNA ligase buffer (lx = 50mM Tris-HC1, JOmM MgC12,10mM DTT, 1mM ATP, 
25gg/m1 BSA, pH 7.5), 1. Oµ1 T4 DNA ligase, 1: 3 vector/DNA ratio and ddH2O to 
a final volume of IOld. Samples were incubated at 4°C overnight or for few hours 
at room temperature. 
Transformation 
Sub-cloning efficiency DH5a competent cells (Invitrogen LT, Paisley, UK) were 
used according to manufacturer's protocol. DH5a competent cells were removed 
from -70 °C freezer and defrosted on wet ice. Required number of autoclaved 
1.5m1 microcentrifuge tubes was placed on wet ice. 100µl of competent cells was 
used for each reaction. 5µl of the DNA ligation reaction was added and the 
mixture was incubated on ice for 30min. Cells were then heat-shocked for 45s at 
37°C and then tubes were placed on ice for 2min. 900µ1 of room temperature LB 
Broth was added in each tube and then incubated with shaking at 225rpm for 1h at 
37°C to express kanamycin or ampicillin resistance. Centrifugation at 6000rpm 
for 5min in a microcentrifuge was followed. 900µ1 of the reaction mixture was 
removed and pellet was resuspended with l001L1 LB and spread on LB agar plates. 
Plates were incubated overnight at 37°C. 
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Media and maintenance 
Bacterial Competent cells were grown in either Luria-Bertani (LB) broth or LB 
Agar. LB Agar was made by mixing 37g/L of LB agar pellets (Miller) with 
deionized water and LB Broth was made by mixing 20g/L of LB broth powder 
(Sigma) with deionized water. Autoclaving for 20min at 120°C was folllowed. 
Preparation of plasmid DNA 
- Minipreps 
Individual colonies were picked from the plate using a sterile loop and inoculated 
in 2m1 of selective media containing kanamycin or ampicillin. Further treatment 
varied according to the scale of the plasmid preparation. For "minipreps" (up to 
20µg DNA) the minicultures were incubated overnight at 37°C in a bacterial 
shaker. The QlAprep Spin Miniprep Kit protocol (Qiagen Ltd. ) was used 
according to the manufacturer's protocol. 1.5m] of culture was then transferred to 
an eppendorf tube and centrifuged at 5000rpm for 5min in bench top microfuge. 
Pelleted bacterial cells were resuspended in 250µ1 Buffer P1 (50mM Tris-HC1 pH 
8.0,1 0mM EDTA, 100µg/m1 RNAse A). 250µ1 of buffer P2 (200mM NaOH, 1% 
SDS) was then added and solution was gently inverted 4-6 times to mix. 350µ1 
Buffer N3 (3. OM sodium acetate, pH 5.5) was added and tube was again inverted 
gently 4-6 times. Centrifugation for 10min at 13,000rpm formed a compact white 
pellet. Supernatant was transferred to QlAprep Spin Columns and centrifuged for 
30-60s. Flow-through was discarded and column was washed by adding 0.5m1 
Buffer PE and centrifuging for 30-60s. Flow-through was discarded and 
centrifugation step was repeated to remove residual wash buffer. The QlAprep 
column was then placed in a clean 1.5m1 microcentrifuge tube and the DNA was 
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eluted with 5011 of ddH2O. 
- Maxipreps 
For Maxipreps the Qiagen Hi speed plasmid maxi kit was used. 250m1 of LB 
containing 100µg/ml ampicillin or kanamycin was inoculated with lml of an 8h 
bacteria culture. Cultures were incubated at 37°C overnight with vigorous 
shaking. Bacterial cells were then harvested by centrifugation at 6000x g for 
15min at 4°C. Pellet was resuspended in 10ml Buffer P1(50mM Tris-HC1 pH 8.0, 
10mM EDTA, 100µg/ml RNAse A) followed by addition of 10ml of Buffer P2 
(200mM NaOH, 1% SDS) and 10ml of Buffer P3 (3mM potassium acetate pH 
5.5). The solutions were mixed and lysates were poured into the barrel of the 
QlAfilter Cartridge followed by incubation at room temperature for 10min. The 
solution was added to a previously equilibrated HiSpeed Maxi Tip (by addition of 
10m1 Buffer QBT), washed with 60m1 Buffer QC (1M NaCl, 50mM MOPS pH 
7.0,15% ethanol) and DNA was eluted with 15ml Buffer QF (1.25M NaCl, 
50mM Tris-HCI pH 8.5,15% Ethanol). DNA was precipitated by adding 10.5m1 
isopropanol and incubated at room temperature for 5min. The eluate/isopropanol 
was filtered through a syringe that was attached to QlAprecipitator Maxi Module, 
70% ethanol is added and the QlAprecipitator is removed from the syringe and the 
plunger was removed. Qiaprecipitator was then attached again and the plunger 
was inserted and by pressing air through the QlAprecipitator the membrane was 
dried. QlAprecipitator was then attached to a 5m1 syringe and lml of buffer TE 
(10mM Tris-HCI, 1mM EDTA, pH 8) was added to elute DNA into a collection 
tube. 
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DNA quantification 
The concentration of DNA was measured using a BioRad spectrophotometer 
(Bio-rad Smart SpecTm3000 Spectrophotometer) by measuring the optical density 
(OD) of the samples at 260nm. The formula used to calculate DNA concentration 
was: 1 OD unit at 260nm = 50µg/m1 ddDNA 
DNA sequencing 
Each sequencing reaction was prepared using 3.2pmol of a forward primer or 
reverse primer and 1µg DNA in a total volume of 10µl made up with ddH2O. 
Prepared samples were sent to MRC Genomics Core Laboratory at Imperial 
College London (Hammersmith Hospital Campus) for sequencing. 
Transfection of plasmid DNA 
Transfection is the general process of bringing foreign DNA into cells and 
monitoring protein expression. A liposome-mediated transfection method was 
performed using the Fugene 6 transfection reagent which complexes and 
transports DNA into the cells. Fugene 6 is a proprietary blend of lipids and other 
components supplied in 80% ethanol, sterile filtered and packaged in 
polypropylene tubes. Twenty four hours prior to transfection, 2-3 x 105 cells per 
well of a 6-well plate were plated so that they reached 50-80% confluency on the 
day of transfection. 
For transfection in 6-well plates, containing a monolayer of cells that is 50-80% 
confluent, transfection was made using Fugene 6 (µ1) to DNA (µg) amounts of 3: 1 
respectively. Before Fugene 6 Reagent: DNA complex was added, wells are 
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washed with PBS and medium replaced. Complexes were added directly to cells 
growing in 2m1 media (DMEM 10%FCS) and incubated for 5h after which cells 
were washed again with PBS buffer and fresh medium added. 
Western Blotting or SDS-PAGE 
Cells where harvested and then lysed with Hepes lysis buffer (50. OmM Hepes 
buffer (pH 7.5), IOmM NaCl, 1% Triton-x 100,1% glycerol, 5mM MgCl2,1mM 
EDTA in dH20) containing protease inhibitors [Pepstatin, Leupeptin, Trypsin 
inhibitor, Aprotinin, Na2VO3 (200mM), PMSF (100mM)] for 30min on ice 
followed by centrifugation for 10min at 4°C. Pellets were discarded and 
supernatants transferred in clean tubes. 20µg of protein was mixed with 4x 
Nupage LDS sample and 1µl of 1M DTT. Samples were then boiled for 2min at 
100 °C followed by centirfugation at 8000rpm for 30s. 20µ1 of each sample and 
5µl of marker are loaded on 4-12% gels and transferred onto nitrocellulose or 
PVDF membranes (Hybond P; Amersham Biosciences UK Limited, Little 
Chalfont, UK). Electrophoresis is carried out according to standard protocols. 
Gels were made of a lower resolving gel [0.375M Tris pH8.8, acrylamide, 0.1% 
(w/v) SDS, 0.1% (w/v) APS, 0.1% (v/v) TEMED] and an upper stacking gel 
[0.126M Tris pH6.8, acrylamide, 0.1% (w/v) SDS, 0.1% (w/v) APS, TEMED] 
according to Table 2.2. Samples were run at a constant current of 100V in running 
buffer (25mM Tris-base, 250mM Glycine, 0.1% (w/v) SDS). Then gel and 
apparatus were assembled in the blotting apparatus (Bio-Rad Laboratories Trans- 
Blot cell) and the proteins transfered to the membrane electrophoretically at 
400mA for lh in transfer buffer (24mM Tris, 193mM glycine, 20% v/v 
methanol). Afterwards, non-specific sites were blocked for lh with blocking 
buffer [5% (w/v) non-fat dried milk (Marvel, Premier Brands) in 136 mM NaCl, 
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120 mM Tris (pH 7.6) with 0.05% (v/v) Tween 20 (TBS-T)] at room temperature 
with shaking. Blots were incubated with primary antibody overnight. Membranes 
were washed four times with TBS-T for 15min each and then incubated with 
secondary antibody for 20min with shaking at room temperature. After washing 
again with TBS-T, bands were visualized by enhanced chemiluminescence 
(Supersignal West Pico; Perbio Science UK Ltd., Cheshire, UK). Membranes 
were incubated for 5min with Luminol enhancer solution and then placed in a 
plastic membrane protector, all air bubbles are removed between the blot and the 
surface of the membrane protector before exposure to autoradiography film 
(Kodak BioMax ML-light or MR-1). 
Resolving gel Stacking 
gel 
7% 10% 12% 14% 5% 
dH2O-ml 5.02 4.02 3.35 2.68 3.67 
1.5M Tris pH8.8 2.5 2.5 2.5 2.5 - 
1.5M Tris pH 6.8 - - - - 0.42 
30%Acrylamide/ 
0.8% Bis mix 
(37.5: 1) 
2.33 3.33 4.00 4.67 0.83 
10% SDS -µl 100 100 100 100 50 
25% APS -µl 40 40 40 40 20 
TEMED-µl 10 10 10 10 10 
Total-ml 10 10 10 10 5 
Table 2.2 SDS-PAGE gels 
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Determination of protein concentration 
Protein concentration was determined using the Bio-Rad D, protein assay (Bio- 
Rad Laboratories), as instructed by the manufacturer. The reaction between 
protein and copper in the alkaline solution and the Folin reagent reduced by the 
copper-treated protein leads to color development. 20gl of reagent S was added to 
1 ml of reagent A. 100µl of this mixture were added to 21il of protein solution and 
subsequently mixed with 800µ1 of reagent B. After 15min incubation, absorbance 
was read at 750nm for each of the experimental samples, with protein 
concentrations ranging from 200 gg/ml to 1.0 mg/ml. Protein concentrations were 
determined by the equation absorbance x 25 = µg/µl. 
Antibodies 
The antibodies used were: 
mouse-monoclonal anti-SPI (sc-420, Santa Cruz Biotechnology, Santa Cruz, CA) 
rabbit polyclonal anti- a tubulin (sc-5546 Santa Cruz Biotechnology, Santa Cruz, CA) 
goat polyclonal anti-actin (sc-1615, Santa Cruz Biotechnology, Santa Cruz, CA) 
rabbit polyclonal anti-FoxMl (sc-502, Santa Cruz Biotechnology, Santa Cruz, CA) 
mouse monoclonal anti-p45s'`P2 (32-3300, Zymed S. San Francisco, California, USA) 
rabbit polyclonal anti-HDAC 1 (ab7028; Abcam Ltd., Cambridge, U. K. ) 
goat polyclonal anti-HDAC2 (sc-6296, Santa Cruz Biotechnology, Santa Cruz, CA) 
rabbit polyclonal anti-CUL-1(ab2964, Abcam Ltd., Cambridge, U. K. ) 
rabbit polyclonal anti-ROC-1 (RB-9287-P0, NeoMarkers, Fremont, CA) 
mouse monoclonal anti-p19skp' (P46020, BD Biosciences, Oxford, U. K. ) 
mouse monoclonal anti-FLAG (M2 antibody, F1804, Sigma-Aldrich, Dorset, U. K. ) 
rabbit polyclonal anti-Bim [Y36] (ab32158-100, Abeam Ltd., Cambridge, U. K. ) 
rabbit anti-acetylated-histone 3 (AcH3) (ab9045-50, Abcam Ltd., Cambridge, U. K. ) 
79 
mouse monoclonal anti-p21c"' (sc-6246, Santa Cruz Biotechnology, Santa Cruz, CA) 
rabbit polyclonal anti-Bad (#9292, New England Biolabs, Hitchin, Herts, U. K. ) 
rabbit polyclonal anti-Bax (sc-493, Santa Cruz Biotechnology, Santa Cruz, CA) 
Im munoprecipitation 
Cells were plated in 10cm plates and grown to 60% confluency in the appropriate 
medium and growth conditions. 24h after transfection of the specified 
recombinant vector, cells were harvested and lysed in lml lysis buffer (50mM 
Tris HCI, pH7.4,150mM NaCl, 1 mM EDTA, 1% Triton x 100 containing 
protease inhibitors) as descibed above. One tenth of solution was kept and loaded 
as a control. The lysate was incubated with the indicated antibody for 3h at 4°C on 
an orbital shaker. 30µ1 of the 50% protein G sepharose slurry, which was 
previously washed four times in lysis buffer, was then added to the cell 
lysate/antibody mix and the samples were incubated at 4°C overnight on an orbital 
shaker. Following incubation, the beads were collected by centrifugation at 4°C 
for 30s at 1000rpm in a microcentrifuge and washed 4 times with 1 ml of lysis 
buffer. The beads were then re-suspended in 20µl of loading buffer and boiled for 
5min to dissociate the immuno-complexes from the beads. The beads were 
separated from the loading buffer by centrifugation and the supernatant was then 
loaded onto SDS-PAGE gels for protein fractionation. 
Suhhorhodamine B (SRB) assay 
SRB is a water-soluble dye that binds to the basic amino acids of cellular proteins. 
Thus, colorimetric measurement of the bound dye provides an estimate of the total 
protein mass that is related to the cell number. In this assay, cells were seeded in 
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96 well plates and incubated overnight. The cell number was such that the cells 
reach confluency on the last day of the assay. In this study, 3,000 cells per well 
were used. On the day of harvesting l00µ1 of ice cold 40% trichloroacetic acid 
(TCA) was added to each well for lh at 4 °C. The plate was then washed five 
times with tap water. 100µ1 of 0.4% SRB in 1% acetic acid was then added to 
each well for 1h at room temperature. The plate was washed five times with 1% 
acetic acid and left to air dry at room temperature. On the day of reading the 
plates, bound dye was solubilised by adding l00µ1 of 10mM Tris base and placed 
on a plate shaker for 30min. Absorbance was read on an Anthos 2001 plate reader 
at 492nm. 
Rapid amplification of 5' and 3' cDNA ends PCR (RACE-PCR) 
The GeneRacer kit (Invitrogen LT), which provides a method to obtain unknown 
full-length 5' and 3' ends of genes, was used in this study, according to the 
manufacturer's protocol. It is based on RNA ligase-mediated rapid amplification 
of 5' and 3' cDNA ends (RLM-RACE) and oligo-capping rapid amplification of 
cDNA ends (RACE) methods. The 3' RACE method was used in this work to 
obtain the 3' end of the rat FBL2. 
For amplification of the 3' ends of genes, mRNA was converted to cDNA by 
reverse transcription, using an oligo-dT adapter primer, binding the poly(A)tail of 
mRNAs. Specific cDNAs could then be amplified by using a 5' gene specific 
primer that anneals to known regions of exons and a 3' adapter primer that targets 
the poly(A)tail. A reverse transcription reaction is performed using the 
Superscript III first-strand synthesis system for RT-PCR according to the 
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manufacturer's protocol (Invitrogen LT). In detail, l OnM dNTP, sterile water and 
primers were first mixed and incubated at 65 °C for 5min. This was then mixed 
with 4µl of 5x first strand buffer, 1µl 0.1 M DTT, 1µl RNaseOut (40U/µ1) and 1 µl 
SuperScript III RT (200U/µ1) to a final volume of 2Oµ1 per reaction. The samples 
were incubated at 50°C for 60min followed by a 15min at 70°C inactivation step. 
1 [d RNase H (2U) was then added and the reaction mix was incubated at 37°C for 
20min. Solutions were stored at 20°C or used directly for PCR amplification. 
PCR products were then purified and sent for DNA sequencing. Samples were 
sent for sequencing to MRC Genomics Core Laboratory at Imperial College 
London (Hammersmith Hospital Campus). Each sequencing reaction was 
prepared using 3.2pmol of primer, 30-90ng/lkb DNA in a total volume of l0µ1 
made up with ddH2O. 
RNA interference 
RNA interference (RNAi) is a post-transcriptional process leading to the silencing 
of genes. It is triggered by double-stranded RNA molecules that cause sequence- 
specific mRNA degradation of homologous single-stranded target RNAs and the 
translated products (Tuschl and Borkhardt, 2002). RNAi is initiated by the 
conversion of dsRNA into 21-23 nucleotide fragments by the RNase III enzyme, 
Dicer. These short RNAs are called small interfering RNAs (siRNAs), containing 
two nucleotide single-stranded overhangs at the 3' end and bearing 5'- 
monophosphate and 3'- hydroxyl groups which are crucial for the degradation of 
target RNAs complementary to the siRNA sequence. siRNAs are incorporated 
into the RNA-induced silencing complex (RISC), in an ATP-dependent step or 
series of steps during which the siRNA duplex is unwound into single strands. 
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The resulting single-stranded siRNA is proposed to guide the RISC to recognize 
and cleave the target RNA without requirement of other nucleotide cofactors 
(Schwarz et al., 2002). 
In this study, genes were silenced using the SMARTpool TM Product Insert- 
Version 2.0 (DHARMACON, RNA technologies). The SMARTpool siRNAs 
used were: siFBXL20 (M-015029-00), siFoxMl (M-009762-00), siSkp2 (M- 
003324-04), siHDACI (M-003493-02), siHDAC2 (M-003495-02), siBim (M- 
004383-02). Oligofectamine (Invitrogen LT) was used as the transfection reagent. 
200,000 cells per well of a 6-well plate, were plated 24h prior to transfection. For 
each well, 70µ1 of OPTIMEN, was mixed with 51il oligofectamine and incubated 
at room temperature for 10min. This solution was then mixed with 250µl 
Optimem and 7.5µ1 (50nM final concentration) siRNA oligos specific for each 
gene. After 25min incubation, 16011 OPTIMEM was added to each mixture, 
reaching a final volume of 500µ1, which was then added to the wells that have 
been previously washed with warmed PBS. The final concentration of siRNA 
oligos in each well was 50nM. After 4h of incubation 2m1 of DMEM containing 
10%FCS was added to each well. 
As a control reaction for the experiment, cells were subjected to transfection with 
the lx Universal Buffer (Mock) (without any siRNA added), in order to detect 
cellular effects caused by the transfection event or delivery process. As another 
control, cells were also transfected with a non-specific (NSC) siRNA (D-001210- 
01-05, Dharmacon) in order to detect off-target effects caused by the introduction 
of any siRNA. These siRNAs have an impaired ability to be processed by RISC 
83 
and share little or no homology with known mRNA targets in the cell. It is a more 
biologically relevant control than the Mock transfection control, as NSC siRNAs 
are expected to have similar properties such as charge density and molecular 
weight. Their effects in the cell, if any, may be through non-RNAi pathways and 
for this reason may be used to check for general side effects associated with 
siRNA delivery. 
RNA extraction 
Total RNA was prepared by harvesting cells and extracted by guanidine 
isothiocyanate lysis followed by silica gel membrane purification (RNeasy kit, 
Qiagen Ltd., West Sussex, U. K. ). Cells were disrupted by adding buffer RLT 
(Qiagen) containing 10% ß-mercaptoethanol. Samples were homogenized, and 1 
volume of 70% ethanol was added. 700gl of the sample was added to an RNeasy 
mini-column placed in a 2m1 collection tube and centrifuged at 10,000rpm for 15s 
in a microcentrifuge. Flow-through was discarded and 700111 of buffer RW 1 
(Qiagen) was added followed by centrifugation for 15s at 10,000rpm. Flow- 
through was again discarded. ' The RNeasy column was transferred to a new 
collection tube and 5001l RPE (Qiagen) buffer was added. The centrifugation step 
was repeated again. Another 500µ1 RPE was added followed by centrifugation at 
10,000rpm for 2min. The RNeasy column was then transferred 'to a new collection 
tube, 50µ1 RNase free water was added and centrifuged at 10,000rpm for 1min to 
elute RNA. The concentration and purity of RNA were determined by measuring 
the spectrophotometric absorption at 260nm and 280nm. 
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Real-time Quantitative PCR (RT-QPCR) 
Total RNA from samples was extracted using the RNeasy kit as explained above. 
RNA was then converted to cDNA using the Superscript III First-strand synthesis 
system for RT-PCR' (Invitrogen LT) as described above. Real time PCR was 
performed with ABI PRISMO 7700 Sequence Detection System using 2x SYBR 
Green Mastermix (Applied Biosystems) according to manufacturer's instructions. 
One minute annealing at 60°C was used for 40 cycles. Gene-specific primer pairs 
were designed using the ABI Primer Express software. Primers were designed so 
that they produce a fragment of 50-150bp. When possible, primers spanned 
intron/exon boundaries to avoid amplification of contaminating genomic DNA. 
The primers used are listed in Table 2.3. Analysis was performed using the 
relative standard curve method. For the standard curve, 1-2µg cDNA from each 
sample was mixed and diluted 1: 2 and then 1: 4 for four serial dilutions. As a 
control, primers for the L19 ribosomal housekeeping protein were used to 
normalize input RNA. The samples were diluted 1 in 4 and 21LI from each was 
used per reaction. The reaction mix also contained 231il of SYBR Master Mix and 
the appropriate amount of primers which have been previously optimized, to a 
final volume of 2S11. All measurements were performed in triplicates. The 
TAQMAN 7700 Real-time PCR machine was used. Efficiency of PCR was 
obtained from the slope of the standard curve (Eff = 10(-1/slope) -1). 90-110% 
was expected with optimal primers with slope between -3.1 and -3.6. 
Primer optimisation 
Each primer set was optimized with IOng cDNA standard to determine the 
minimum concentration required for maximum yield and minimum non-specific 
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amplification. Dilutions of 50-900nM forward and reverse primers (table 2.4) 
were tested with different combination (table 2.3). The concentration that gave the 
lowest Ct value with standard DNA and highest with water was used in further 
experiments. Specificity of PCR product was confirmed by agarose gel 
electrophoresis. The concentrations of primers used to amplify FoxMl and L19 
were optimized by Dr. Rosaline Hui and Dr. Demetra Constantinidou. 
Forward Primer 
Reverse 
primer 
SOnM 300nM 900nM 
5OnM 50150 300/50 900150 
300nM 50/300 300/300 9001300 
900nM 50/900 3001900 9001900 
Table 2.3 Combination of different primer concentrations 
The concentrations of primers used were: 
For L19: 900nM Forward primer /300nM Reverse primer 
For FoxMl: 300nM Forward primer /900nM Reverse primer 
For Bim: 300nM Forward primer/900nM Reverse Primer 
For FBXL20, Skp2, HDACI, HDAC2: 300nM Forward primer/300nM Reverse 
primer. 
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RT-QPCR 
PRIMER 
SEQUENCE (5'-3') GENE 
FoxMl-F TGCAGCTAGGGATGTGAATCTTC FoxMl 
FoxMl-R GGAGCCCAGTCCATCAGAACT FoxMl 
FBXL20-F GGATATTGAGGGCCGAGTAGTG FBXL20 
FBXL20-R AAGCCCCCACATCGTTTTG FBXL20 
Skp2-F AAACCTGGGCCACCCG Skp2 
Skp2-R TTGTCACTCCCTTTGCTCTTCA Skp2, 
L19-F GCGGAAGGGTACAGCCAAT L19 
L19-R GCAGCCGGCGCAAA L19 
Bim-F CACAAAACCCCAAGTCCTCCTT Bim 
Bim-R . TTCAGCCTGCCTCATGGAA 
Bim 
HDAC1-F CGATGAGGACGAAGACGACC HDACJ 
HDAC1-R TCACAGGCAATTCGTTTGTCA HDACI 
HDAC2-F I TTGGAGGAGGTGGCTACACAA 
HDAC2-R IACAATCAAGGGCAACTGCAGT 
Table 2.4 RT-QPCR primer sequences 
Pronidium Iodide (PI) staining and FACS (cell cycle) analysis 
u LMLL 
HDAC2 
Cells were treated as indicated. Floating and adherent cells were collected by 
centrifugation and washed with PBS. Cells were resuspended in 10% PBS with 
90% ethanol and stored at -20°C. On the day of analysis, samples were 
centrifuged to remove ethanol and stained by resuspension in PBS containing 
propidium iodide (final concentration of PI: 50µg/ml) and RNase A (5µg/m1) for 
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30min at 4°C. The cell suspension was subsequently passed through a 0.6 mm 
bore needle in order to generate single cell `suspensions and samples were then 
analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK) 
using the FACSDivaTM (BD Biosciences) acquisition software. Graphs represent 
the percentage of cells (Y-axis) in each phase of the cell cycle determined by their 
DNA contents (X-axis). Data were acquired using a minimum of 10,000 single 
cells defined by a dot plot of PI width versus PI area. 
Sub-cellular fractionation 
The NE-PER nuclear-cytoplasmic kit (Perbio, Erembodegem, Belgium) was used 
to separate and prepare cytoplasmic and nuclear extracts from asynchronously 
growing human breast cancer cells, according to the manufacturer's instructions. 
Fistly, the two reagents named CERI and CERII were added to the cell pellet, 
causing distruption of the cell membrane and release of cytoplasmic contents. 
After recovering the intact nuclei from the cytoplasmic extract by centrifugation, 
the nuclei were lysed with another reagent named NER to yield the nuclear 
extract. The protease inhibitors mentioned above, were firstly added to the 
reagents CERI and NER before addition to the pellets. 
Alternatively, cytoplasmic, membrane/organelle and nuclear fractions were 
prepared using a ProteoExtract® Subcellular Proteome Extraction Kit 
(Calbiochem, V WR International Ltd., Lutterworth, United Kingdom) according 
to the manufacturer's instructions. 
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Extracts were then used for immunoblot analysis. The purity of the cytoplasmic 
fraction was analysed by immunoblotting with the antibody against tubulin and 
the nuclear lysate with an antibody against Sp I. 
Fluorescence microscopy 
MCF-7 cells were plated on coverslips and transfected with FBXL20-GFP 
(obtained from RZPD, Berlin, Germany) or GFP alone. 24h later, coverslips were 
washed gently with PBS and fixed in methanol for. 5min. The cells were 
subsequently mounted in Vectashield, mounting medium containing 4', 6'- 
diamidino-2-phenylindole dihydrochloride (DAPD (Vector Laboratories Ltd., 
Peterborough, UK) to counterstain DNA and analyzed using a fluorescence 
microscope. 
Immunofluorescent cytochemical staining 
Cells were grown on coverslips and transfected with Flag-FBXL20 with Fugene 6 
as described above. 24h later cells were washed with PBS and then fixed with 
PBS containing 4% paraformaldehyde for 15min at room temperature (RD. Cells 
were then washed four times with PBS for 5min each. PBS was removed and cells 
were permeabilized by incubation with 0.25% Triton x-100 in PBS for 30min at 
RT. Cells were washed again with PBS for 10min followed by blocking by 
incubation with 10% BSA blocking solution for 30min at RT. Antibody for 
phaloidin that stains the actin filaments, in blocking solution was then added for 
lh. The monoclonal anti-Flag antibody (200µg/ml), in blocking solution was then 
added in order to bind to the Flag-FBXL20 in the cells for lh followed by washes 
with PBS. Secondary antibody anti-mouse FITC conjugate in blocking solution 
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was added and incubated for 45min. Cells were again washed with PBS and then 
stained with DAPI for 3-4 min to identify the nuclei. Coverslips were put on 
microscope slides and examined by fluorescent microscopy. 
HDAC Fluorimetric Assay 
The HDAC Fluorimetric Assay/Drug Discovery Kit (AK-500, " Biomol 
International) was used according to the manufacturer's instructions. This assay is 
designed to measured HDAC activity in cells. It is based on the Fluor de Lys 
(Fluorogenic Histone deAcetylase j1 Substrate/Developer) substrate and 
developer combination. The Fluor de Lys substrate comprises an acetylated lysine 
side chain which is incubated with a sample containing HDAC activity. 
Deacetylation of the substrate sensitizes the substrate so that after the addition of 
the Fluor de Lys developer there is production of a fluorophore. During 
measurement, a microplate fluorimeter (Fluorskan Ascent FL from Thermofisher 
UK) was used capable of excitation at a wavelength in the range of 350-380nm 
and detection of emitted light in the range 440-460nm. 
Firstly, compounds diluted in the provided assay buffer are added to the wells in a 
final volume of IOµ1. The HeLa nuclear extract, which was used as the source of 
HDAC activity, was then added to all wells except those that were used as "no 
enzyme controls" in a volume of 1511. The Fluor de Lys substrate and the samples 
in the plate were equilibrated to assay temperature of 25 °C. HDAC reactions were 
then initiated by the addition of 25gl of the diluted substrate in each well and 
incubated for 20min. Reactions were stopped by adding the Fluor de Lys 
developer (50µ1) and incubated at room temperature for 10-15min. Samples were 
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then read in the fluorimeter. As a positive control, the HDAC inhibitor TSA was 
used at 1 µM concentration. 
'Muwt de 
Sample Assay HeLa Inhibitor &P Tý 
Buffer Extract (5x) Substrate 
(Dilution) (2x) 
Blank 25 pi 0 0 25 pl 
(No Enzyme) 
Control 10 PI 15p1 0 25 N1 
Trichostatin A 0 15 pi 10 l 25 pi 
Test Sample 0 15 pi 10 I 25 pl 
Table 2.5 From Biomol Internation LT instruction manual 
Statistical tests 
The concentration of the compounds that inhibited cell proliferation by 50% 
(IC50)) was determined graphically in each case with nonlinear regression 
analysis to fit data to the appropriate dose-response curve (GraphPad Prism 
version 4.0; Graph- Pad Software Inc., San Diego, CA). The Mann-Whitney test, 
is a nonparametric test that compares sums of ranks. One- way ANOVA was 
followed by Dunnet's or Bonferrroni test. Dunnett's test was used when one 
column represented control data and wanted to compare all other columns to that 
control column but not to each other. Bonferroni test was used for selected pairs 
of columns when wanted to compare certain column pairs. Ap value of less than 
0.05 was considered significant. 
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CHAPTER III 
CHARACTERISATION OF FBXL20 
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111.1 BACKGROUND AND OBJECTIVES 
FBXL20 (F-Box/Leucine-rich repeat protein 20) belongs to the F-Box group of 
proteins that are mainly involved in targeting proteins for ubiquitin- dependent 
degradation by the proteasome. In doing so, they form part of a complex, such as 
the SCF complex that consists of a cullin family member of proteins, a: ROC ring 
finger protein and the Skpl protein. An example of a F-Box protein is the well 
known Skp2 protein, which has been shown to be responsible for the degradation 
of the cell cycle inhibitor p27K'p'(Carrano et al., 1999). Similarly to Skp2, the N- 
terminal of FBXL20 contains an F-box domain that binds Skpl, whilst the C- 
terminus contains LRR repeats that bind target proteins. The rat FBXL20 
homologue FBL2 was shown to interact with Skpl suggesting a possible role for 
FBL2 in the ubiquitin-dependent proteasomal degradation of target proteins (Iliyn 
et al, 1999). In contrast to Skp2, FBL2 localised in the cytoplasm of rat liver 
epithelial cells and its expression increases in growth-arrested cells, indicating 
that although both proteins bind Skpl and are structurally related, they probably 
have different cellular functions (Ilyin et al., 1999). Additionally, Skp2 has been 
shown to be transcriptionally regulated by the FoxMl transcription factor (Wang 
et al, 2005). The first aim of this project was to characterize the novel FBXL20 F- 
Box protein in human cells. 
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111.2 RESULTS 
Analysis of the FBXL20 DNA sequence 
A GenBank search for the gene encoding the human FBXL20 (GenBank 
Accession number B0007557), revealed that this gene is located on chromosome 
17. Comparison of the human FBXL20 cDNA sequence to the human genome 
allowed the exon/intron organisation of the FBXL20 gene to be determined 
(Fig. 3.1). Ilyin et al. (1999) working on FBL2 in rat hepatocyte cells performed 
experiments using only part of the gene observed in human cells. Comparing the 
sequences between different species it was observed that FBXL20 is very similar 
in all species (Fig. 3.2A) and human FBXL20 is very similar to the human Skp2 F- 
Box protein (Fig. 3.2B). Comparative analysis of the FBXL20 amino acid 
sequence showed very high levels of homology with the rat counterpart (more 
than 99% identity); however, mutations or polymorphisms have created a stop 
codon in the end of exon 10 thereby producing a truncated protein (Fig. 3.1). A 
Blast search for the full-length human FBXL20 sequence in the rat genome 
revealed that the whole gene exists in the rat cells but it is not expressing a full- 
length protein. In order to identify the unknown 3' untranslated region of the rat 
FBL2, the 3'-Race technique was performed and sequencing results using the 
primers FBL216-F (5'-tttccagagggacattgagg-3') FBL721-F (5'- 
accatatgcagagggtgtca-3) showed that there is a poly-A-tail after the 10th exon in 
RAT-1 cells (Fig. 3.4). 
Utilising genome DNA extracted from the human MCF-7 breast cancer cell line, 
the full length FBXL20 gene was amplified using the FailSafe PCR kit with the 
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FBL2ORF2-F and FBL2ORF-R primers. Interestingly, when using the 
FBL2ORF2-F forward primer and the reverse FBL2-R located in the middle of 
the FBXL20 cDNA, two bands were detected on a 1% agarose gel (Fig. 3.1C). 
Both bands were gel extracted and sequenced. Sequencing results indicated a 
novel splice variant of FBXL20 lacking exon 7 exists, which was submitted to 
GenBank (Accession number DQ223959). When the primers FBL2-F (in exon 7) 
and FBL2-R were used in a PCR reaction, only the full-length FBXL20 band was 
detected. The forward primer FBL2-F was binding a region in exon 7 and 
therefore only the full length transcript can be amplified since the splice variant 
lacks exon 7. However, the open reading frame downstream of the deletion is the 
same as the full-length FBXL20 cDNA. Identification of the position of the splice 
donor and acceptor sites was performed using the Blast program. Analysis of the 
amino acid sequence showed that in addition to the F-box motif located at the N- 
terminal region, 12 LRR repeats (Fig. 3.3) (LxxLxLxxN/CxL)(Kajava et al., 1995) 
were also found in the C-terminal half of the protein. 
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5' 3intron 
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Figure 3.1 FBXL20 gene organisation. A) Representation of the exon-intros 
organisation of the FB. XL 20 gene. B) Representation of the hill length FB. VL 20 in 
contrast to its splice variant and the rat homolog FBL2. C) RNA extraction 
followed by RT-PCR analysis of MCF-7 cells using primers 1) FBL2ORF2-F and 
FBL2-R and 2) FBL2-F and FBL2-R. 
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Figure 3.2 Comparison of FBXL20 protein sequences between species (A) 
and with Skp2 (B). Sequences were obatiend from Genbank with Accession 
numbers: Rat FBXL20 NM_022272, Bos Taurus FBXL20 NM 001035096, 
Human FBXL20 B0007557, Mus musculus FBXL20 NM_028149, Human Skp2 
NM_005983. In-color alignments were compiled using the BioEdit programme. 
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A) 
RRDVNGVTKSRFEMFSNSDEAVINKNLPKELLLRIFSFLDVVT 
LCRCAQVSRAWNVLALDGSNWQRIDLFDFQRDIEGRVVENISKRCGGFLRKLSLRGCL 
GVGDNALRTFAQNCRNIEVLNLNGCTKTTDATCTSLSKFCSKLRHLDLASCTSITNMS 
LKALSEGCPLLEQLNISWCDQVTKDGIQALVRGCGGLKALFLKGCTQLEDEALKYIGA 
HCPELVTLNLQTCLQITDEGLITICRGCHKLQSLCASGCSNITDAILNALGQNCPRLR 
ILEVARCSQLTDVGFTTLARNCHELEKMDLEECVQITDSTLIQLSIHCPRLQVLSLSH 
CELITDDGIRHLGNGACAHDQLEVIELDNCPLITDASLEHLKSCHSLERIELYDCQQI 
TRAGIKRLRTHLPNIKVHAYFAPVTPPPSVGGSRQRFCRCCIIL 
B) 
Nlethionine F-Box LLR repeats CAAX domain 
96 LSLRGCLGVGDNALRTFAQNCRNIEV 
122 LNLNGCTKTTDATCTSLSKFCSKLRH 
148 LDLASCTSITNMSLKALSEGCPLLEQ 
174 LNISWCDQVTKDGIQALVRGCGGLKA 
200 LFLKGCTQLEDEALKYIGAHCPELVT 
226 LNLQTCLQITDEGLITICRGCHKLQS 
252 LCASGCSNITDAILNALGQNCPRLRI 
278 LEVARCSQLTDVGFTTLARNCHELEKMD 
308 LEECVQITDSTLIQLSIHCPRLQVLS 
334 LSHCELITDDGIRHLGNGACAHDQLEVIE 
363 LDNCPLITDASLEHLKSCHSLERIE 
388 LYDCQQITRAGIKRLRTHLPNIK 
Figure 3.3 FBXL20 contains an F-Box, 12 LRR repeats and a CAAX domain. 
A) Amino acid sequence of FBXL20 (B0005757) B) The LRR consensus 
sequence (LxxLxLxxN/CxL) was used to find LRRs in the FBXL20 protein. 
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atgaggagggacgtgaacggagtgaccaagagcaggtttgagatgttctcaaacagtgacgaagccgtaatcaataaa 
aaacttcccaaagaactcctgctaaggatattttctttcctggatgttgttaccctttgtcgctgtgctcaggtctccagggcc 
tggaatgtcctagctctggatggcagtaactggcaacggatagacctgttcgatttccagagggacattgagggccggg 
tagtggaaaatatttctaaacgatgcggaggctttttacggaagttaagtcttcgtgggtgtctcggagtaggagacaatgc 
actgaggacctttgcacaaaactgtaggaatattgaagtactaagtctcaacggatgtacaaagacgacagacgccacct 
gcactagccttagcaagttctgctccaaactcaggcacctcgacctggcttcctgtacgtcaataacaaacatgtctctcaa 
agctctgagtgagggctgtccactgttggagcagttgaacatctcctggtgtgaccaagtaaccaaggatggcattcaag 
cactagtgagaggctgtgggggtctcaaggccttattcttaaaaggctgcactcagctagaagatgaagctctcaagtac 
ataggtgca. cactgccctgagctggtgactttgaacttgcaaacttgcttacaaatcacagatgaaggcctcatcaccatat 
gcagagggtgtcataagttgcagtctctctgtgcctctgggtgctccaacatcacagatgccatcctgaatgctctaggtc 
agaactgccctcggcttaggtaaacgtgtttatttagctcaaaaaaaaaaaaaaaaaaaaaaaaa 
Figure 3.4 Sequence of the Rat FBL2. FBL2 has a stop codon at the end of exon 
10 followed by a poly(A)tail underlined, determined by 3' RACE as described in 
the materials and methods section. 
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FBXL20 is expressed in a variety of cancer cell lines 
To gain an insight into the possible role of FBXL20, a comparative expression 
analysis among different cancer cell lines was performed. A commercially 
available human cancer cell line cDNA panel (BD Biosciences), was used in a 
PCR amplification reaction using primers FBL2-F and FBL2-R, which detected 
FBXL20 in all cell lines (Fig. 3.5). 
FBXL20 is expressed at higher levels in growth arrested compared to 
proliferating cells 
The expression of F-Box proteins similar to FBXL20, such as Skp2, has been 
shown to be cell cycle-dependent. In order to investigate whether the expression 
pattern of FBXL20 is cell cycle-dependent, MCF-7 cells were synchronised by 
serum starvation overnight and then RNA extracted and analysed by RT-QPCR. 
Cell cycle analysis confirmed that cells were synchronised and that the cells 
entered S phase after 16 hours of addition of media containing serum (Fig. 3.6A). 
Results showed that FBXL20 niRNA expression was maximal when cells were 
arrested (0h) and significantly decreased upon entry into the cell cycle and 
remained low throughout it. Primers against FoxMl were used as a control since 
FoxMl levels are known to increase after entry into the S phase (Fig. 3.6B). 
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Figure 3.5 FBAL20 is expressed in a variety of cancer cell lines. cDNA from 
human cancer cell lines were used in PCR reactions to amplify FBXL20 using 
specific primers. GAPDH was used as a loading control. 
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Figure 3.6 FBXL20 mRNA expression is increased in growth arrested cells. 
MCF-7 cells were synchronised overnight by serum starvation in a phenol red free 
medium containing 0.5% DSS, followed by re-entry into the cell cycle after serum 
addition (0h). Cells were harvested at the indicated times for A) FACS analysis, 
B) RT-QPCR Graphs show FoxMl mRNA levels normalised by L19 mRNA, and 
FBXL20 mRNA levels normalised by L19 mRNA levels. Results represent the 
mean ± SD of three individual experiments. Statistical analysis was performed 
using ANOVA with Dunnett's post-hoc analysis for all time points compared to 
control (0 hr) and *p<0.05. . 
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FBXL20 is localised in the cytoplasm and mainly concentrated around the 
nucleus of MCF-7 cells 
FBXL20 has a CAAX domain in its C-terminus, which has been shown to target 
proteins, such as FBL2, to the membrane (Wang et al. 2005). In order to test if 
FBXL20 is localised in the membrane, a sub-cellular fractionation kit was used to 
separate the nucleus, cytoplasm and membrane fractions of cells. MCF-7 cells, 
were transfected with Flag-FBXL20 and subsequent SDS-PAGE analysis showed 
that the exogenous FBXL20 was only expressed in the cytoplasmic fraction (Fig. 
3.7A). In order to confirm efficient separation of fractions, antibodies against the 
membrane protein HSP60, the nuclear SP1 and the cytoplasmic tubulin were used. 
HSP60 was located in the membrane fraction, SP I was located in the nuclear 
fraction and Tubulin was in the cytoplasmic fraction. 
In order to examine the subcellular localisation of FBXL20 in MCF-7 cells, it was 
expressed as a GFP fusion protein for 24h, counterstained with DAPI (nuclear 
stain) and visualized by fluorescence microscopy. The control cells were 
transfected with pEGFP-C2 empty vector. FBXL20-GFP was localised in the 
cytoplasm, with higher intensity around the nuclei (Fig. 3.7B). This was also 
confirmed by transfecting with Flag-FBXL20 and staining with an anti-Flag 
antibody. Phalloidin detected the actin filaments and DAPI stained the nuclei. 
Consistently, fluorescence microscopy revealed Flag-FBXL20 localisation in the 
cytoplasm, concentrated mainly around the nuclei. Control (not transfected with 
Flag-FBXL20) cells display a regular distribution of F-actin, with strong staining 
around cell periphery and in cytoplasm (Fig. 3.7C). 
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Figure 3.7 FBXL20 is localised in the cytoplasm of MCF-7 cells concentrated 
mainly around the nuclei. A) Nuclear, cytoplasmic and membrane fractions 
were separated. Cell lysates were separated by SDS-PAGE and immunoblot 
analysis was done using the indicated antibodies Immunoblots against Tubulin 
(cytoplasm), SPI (nuclear) and Hsp60 (membrane) served to ensure efficient 
subcellular fractionation. B) Fluorescence microscope images of FBXL20-GFP 
localisation (in green) in respect to DAPI (in blue) in MCF-7 cells. Cells were 
transfected with an empty GFP vector or FBXL20-GFP and 24h later were fixed 
in methanol, counterstained with DAPI and visualised by Fluorescent microscopy. 
C) Fluorescence microscope images of FBXL20 localisation (in green) in respect 
to F-actin (in red) and DAPI (in blue) in MCF-7 cells. Cells were transfected with 
Flag-FBXL20 and control cells remained untransfected. 24h later, cells were 
subjected to immunofluorescent cytochemical staining, using an anti-Flag 
mococlonal antibody and phalloidin, as described in the materials and methods 
section. 
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FBXL20 is part of a SCF complex 
The presence of the F-box domain in FBXL20 led me to investigate whether this 
protein could bind the components of the SCF complex, Skp 1, CUL-1 and ROC- 
1, and be part of a novel SCF-complex. Similar proteins like Skp2, and other F- 
Box proteins such as FBXO31 (Kumar et al., 2005), have been demonstrated to 
bind all three components. MCF-7 cells were transiently transfected with Flag- 
FBXL20, myc-ROC-1 (kind gift from Prof. Xiong) or both. Subsequent 
immunoprecipitation (IP) with a monoclonal anti-Flag antibody, followed by 
sequential immunoblotting with monoclonal anti-Flag and anti-Skpl antibodies, 
revealed that FBXL20 binds Skpl (Fig. 3.8). The other members of the SCF- 
complex, CUL-1 and ROC-1, were also shown to bind FBXL20. IP using the anti- 
Flag antibody in untransfected cells did not precipitate any protein (Fig. 3.8). 
These results together suggested that FBXL20 forms a SCF complex and is 
potentially a novel E3 ligase. 
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Figure 3.8 FBXL20 is part of a SCF complex. MCF-7 cells were transfected 
with Flag-FBXL20 or myc-ROC- I or the combination and harvested 24h later. 
Whole cell extracts were prepared in lysis buffer and immuprecipitations (IP) 
were performed using an anti-Flag antibody as described in materials and 
methods. The IP samples along with samples from the whole cell lysates were 
then analysed by SDS-PAGE and immunoblotted with anti-Flag, anti-Skpl, anti- 
ROC-1 and anti-CUL-1 antibodies. Results are representative of 3 individual 
experiments. 
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Silencing FBXL20 induces Skp2 protein expression 
As seen in other studies (Ilyin et al., 1999), Skp2 and FBXL20 are structurally 
similar proteins, but have different substrate specificities and thus regulate 
different proteins and have different functions. siRNA technology was used to 
silence FBXL20 and subsequent immunoblot analysis revealed that when FJ3XI. 20 
was silenced, the protein expression of Skp2 was increased (Fig. 3.9). However, 
when Skp2 was silenced, the levels of FRXI, 20 mRNA were not significantly 
increased (Fig. 3.10). Once again the protein levels of FBXL20 could not be 
examined as the antibody against FBXL20 was not able to detect the protein by 
immunoblotting. 
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Figure 3.9 Knockdown of FBAL20 induces the mRNA and protein expression 
of Skp2. Cells were transfected with siRNA against FBXL20 and harvested 72h 
later. A) Lysates were analysed by SDS-PAGE. Immunoblot analysis was 
performed using the anti-Skp2 antibody. Actin was used as a loading control. 
Results are representative of three individual experiments. B) Results represent 
the average protein concetration of Skp2 from three individual experiments 
normalised by actin protein levels. Statistical analysis was performed using the 
Mann-Witney U test and *p<0.05 (NS = no significant change). C) RNA was 
extracted and reverse transcribed and cDNA was analysed by RT-QPCR. Results 
show the levels of FBXL20 mRNA normalised by L19 mRNA levels. 
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Figure 3.10 Silencing Skp2 does not significantly induce the expression of 
FBXL20 mRNA. Cells were transfected with siRNA against Skp2 and harvested 
72h later. RNA extraction and cDNA synthesis was followed and finally analysed 
by RT-QPCR. Graph shows the levels of FBXL20 and Skp2 mRNA normalised by 
L19 mRNA levels. Results represent the average ± SD of three independent 
experiments. Statistical analysis was performed using the Mann-Witney U test 
*p<0.05. 
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FoiM1 does not regulate the transcription of FBAL20 
The transcription factor FoxMl has been shown to regulate the transcription of 
Skp2 (Wang et al., 2005). This suggests that the FoxMl transcription factor may 
regulate the mRNA expression of FBXL20 as well. In order to test this, siRNA 
pools targeting FoxMl was used to knockdown FoxMl in MCF-7 cells and then 
protein and mRNA expression were analysed by SDS-PAGE and RT-QPCR. 
Immunoblot analysis confirmed the FoxMI knockdown and revealed that Skp2 
expression is decreased upon silencing FoxMl. RT-QPCR analysis showed that 
knockdown of FoxMl leads to a significant downregulation of Skp2 mRNA levels 
(p<0.05) but does not significantly affect the FBXL20 mRNA (p>0.05), 
suggesting that in contrast to Skp2, FoxMl does not regulate the transcription of 
FBXL20 (Fig. 3.11). 
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Figure 3.11 FoxMl regulates Skp2 but not FBXL20. Cells were transfected 
with siRNA against FoxMl and harvested 72h later. A) Lysates were analysed by 
SDS-PAGE and immunoblotting analysis was performed with antibodies against 
Skp2 and FoxMl. Tubulin is used as a loading control. Results are representative 
of three independent experiments. B) cDNA was synthesised and analysed by RT- 
QPCR. Graph shows the levels of FBXL20, FoxMl and Skp2 mRNA normalised 
by L19 mRNA levels. Results represent the average ± SD of three independent 
experiments. Statistical analysis was performed using the Mann-Witney U test 
*p<0.05 
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M. 3 DISCUSSION 
In this study, the novel FBXL20 F-Box protein was characterised in the MCF-7 
cancer cell line. Sequence analysis revealed that it has 12 LRR repeats that are 
known to be responsible for recognising and binding target proteins. Furthermore, 
FBXL20 in human cells appears to have a splice variant. This transcript appears to 
lack the exon 7 of the full-length gene, but this deletion does not change the 
reading frame of the remaining protein. FBL2 splice variants have also been 
detected in the rat cells (Ilyin et al, 1999). 
Comparison of the FBXL20 protein sequence between species showed that 
FBXL20 is conserved among species. However, the rat expresses only a partial 
protein compared with that found in humans. Possibly, a mutation in the last 
codon of exon 10 creates a stop codon, which leads to the production of a 
truncated protein. Therefore, as the full length protein is expressed in humans and 
only the truncated protein in the rat, this suggests that human FBXL20 may bind 
different proteins and have different functions than its rat homolog, since the rat 
does not express all the LRR repeats found in the human FBXL20. 
PCR analysis using cDNA from different cancer cell lines showed that FBXL20 
mRNA appeared to be expressed ubiquitously. Also, as seen with the homolog 
FBL2 in rat cells (Ilyin et al., 1999), FBXL20 was mostly expressed in growth 
arrested cells rather than proliferating cells. This implies that it negatively 
regulates proteins that promote growth. 
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This study also showed that FBXL20 is localised within' the cytoplasm, 
predominantly around the nucleus of MCF-7 mammalian breast cancer cells as 
has been seen with FBL2 in rat cells. Subcellular fractionation followed by 
immunoblot analyses indicated that Flag-FBXL20 recombinant protein is 
localised within the cytoplasm. Fluorescence microscopy studies on cells 
expressing FBXL20-GFP confirmed this result and also revealed that FBXL20 is 
mainly concentrated around the nucleus of MCF-7 cells. Furthermore, 
immunofluorescent cytochemical staining of cells expressing the Flag-FBXL20 
recombinant vector was also used to provide further evidence of the FBXL20 
perinuclear localisation. FBXL20 is targeted to the perinuclear compartment by 
yet unidentified proteins. 
Based on its similarity to other SCF based E3-ligases and its reported interaction 
with Skpl in the rat cells (Ilyin et., 1999), it is possible that FBXL20 is part of a 
novel SCF complex. Immunoprecipitation experiments showed that FBXL20 in 
human cells binds Skpl, ROC-1 and CUL-1, suggesting that FBXL20 forms the 
classic tetrameric SCF complex. 
Interestingly this study showed that when FBXL20 is silenced, the expression of 
Skp2 protein is increased. FBXL20 is very similar in sequence and structure to 
Skp2 but they differ in their functions. Expression of Skp2 is known to be 
increased during S phase of the cell cycle (Ang and Wade Harper, 2005). It is 
localised in the nucleus and is strongly expressed in proliferating cells and 
downregulated in growth arrested cells. In contrast, my results show FBXL20 to 
be preferentially expressed in growth-arrested cells and detected in the cytoplasm. 
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These two proteins seem to exert different functions and bind different substrates. 
Skp2 is known to target cyclin E and the CDK inhibitor p27K'pl for ubiquitination 
and subsequent degradation (Carrano et al., 1999; Sutterluty et al., 1999; Zhang et 
al., 1995). However, FBXL20 does not appear to have the same functions. 
Therefore, the inverse relationship between Skp2 and FBXL20 could be cell cycle 
phase mediated. Silencing Skp2 expression leads to a G1/S arrest by inducing the 
expression of p27K'" and p21' '. This arrest can result in the upregulation of 
FBXL20 levels since FBXL20 appears to be ovexpressed in arrested cells and 
downregulated in cycling cells. Furthermore, when FBXL20 is silenced Skp2 
levels are significantly increased, which suggests that since Skp2 levels are high 
in proliferating cells, cells acquire a growth advantage upon FBXL20 silencing 
and Skp2 is increased in order to downregulate proteins such as p27 Kip' and lead 
to the progression of cells from Gl to S phase. A yet unknown relationship is 
likely to exist between Skp2 and FBXL20 in MCF-7 cells. 
A major regulator of proliferation and the transition of cells from Gl to S phase 
and from G2 to M phase is the FoxMl trascription factor. This protein has been 
shown to regulate the transcription of Skp2 (Wang et al., 2005b). Silencing 
FoxMl leads to the downregulation of Skp2 mRNA and protein levels. Since 
FBXL20 resembles Skp2, and both their expression is dependent on cell cycle 
phase, it was thought that FoxMl could perhaps regulate the expression of 
FBXL20. However, this was not the case as siRNA experiments where FoxMl 
was silenced in MCF-7 cells revealed that there was no significant change in the 
mRNA expression of FBXL20. Skp2 was significantly downregulated in response 
to FoxMl silencing. 
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Future work 
Further studies are required to lead to a better understaning of the role of FBXL20 
in cells. The question of the binding partners of FBXL20 remains unanswered and 
needs to be addressed in further studies. In order to identify its binding partners 
the RePCA system (Ding et al., 2006) could be used or many other techniques 
such as GST pulldown, yeast-two hybrid or others. Further experiments using 
siRNA to silence FBXL20 expression could then be performed to test its effect on 
its binding partners. 
To be able to study the role, expression and cofactors of FBXL20 the antibody 
raised against FBXL20 has to be purified and optimised and used in western blot 
experiments and also in immunohistochemical staining. For example, transformed 
and non-transformed cells could be compared for their expression of FBXL20 
mRNA and protein levels. Also, expression could be compared between cells 
from low grade and more aggressive, high grade tumours. FBXL20 could play a 
role in tumourigenesis, apoptosis, proliferation and cancer progression. 
Also, the interplay between Skp2 and FBXL20 has to be further investigated. 
Further experiments could be done to understand the differences between the rat 
and human FBXL20 protein. FBL2 can be overexpressed and silenced in rat cells 
to test whether it functions similarly to the full length protein in human cells. 
Furthermore, the part of FBXL20 that is similar to the rats can be examined for 
potentially similar functions to the full length protein in human cells. The full- 
length FBXL20 protein can be expressed in rat cells and the functional differences 
between the full length and the truncated proteins can be examined. 
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CHAPTER IV 
TSA AND FBXL20 
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IV. 1 BACKGROUND AND OBJECTIVES 
HDAC inhibitors bind and inhibit HDACs, leading to an open chromatin structure 
where transcription factors and other regulatory elements can bind to the DNA 
and regulate transcription of target genes. They preferentially target transformed 
rather than non-transformed cells and have been shown to inhibit proliferation of 
cancer cells and induce cell cycle arrest, differentiation and different kinds of cell 
death such as autophagy or apoptosis (Johnstone et al., 2002; Narlikar et at., 
2002). This chapter studies the mechanism of action of the HDAC inhibitor TSA 
by characterising its effect on the novel F-Box protein FBXL20. TSA is being 
used as a benchmark HDACi that is very well studied compared to other HDACi. 
TSA induces the expression of p2lc`P' and the pro-apoptotic protein Bim (Fandy 
et at, 2006), while it decreases the expression of proteins important for 
proliferation such as ERa and cyclin D1 (Alao et at., 2004). TSA has been shown 
to lead to both Gl/S cell cycle arrest and G2/M arrest dependent on the 
concentration used (Kim et at., 1999; Li et at., 2006; Rokhlin et at., 2006; Sowa et 
al., 1999; Yamashita et al., 2003). TSA has been demonstrated to cause GI/S 
arrest by repressing ERa and cyclin D1 transcription and inducing ubiquitin 
dependent proteasomal degradation of cyclin D1 (Alao et al., 2004). 
Disadvantages of TSA include that it is very toxic and that it is not very specific 
in targeting only HDACs as it has been reported to directly target a number of 
proteins like the tumour suppressor p53. This chapter suggests that the novel F- 
Box protein FBXL20 is crucial for the action of TSA. 
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IV. 2 RESULTS 
TSA causes G2IM arrest at high concentrations 
In order to investigate the mechanism of action of TSA MCF-7 cells were treated 
with 1µM TSA to study the cell cycle profile of cells after 0,6,16,24,48,72 
hours. Previous work in our lab has shown that TSA at the concentration of I µM 
induces hyper-acetylation of histone H3 and H4 and inhibits proliferation of 
breast cancer cell lines by 90% (IC90) at 48h. Cell cycle analysis showed that 
after 16h of treatment with 1µM TSA, the majority of cells arrested at the G2/M 
phase, whereas a small population arrested at the GI/S phase and a small 
percentage accumulated at the sub-G1 phase. Cells at sub-Gl have a DNA content 
of less than 2N, characteristic of apoptotic or necrotic cells. In the later time 
points, sub-G1 population was increasing with time and after 72h, 60% of cells 
were at the sub-Gl phase (Fig. 4.1A). This concentration was used in further 
experiments. 
The action of TSA on the cell cycle were concentration dependent; as cell cycle 
analysis of MCF-7 cells treated with 1,10,100 and 1000nM TSA showed 
differential effects. 1nM and lOnM TSA for 48h did not affect the cell cycle 
distribution, 100nM TSA arrested MCF-7 cells in Gl/S phase and G2/M phase 
and with 1000nM TSA cells were primarily arrested at the G2/M phase and the 
sub-GI concentration was increased (Fig. 4.1B). However, these observations 
might only affect the different kinetics of cell cycle arrests by different 
concentrations of TSA. 
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Figure 4.1 TSA causes G2/M arrest. A) MCF-7 cells were treated with 1µM 
TSA, and harvested at the indicated times. Cells were fixed in 90% ethanol. DNA 
content was then analyzed by FACS analysis after propidium iodide staining. The 
percentages of cells (Y-axis) in each phase of the cell cycle determined by their 
DNA contents (X-axis) are indicated (<2N, hypo-diploid). B) MCF-7 cells were 
treated with TSA at the concentrations specified for 48h. Cells were fixed in 90% 
ethanol. DNA content was then analyzed by FACS analysis after propidium 
iodide staining. The percentages of cells (Y-axis) in each phase of the cell cycle 
determined by their DNA contents (X-axis) are indicated (<2N, hypodiploid). 
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TSA induces the expression of FBXL20 mRNA 
There is no commercially available antibody against FBXL20, and so one was 
designed against the N-terminal region of FBXL20. However, the antibody was 
very non-specific and could not be used in further experiments; therefore it was 
not possible to look at the effect of TSA on FBXL20 protein levels. 
Treatment of cells with 1µM TSA lead to a significant increase in the mRNA 
levels of FBXL20 (Fig. 4.2A). In order to examine whether this is a direct effect, 
cells were treated with cycloheximide (CHX) alone or the combination of CHX 
and TSA for 1-8hours in a time-course experiment. RT-QPCR analysis showed 
that CHX treatment did not alter the mRNA levels of FBXL20 whereas 
cotreatment with TSA leads to an induction of FBXL20 expression (Fig. 4.2B). 
The amount of primers used was optimised for each set of primers. 
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Figure 4.2 TSA directly induces the expression of FBXL20 mRNA in MCF-7 
cells. A) Cells were treated with 1µM TSA and harvested at the indicated times 
followed by RNA extraction and analysis by RT-QPCR. B) Cells were treated for 
the indicated times with TSA (1µM), CHX (10µg/µl) or TSA+CHX. When TSA 
was used in combination with CHX, cells were pre-treated with CHX for 30min, 
and then treated with TSA and analysed by RT-QPCR for FBXL20 rRNA levels. 
Graphs show the levels of FBXL20 mRNA normalised by L19 and represent the 
average +SD of three independent experiments that included 3 replicates each. 
Statistical analysis was performed using ANOVA with Dunnett's post-hoc 
analysis for all time points compared to control (0 hr) and *p<0.05. 
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TSA does not affect the localisation of FBXL20 
Experiments in the human uterine leiomyosarcoma SK-UT cell line, which has a 
splice variant of Skp2 retained in the cytoplasm, showed that the Skp2 variant 
failed to direct cyclin D1 ubiquitination; however expression of full-length Skp2 
rescues the cyclin D1 and p27K`pl degradation. Therefore, the absence of the Skp2 
from the nucleus of SK-UT-1B cells is the mechanism underlying the 
ubiquitination defect observed in this cell line (Ganiatsas et at., 2001). This leads 
to the conclusion that localisation of F-Box proteins is a very important factor 
affecting their functions in cells. In order to test if TSA affects FBXL20 
subcellular localisation and thus potentially change its functions, a sub-cellular 
fractionation experiment was carried out. Flag-FBXL20 was predominantly 
detected in the cytoplasm of untreated asynchronously growing MCF-7 cells. 
Culture with 1 pM TSA for 6h resulted in upregulation of Flag-FBXL20 levels but 
did not alter its localisation. SP1 was used as a control and was detected in the 
nuclear fraction while tubulin was detected in the cytoplasm (Fig. 4.3). 
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Figure 4.3 TSA does not alter the localisation of FBXL20 in MCF-7 cells. 
Asynchronously growing cells were treated with and without 1µM TSA for 6h 
and were then subjected to proteomic fractionation. Nuclear (N) and cytoplasmic 
(C) fractions of cells were separated. Cell lysates were separated by SDS-PAGE 
and immunoblot analysis was done using the indicated antibodies Immunoblots 
against Tubulin (cytoplasmic) and Spl (nuclear) served to ensure efficient 
subcellular fractionation. 
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Silencing FBXL20 increases the proliferation and abrogates the G2/M arrest 
induced by TSA. 
In order to examine the effect of silencing FBX1.20 in the cell cycle progression of 
MCF-7 cells, I BXL20-specific or non-specific scrambled siRNA pools were 
transfected into MCF-7 cells. FACS analysis 24 and 48h after trasfection showed 
that knockdown 173X1.20 resulted in a slight decrease in the number of cells in the 
G2/M phase of the cell cycle (Fig. 4.4A). RT-QPCR confirmed the knockdown of 
I BXL20 (Fig 4.4B). Next, I examined the effect of overexpressing Flag-FBXL20 
in TSA treated cells on the cell cycle progression of MCF-7 cells. Cells 
transfected with Flag-FBXL20 showed an increase in apoptosis induced by TSA 
(Fig 4.5). In a reverse experiment, the functional effects of silencing / BXL20 
gene expression on the MCF-7 cell proliferation in response to TSA were 
examined. FRXL20-specific siRNA pools or scrambled siRNA control pool 
duplexes were transfected into MCF-7 cells, and cell proliferation was then 
quantified by SRB assay at 0 and 24h after treatment with 100,500 and 1000nM 
TSA (Fig. 4.6A). Knockdown of bRX1.20 expression led to an apparent growth 
advantage of MCF-7 cells compared to the non-specific control transfected cells. 
Furthermore, non-specific and EBXL20-specific siRNA pools were used to 
examine whether silencing h'8XL20 changes the cell cycle profile of MCF-7 cells 
treated with TSA for 24h. FACS analysis showed that after 24h of I µM '1'SA 
treatment there was a decrease in the number of cells in the G2/M phase compared 
to the non-specific control transfected cells (Fig. 4.6B). RT-QPCR analysis was 
used to confirm the knockdown of the I, 73XI, 20 gene expression (Fig. 4.6C). 
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Figure 4.4 siRNA-mediated FRX1.20 knockdown causes a non-significant 
change in the cell cycle progression of MCF-7 cells. MCF-7 cells were 
transfected with oligo pools specifically targeting FBXL20 or NSC. A) Cells were 
then harvested at 24 and 48h after transfection and fixed with 90% ethanol and 
analysed by FACS. B) RNA from cells transfected in parallel was used in RT- 
QPCR reaction with primers specific for 1BX1,20 to monitor siRNA 
. efficiency. 
Graph represents the FBXL20 mRNA levels normalised by 1,19 
Statistical analysis was performed by Mann-Witney U test and *p<0.05. 
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Fig 4.5 Overexpression of Flag-FBXL20 increases the cell death induced by 
TSA. Cells were transfected with Flag-FF3XL20 or remained untranstccted and 
were then treated with 1 gM TSA for 0,6,24 and 48h. Cells were harvested and 
fixed with 90% ethanol and then analysed by FACS. 
127 
A) Effect of silencing FBXL20 on the proliferation 
of TSA treated MCF-7 cells 
110 
100 
> 
90 
N 
O 
so 
I 
70 
60 
(ouc enh ahoi 4 JIM 
B) 
FBXL20 sIRNA NSC s ZNA 
Oh 
0.5 0.3 
75.4 73.5 
6.1 7.0 
180 19.2 
12.0 
24h 57.4 
5.1 
TSA 25.5 
(1) 
118 t %<2N 
215 4-- %Gi 
49 t %S 
618 %G2IM 
FBXL20 siRNA 
NSC siRNA 
FBX L20 niRN A 
'tprrssion 
oti 
0 
Ir 
[i i. 
. L,:,. " VFtri 
Figure 4.6 Specific knockdown of FBXL2O attenuates the cytotoxic effect of 
TSA on MCF-7 cells. A) Cells were transfected with siRNA oligos specific for 
FBXL20 and NSC. 24h after transfection cells were harvested and reseeded in 96- 
well plates and incubated for 24h. Cells were then treated with the indicated 
concentrations of TSA for 24h and were then analysed by the SRB assay. Results 
are the average of three independent experiments that included 4 replicates 
expressed as the percentage of the Oh. Statistical analysis was performed using 
ANOVA with Bonferroni post-hoc analysis for all points compared to control 
(0µM) and between FBXL20 sIRNA and NSC siRNA samples and *p<0.05 (NS 
no significant change). B) Cells were transfected with siRNA oligos specific for 
F'BXI, 20 and NSt' and then treated with I µM TSA for 24h, harvested and fixed 
with 90% ethanol and then analysed by FAGS. C) RNA from cells transfected in 
parallel were used in RT-QPCR reaction with primers specific for 1'BX1.20 to 
monitor siRNA efficiency. Graph represents FBXL20 mRNA levels normalised 
by L19 mRNA levels. Statistical analysis was performed using the Mann-Witney 
U test and *p<0.05. 
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Silencing F13X/, 20 abrogates the G2/M arrest induced by SAHA and SBHA. 
To test whether the observed effect of FBXL20 in the TSA-induced G2/M arrest is 
TSA specific or it is common for all HDACi, the HDACi SBHA and SAHA were 
used in similar experiments as for TSA. To determine which concentration of 
those two HDACi to use, the SRB assay was employed in dose-response 
experiments. The results showed a clear decrease in the proliferation of cells 
treated with both inhibitors in a dose-dependent manner. Cells were treated for 24 
and 48h with 25,50,75,100,125 and 150µM SRHA (Fig. 4.7A) or 1,5,10, 
50µM SAHA (Fig. 4.7B). From these results I concluded that 100µM SBIIA and 
5µM SAHA would be used in further experiments. 
Cells transfected with FRXL20-specific siRNA pools or non-specific (NSC) 
siRNA were treated with 100µM SBHA and 5µM SAHA for 24h followed by 
FACS analysis. The results obtained were similar to the TSA treated cells. 
FBXL20 knockdown cells could not arrest in the G2/M phase compared to the 
Mock and NSC control cells (Fig. 4.8A, Fig. 4.811). Knockdown was again 
confirmed by RT-QPCR analysis (Fig. 4.8C). 
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Figure 4.7 Effect of SBHA and SAHA on the proliferation of MCF-7 cells. A) 
Cells were cultured in 96-well plates with 25-150µM SBHA. Relative cell 
survival was determined after 24 and 48 h as described in materials and methods 
section. Results are the average ± SD of three independent experiments that 
included 4 replicates each. B) MCF-7 cells were cultured in 96-well plates with l- 
5µM SAHA. Relative cell survival was determined after 24 and 48h as described 
in materials and methods section. Results represent the average ± SD of three 
independent experiments that included 4 replicates each. 
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Figure 4.8 siRNA-mediated FBXL20 knockdown attenuates the cytotoxic 
effect of SAHA and SBHA on the cell cycle progression of MCF-7 cells. A) 
Cells were transfected with oligo pools specifically targeting FBXI, 20 or N, 5(7 and 
24h later treated with 5µM SAHA (A) or 100µM SBHA (B) for 24h. Cells were 
then harvested and fixed with 90% ethanol followed by FACS analysis. C) RNA 
from cells transfected in parallel was used in a RT-QPCR reaction with primers 
specific for FBXL20 to monitor siRNA efficiency. Results represent FBXL20 
mRNA levels normalised by L19 mRNA levels. Statistical analysis was 
performed using the Mann-Witney U test and *p<0.05. 
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Silencing HDAC2 leads to induction of FBXL20 mRNA levels 
Since TSA leads to inhibition of HDACs and induces the expression of FBXL20, 
I next asked the question if a particular HDAC is responsible for this effect. 
HDAC I and HDAC2 have been shown to be very important in the regulation of 
expression of many proteins in MCF-7, therefore these two HDACs were chosen 
for the subsequent experiment (Bicaku et al., 2008; Harms and Chen, 2007; 
Kawai et al., 2003). HDACI and HDAC2 specific siRNA pools were transfected 
into MCF-7 cells and 48h later RNA was extracted and analysed by RT-QPCR. 
Silencing HDAC2 caused a profound increase in the mRNA expression of 
FBXL20, in contrast, HDACI siRNA did not alter the FBXL20 mRNA levels (Fig. 
4.9A). Knockdown of HDACI and HDAC2 was confirmed by RT-QPCR (Fig. 
4.9A) and immunoblotting (Fig. 4.9B). 
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Figure 4.9 Specific knockdown of HDAC2 induces expression of FBXI, 20 
mRNA. MCF-7 cells were transfected with oligo pools specifically targeting 
HDACI-2 or NSC. 72h after transfection, cells were harvested. A) RNA was 
extracted followed by cDNA synthesis. HDACI, HDAC2 and PBXL20 expression 
was analysed by RT-QPCR. Graphs represent the indicated levels of mRNA 
normalised by L19 mRNA. Results are the mean ± SD of three independent 
experiments that included 2 replicates each. Statistical analysis was performed 
using the Mann-Witney U test and *p<0.05 B) Lysates were also made and 
analyzed by SDS-PAGE and immunoblotted with HDAC 1 -2 to confirm the 
silencing in the protein level. 
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FBXL20 regulates Bim protein levels 
My previous results showed that TSA induces FBXL20 expression and also 
causes G2/M arrest followed by cell death. It was thought that FBXL20 might 
exert its effects by regulating pro-apoptotic proteins. In order to examine this, 
siRNA pools of FBXL20 were transfected in MCF-7 cells and 48h later cells were 
harvested and analysed by immunoblotting, using an antibody against Bim. The 
results showed that Bim protein levels decreased when FBXL20 was silenced (Fig. 
4.11A) but mRNA levels were unaffected (Fig. 4.12). It was then suggested that 
silencing FBXL20 may affect other pro-apoptotic proteins as well and therefore 
immunobloting experiments in FBXL20 knockdown cells were performed. 
However, the protein levels of the pro-apoptotic proteins Bax and Bad remained 
unchanged (Fig. 4.12B). In addition, in agreement with other studies (Fandy et al, 
2006), TSA treatment lead to an increase in the Bim protein (Fig. 4.10A) and 
mRNA levels (Fig. 4.10B). In cells where the expression of FBXL20 is silenced, 
TSA failed to induce the expression of Bim in the protein level as analysed by 
immunoblotting (Fig. 4.11A), which strongly suggest that TSA-induced Bim 
upregulation is a FBXL20-dependent event. BecauseBimEL was the major form of 
Bim expressed under these experiments, with only low levels of BimL seen, 
further analysis focused on the regulation of BimEL,. In addition, cells were 
transfected with Flag-FBXL20 and 24h later cells cell were analysed by 
immmunoblotting. Bim expression was induced in cells that overexpressed 
FBXL20 but not mock transfected control cells (Fig. 4.13). 
In order to test if FBXL20 binds Bim, cells were transfected with Flag-FBXL20 
recombinant vector which was then immunoprecipitated and samples were 
134 
analysed by SDS-PAGE. Immunobloting analysis showed that FBXL20 binds 
Bim (Fig. 4.14). Skpl, ROC-1 and CUL-1 were also able to bind FBXL20 
proving that the immunoprecipitation experiment has worked. As a negative 
control for the immunoprecipitation, an antibody against ERa was used and 
showed that ERa does not bind FBXL20. 
Cell cycle analysis revealed that when silencing both FBXL20 and Bim in the 
same cells, cells arrested in the G? JM phase after treatment with 1µM TSA for 
24h, in contrast to cells where only FBXL20 is silenced (Fig. 4.15A). In cells 
where only FBXL20 was silenced, there was also a slight decrease in the number 
of cells in G2IM phase before TSA treatment. In cells where Bim was silenced, 
there were fewer cells in the sub-G1 phase after TSA, indicating that Bim 
contributes to protecting cells from the growth inhibition by TSA, as observed in 
other studies (Donadelli et al, 2007). Knockdown of FBXL20 was confirmed by 
RT-QPCR and silencing of Bim was confirmed by SDS-PAGE (Fig. 4.15B). 
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Figure 4.10 TSA induces the expression of Bim mRNA and protein. MCF-7 
cells were incubated with 1µM TSA for the indicated times. A) Following 
incubation, the cells were harvested and lysates were resolved by SDS-PAGE. 
Proteins were detected using the indicated antibodies. Results are representative 
of three independent experiments. B) Protein concetration of Bim normalised by 
the concetration of tubulin from cells treated with 1µM TSA Results represent the 
average of three independent experiments. Statistical analysis was performed 
using ANOVA with Dunnett's post-hoc analysis for all time points compared to 
control (0 hr) and *p<0.05. C) RNA extraction was followed by cDNA synthesis 
and finally analysed by RT-QPCR for Bim mRNA levels. Graph shows the levels 
of Bim mRNA normalised by L19 mRNA levels. Statistical analysis was 
performed using ANOVA with Dunnett's post-hoc analysis for all time points 
compared to control (0h) and *p<0.05. 
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Figure 4.11 Silencing FBXL20 leads to downregulation of Bim protein levels. 
A) Cells were plated out in 6cm plates and transtected with siRNA oligos 
specifically targeting FBXL20, or NSC siRNA. Mock cells were not treated with 
any siRNA. 24h later cells were treated with 1 pM TSA or remained untreated. 
Lysates were then made and analysed by SDS-PAGE and immunobloted by the 
indicated antibodies. Results are representative of three independent experiments. 
B) Cells were transfected with siRNA specifically targeting FBXL20 and lysates 
were analysed by immunoblotting. C) RT-QPCR analysis of cells transfected in 
parallel were used to confirm 1EHXL20 knockdown and the results represent 
1, BXL20 mRNA levels normalized by L19 mRNA levels. Statistical analysis was 
performed using the Mann-Witney U test and *p<0.05. 
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Figure 4.12 Silencing FBX/. 20 does not affect Rim mRNA levels. Cells were 
transfected with siRNA oligos specifically targeting; 173X/. 20, or NS('. RNA 
extraction was followed by cDNA synthesis and finally analysed by RTQPCR for 
l, 'RXL20 and Rim mRNA levels. Graphs show the levels of E'RXL20 mRNA 
normalised by 1.19 mRNA levels. Results are the mean f SD of three independent 
experiments that included 3 replicates each. Statistical analysis was performed 
using the Mann-Witney U test and *p<0.05. 
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Figure 4.13 Overexpression of FBXL20 leads to upregulation of Bim protein 
levels. Cells were transfected with Flag-FBXL20 and harvested 24h later. Lysates 
were made, analysed by SDS-PAGE and immunobloted by the indicated 
antibodies. Results are representative of three independent experiments. 
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Figure 4.14 FBXL20 binds Bim. MCF-7 cells were transfected with Flag- 
FBXL20 and harvested 24h later. Whole cell extracts were prepared in lysis 
buffer and immuprecipitations (IP) were performed using a monoclonal anti-Flag 
antibody. The IP samples along with samples from the whole cell lysates were 
then analysed by SDS-PAGE and immunoblotted with the indicated antibodies. 
Results are representative of three independent experiments. 
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Figure 4.15 Effect of siRNA-mediated FBXL20 and Bim knockdown on the 
cell cycle progression of MCF-7 cells treated with TSA. A) Cells were 
transfected with oligo pools specifically targeting 1 13X1.20, Bim, EBXL20 and Him 
together or NSC and 24h later treated with 1 µM TSA for 0 and 24h. Cells were 
then harvested and fixed with 90% ethanol and analysed by FACS analysis. B) 
RNA from in parallel transfected cells was used in RT-QPCR reaction with 
primers specific for FBXL20 to monitor siRNA efficiency. Graphs represent 
1F'BXL20 mRNA levels normalised by 1,19 mRNA levels. Statistical analysis was 
performed using the Mann-Witney U test and *p<0.05. Protein from cells 
transfected in parallel was used in SDS-PAGE experiment to monitor Rim siRNA 
efficiency. 
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IV. 3 DISCUSSION 
Research over the last decade has focused on finding novel HDACi that are more 
potent and less toxic than currently known ones. Studies are also being done in 
order to understand the mechanism of action of HDACi. It is unclear how exactly 
HDACi lead to cell death. One way to understand how these compounds function 
is by studying their effects on target proteins. In this study, the oestrogen- 
responsive MCF-7 breast epithelial cancer cell line was used as a relevant model 
to study the anti-proliferative effects of TSA. TSA is one of the best studied 
HDAC inhibitors, used as a benchmark HDACi. The mechanism of action of TSA 
was studied by examining its effect on its novel FBXL20 target. FBXL, 20 may 
prove to be an important target of other HDACI as well as TSA. 
Since there is not much known about FBXL20, this work first set out to 
characterize it. As shown in the previous chapter, FBXL20 is a novel E3 ligase, 
localised in the cytoplasm, ubiquitously expressed and its expression is maximal 
in arrested cells rather than proliferating cells. This chapter focused on the 
functional role of FBXL20 in MCF-7 cells. Examining the role this protein plays 
in the TSA-induced effect in cells, I discovered many properties of FBXL20 and 
also one of its binding partners. 
Treatment of MCF-7 cells with 1 µM TSA caused a G2/M arrest after 16h of 
treatment. Arrest in this phase seems to be an important checkpoint mediated by 
HDACi in cancer cells. While a lot is known about how the G1/S arrest occurs at 
low concetrations of TSA, little is known about how the G2/M arrest is mediated. 
TSA has been shown to cause G, /S arrest by inducing the expression of p21C'p' 
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and downregulating the expression of cyclin Dl and ERa, proteins that are 
involved in the transition from the G, phase to the S phase of the cell cycle (Alao 
et at., 2004). The results shown in this chapter strongly suggest the involvement of 
FBXL20 in mediating TSA-induced G2/M arrest in MCF-7 cells. 
TSA caused an upregulation of I73XL20 mRNA levels. This is a direct effect, 
since co-treatment with CHX was unable to inhibit the induction of FBXI, 20 
mRNA. Thus, it is possible that FBXL20 is a direct target of TSA. The best 
known direct target of TSA is p21C'p '. TSA has previously been shown to 
modulate 121` " promoter activity through the proximal Sp 1 sites of its promoter 
region (Han et al, 2000; Margueron et al, 2003, Sowa et al, 1999). It is possible 
that since I'BX1,20 is upregulated upon induction of cell death, it may play a role 
in degrading proteins that promote cell growth. 
TSA led to the upregulation of Flag-FBXL20 protein levels suggesting that TSA 
may regulate FBXL20 at the protein and mRNA level, since Flag-FBXL20 
protein is driven by a different promoter than the endogenous FE3XL2O It is 
possible that the induction of Flag-FBXL20 protein levels is due to decreased 
degradation of the protein. More work has to be done to understand how TSA 
regulates FBXL20 Promoter assays have to be performed and the stability of 
FBXL20 has to be examined. Also the binding partners of FBXL20 have to be 
identified. Furthermore, the full-length 1,73X1.20 cDNA was cloned in the Flag- 
tagged vector without any of the 3' untranslated region of the gene included. This 
suggests that the action of TSA does not involve the regulation of miRNAs that 
could subsequently regulate FBX1.20. miRNAs are known to target the 3' 
143 
untranslated region of genes and lead to translational repression of many different 
mRNAs. In comparison to the well known siRNAs, where the target mRNA is 
degraded due to their perfect complementarity to their respective siRNA, miRNAs 
are not perfectly complementary to the corresponding mRNAs (Arenz, 2006). 
Silencing I BXL20 caused a no significant change in the cell cycle profile of 
MCF-7 cells, as it showed a small decrease in the number of cells in the G2/M 
phase. However, upon treatment with TSA, the changes are more significant. 
Knockdown of FHX1.20 gave a growth advantage to MCF-7 cells in response to 
TSA, since the proliferation assay (SRB assay) showed an increase in the rate of 
proliferation in cells where PBX/, 20 was silenced compared to the control 
transfected cells. However, this was seen particularly at the higher concentration 
of TSA (1 µM) where cells are undergoing cell death. At lower concentrations of 
TSA, where this is not the case, the growth advantage induced by silencing 
1,13X1.20 is not so obvious, indicating that FBXL20 plays a role in mediating cell 
death. Also, cell cycle analysis of cells transfected with FBXL20 siRNA revealed 
that knockdown of FBX1,20 and subsequent treatment with TSA led to a reduction 
in the number of cells at the G2/M phase compared to the NSC and Mock 
transfected cells. Moreover, FACS analysis showed that transfection of cells with 
Flag-FBXL20 and subsequent treatment with TSA, led to an induction of cell 
death compared to untransfected TSA treated cells. This further suggests that 
FBXL20 is involved in the induction of cell death. Cell cycle analysis of the Flag- 
FBXL20 transfected cells also showed that the arrest at the G2/M phase was 
abrogated and cells had undergone apoptosis. This could possibly be explained by 
the induction of Bim caused by overexpressing FBXL20. 
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The findings that silencing of FBXI, 20 expression by siRNA can overcome the 
G2/M cell cycle arrest induced by TSA, lead to a growth advantage of cells as it 
increases their proliferation and the fact that overexpression of FBXL20 led to an 
induction of cell death, suggest that FBXL20 could act as a tumour suppressor. It 
is also possible, that FBXL20 plays a role in the G1/S transition. The similar 
protein Skp2 is known to contribute to G1/S transition by degrading p27'"p' 
(Carrano et al., 1999; Sutterluty et at., 1999; Zhang et at., 1995). 
FBXL20 is important for the action of possibly all HDACi and not just TSA, as 
MCF-7 cells treated with the HDACi SAHA and SBHA showed similar results to 
those obtained with TSA. Cells where FBXL20 was silenced, failed to arrest in 
the G2/M phase. Furthermore, in contrast to H1)ACI, silencing HI)A('2 caused an 
increase in the mRNA levels of EBXI, 20, suggesting that this HDAC may play a 
role in the regulation of FBXL20. It is possible that TSA leads to the 
downregulation of HDAC2 which might subsequently lead to the induction of 
FBXL20 mRNA and protein levels. 
As shown in other studies (Fandy et al, 2006), TSA induced the expression of Bim 
at the mRNA and protein level, which plays an important role in TSA-induced 
apoptosis in cells. This work shows that the TSA induced upregulation of Bim is 
abrogated when FBXL20 is silenced. In untreated cells, knockdown of FBX1,20 
leads to a decrease in the protein expression of Bim, but no change is observed in 
the Bim mRNA levels. No change was also seen in the protein levels of Bax and 
Bad therefore FBXL20 does not affect the levels of all pro-apoptotic proteins. 
Immunoblotting experiments should be done to test the effect of silencing 
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FBXL20 on other pro-apoptotic proteins as well. Furthermore, overexpression of 
FBXL20 led to an induction of Bim protein levels. Moreover, 
immunoprecipitation experiments showed that FBXL20 binds Bim. Taken 
together these results suggest that FBXL20 does not directly lead to the 
degradation of Bim. It is likely that FBXL20 actually binds Bim in order to 
stabilise it, preventing it from being degraded by another E3 ligase. It would be 
interesting to see whether FBXL20 also binds the smaller Bim isoforms Bims and 
Bimu GST-pulldown experiments have to be performed with FBXL20 mutated at 
different sites to find which region is responsible for binding Bim. Mutation of 
these sites would inhibit binding of these two proteins. Also, cell cycle analysis 
showed that in the absence of FBXL20, Bim is required for the abrogation of 
TSA-induced G1/M arrest, suggesting that FBXL20 acts through Bim to exert its 
effect on MCF-7 cells upon TSA treatment. Bim is regulated by ubiquitination 
and proteasomal degradation. Inhibiting its degradation could lead to the 
induction of apoptosis in cancer cells. This suggests that a combination of 
HDACi, such as SAHA, with proteasome inhibitors could be more effective in 
killing cancer cells. 
Collectively, the results from this work suggest that FBXL20 is a target of TSA. 
Knockdown of FBXL20 causes a change in how TSA exerts its effects on MCF-7 
cells, as it leads to an abrogation of TSA-mediated GZJM arrest. FBXL20 acts 
through regulating the pro-apoptotic protein Bim. 
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Figure 4.16 Schematic to represent the role of FBXL20 in TSA-induced cell 
cycle arrest and apoptosis. 
Future work 
In order to understand the regulation of FBXL20 by TSA at the transcriptional 
level, the promoter of FBXL20 could be studied. Analysis of the sequence of the 
promoter, to see which sites it contains, may help to identify which proteins bind 
to it. Subsequent cloning of the promoter followed by chromatin 
immunoprecipitation (ChIP) experiments using antibodies against the proteins 
thought to bind the particular sequences in the promoter, could be used to 
determine if these proteins bind the promoter of FBAL20 in untreated and TSA 
treated cells. Gene silencing using siRNA technology could be used to silence the 
expression of these regulators of FBXL20 expression to characterise their effects 
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on FBXL20 expression. Also, luciferase assays could be done to test the effect of 
TSA on the promoter activity of FBXL20 which would help in the better 
understanding of how TSA regulates FBXL20 at the transcriptional level. 
Furthermore, assays such as the yeast-two hybrid system, could be performed to 
find the targets of FBXL20 to further understand its functional role in the cell. In 
order to test whether the effect of FBXL20 on the HDACi-induced cell death in 
MCF-7 cells is cell type specific, similar experiments could be performed in other 
breast cancer cell lines and in other cancer types. 
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CHAPTER V 
ANALYSIS OF NOVEL HDAC 
INHIBITORS 
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V. 1 BACKGROUND AND OBJECTIVES 
The development of HDACi, such as SAHA, has inspired many researchers to 
search for better inhibitors in the quest for more effective cancer therapy. HDACi 
have shown promising anti-tumour activity in a variety of cancers. A great 
advantage of HDACi is that normal cells are relatively more resistant to HDACi- 
induced cell death than cancer cells (Xu et al., 2007). HDACs deacetylate 
histones and this eventually leads to repression of transcription as transcription 
factors are unable to access DNA (Kouzarides, 1999). More precisely, the N- 
terminal tails of the histones, which are protruding out of the nucleosomes, 
contain c-amino groups on their lysine residues and these become deacetylated by 
HDACs. This deacetylation, catalysed by HDAC enzymes, leads to a compact 
chromatin structure thus preventing the access of other molecules to DNA, 
therefore leading to repression of transcription (Strahl and Allis, 2000). HDACi 
inhibit HDACs, resulting in an increase in acetylation and subsequently 
transcription of target genes involved in various cellular processes such as 
proliferation, differentaition and cell death. 
Besides histones, HDACi are also known to target other protein substrates, and 
cause inhibition of proliferation, induce cell cycle arrest, apoptosis and 
differentiation (Johnstone et al., 2002; Jung et al., 1999; Sambucetti et al., 1999). 
HDACi are categorised as hydoxamic acids, short chain fatty acids, benzamides 
and cyclic peptides. 
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The efficacy of hydroxamic acids depends upon the presence of three domains: a 
terminal group (in this study it is the hydroxamic acid), a linker unit and an end 
moiety. The terminal group binds to the zinc in the enzyme's active site which is 
connected to the linker unit in the channel. This linker is also bound to the end 
moiety that occupies the external entrance to the channel of the enzyme. This 
model agrees with structures of histone deacetylase-like protein (HDLP) co- 
crystallized with either TSA or SAHA (Finnin et al., 1999). 
The well known hydroxamic acid SAHA inhibits the class I, II and IV HDACS 
but not the class III sirtuin family and has been shown to be effective and well 
tolerated by patients with haematological or solid cancers. However, a number of 
HDAC inhibitors have toxic side effects at high doses and therefore, are of little 
use in the clinical setting. Others degrade rapidly, therefore patients will require 
high dose administration (Warrell et al., 1998). Moreover, HDACi usually cause 
many non-specific effects affecting other proteins and processes in the cell 
(Newmark and Young, 1995). 
This study focuses on bringing together the knowledge gained from my earlier 
findings in order to identify a novel hydroxamic acid that shows anti-tumour 
activities but less toxic and more potent than currently known hydroxamic acids. 
This work aimed to identify more potent agents by studying their effect on the cell 
cycle, cell proliferation and deacetylation. The novel compounds were designed 
and synthesized in collaboration with Prof. Marson's group (UCL University, 
London). 
151 
V. 2 RESULTS 
Compounds 201,202,203,204,205,207,208,209,211,212,213,216,217, 
218,219 do not have a significant effect on MCF-7 cell proliferation 
The framework of SAHA was used to design novel HDAC inhibitors which were 
then analysed by proliferation assays to assay the activity of these agents as has 
been done in my previous studies with TSA. The SRB proliferation assay was 
used to test if any of them can inhibit the proliferation of MCF-7 cells. Activities 
of compounds were compared to SAHA as a benchmark. The concentration used 
for all compounds in this assay was 5µM as this is the IC50 of SAHA in the MCF- 
7 cell line. TSA was also used as a control. However, it is a much more toxic 
compound and as a consequence the lower concentration of I pM was used in all 
experiments and was enough to inhibit the growth of cells. Results showed that 
SAHA and TSA decreased the proliferation of cells but none of the novel 
compounds (201,202,203,204,205,207,208,209,216,217,218,219) had any 
significant effect (Fig. 5.2A, B). The chemical structures of these compounds are 
shown in figure 5. IA. These compounds were thus considered having little anti- 
tumour properties and were not analysed in further experiments. Compounds 211, 
212 and 213 caused a small decrease in the proliferation but were not as good as 
SAHA and were therefore not considered as good compounds. 
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Figure 5.1 Representation of the chemical structures of all the compounds 
synthesized in this work. A) Chemical structures of all inactive compounds B) 
Chemical structures of all the active compounds in comparison to SAHA. RI, R2, 
R3, R4 and R5 represent the active moiety attached to the carbon atom shown. 
The complete structures of the active compounds are not shown in this thesis as 
patents are being sought to cover the intellectual properties arising from these 
findings. 
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Figure 5.2 Compounds do not affect the proliferation of MCF-7 cells. MCF- 
7cells were cultured in 96-well plates with 5µM SAHA, 1µM TSA and 5µM of 
each compound A) 201,202,203,204,205,207,208 and 209. B) 211,212,213, 
216,217,218,219. Relative cell survival was determined after 24 and 48h using 
the SRB assay as described in the materials and methods section. Results are the 
mean ± SD of three independent experiments that included 4 replicates each. 
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Compounds 214,215,220,221 inhibit proliferation of MCF-7 cells 
The SRB assay was again used as a tool to test if compounds 214,215,220 and 
221 affect the proliferation of breast cancer cells. All these compounds inhibited 
the proliferation of MCF-7 cells after 48h treatment. Compound 220 was the best 
inhibitor of cell proliferation (Fig. 5.3). All four compounds that inhibited 
proliferation of MCF-7 cells were analyzed again by the SRB assay to determine 
the IC50 for each individual molecule. Concentrations from 0.5 to 10µM were 
used in these SRB assays. The results showed that compound 214 had an IC5o of 
2.3,215 had an IC50 of 2.4,220 had an IC50 of 0.3 and 221 had an IC5o of 2.4 (Fig. 
5.4). Taken together these proliferation assays showed that compound 220 was 
indeed the best compound for inhibiting proliferation of MCF-7 cells. The 
chemical structures of all the active compounds are shown in figure 5.1 B. 
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Figure 5.3 The effect of compounds 214,215,220 and 221 on MCF-7 cell 
proliferation. Cells were plated in 96-well plates and 24h later treated with I µM 
TSA or 5µM 214,215,220 and 221 for 48h. Cells were then fixed with 40% 
TCA, stained with SRB, and cell density was measured as described in materials 
and methods. Results are the mean ±SD of three independent experiments that 
included 4 replicates each. 
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Figure 5.4 Concentration response curves for the impact of selected HDACi 
on cell survival.. Cells were plated in 96 well plates and 24h later treated with the 
indicated amounts of 214,215,220 and 221 for 48h. Cells were then fixed with 
40% TCA, stained with SRB, and cell density was measured as described in 
materials and methods. Graphs were plotted using Prism and represent the mean ± 
SD of three independent experiments that included 4 replicates expressed as the 
percentage of the control value in vehicle treated cells. 
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Compounds 214,215,220,221 induce expression of Ac-H3, Bim and p2l° ' 
It is likely that these novel compounds could cause proliferation arrest due to their 
toxicity rather than their HDAC activity. In an attempt to test if these compounds 
have HDAC activity, and in order to deduce the mechanism of cell death induced 
by the compounds, immunoblot analyses were employed to evaluate the 
expression level of known pro-apoptotic proteins such as Bim. As shown in figure 
5.5, all four compounds were able to induce Bim protein levels. The compounds 
were also tested for their ability to induce expression of acetylated-H3 and the cell 
cycle inhibitor p21c`P'. An eleveted level of acetylated-H3 and p2lc'P' was 
observed post-treatment, further confirming that these compounds possess 
HDACi activity (Fig. 5.5). 
In order to investigate the effect of the compounds on the cell cycle progression of 
MCF-7 cells, FACS analysis was performed with increasing doses of the 
compounds. As shown in figure 5.6, the inhibitory effect on the cell cycle caused 
by the compounds was clearly concentration dependent. All four compounds 
induced Gl/S arrest at low concentrations, and G2/M arrest and an increase in sub- 
GI population at the higher concentrations as has been shown for SAHA, TSA 
and other 1-IDAC inhibitors (Fig. 5.6). 
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Figure 5.5 214,215,220,221 induce expression of acetylated 113 (Ac-113), 
Bimi; i, and p21("Pl. Cells were treated with the indicated amounts ol'214,21 S, 
220 and 221 for 48h, harvested, lysed and analysed by Sl)S-PAGF, using 
antibodies against Bim, p21(ý'P', Ac-H3. Tubulin was used as a loading control. 
Results are representative of three independent experiments. 
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Figure 5.6 Cell cycle profiles of cells treated with 214,215,220 and 221. Cells 
were treated with 214,215,220,221 at the concentrations specified for 48h. Cells 
were then fixed in 90% ethanol and analysed by FACS after propidium iodide 
staining. 
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Figure 5.6 Cell cycle profiles of cells treated with compounds 214,215,220 
and 221. Cells were treated with 214,215,220,221 at the pM concentrations 
specified for 48h. Cells were then fixed in 90% ethanol and analysed by FACS 
after propidium iodide staining. 
163 
Compound 220 inhibits HDACs 
The most potent compound tested so far is 220, and therefore it was decided that 
more compounds would be synthesized that resemble its structure and also more 
experiments would be done to understand its mechanism of action. In order to 
measure the HDAC inhibitory activity of cells treated with the compound 220 and 
to verify that this compound is indeed targeting HDACs, the HDAC Fluorimetric 
Assay/Drug kit was used. To determine the HDAC inhibitory activity of 
compound 220 treatment with different concentrations of 220 for 20 min resulted 
in a decrease in HDAC activity. This decrease in HDAC activity was associated 
with increasing amounts of compound 220. The IC5o of compound 220 was 
calculated to be approximately 0.3µM. The control TSA showed a clear inhibition 
of I DAC activity as reported in other studies (Fig. 5.7). 
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Figure 5.7 Compound 220 inhibits HDAC activity. HeLa Nuclear Extract 
(0.5µ1/well) were incubated (25°C) with 116µM substrate and the indicated 
concentrations of 220 or TSA as a control. Reactions were stopped after 20min 
with the Fluor de LysTM developer and fluorescence was measured on a 
fluorometric plate reader (460nm). Graphs were plotted using Prism. 
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V. 3 DISCUSSION 
The hydroxamic acids are potent inhibitors of histone deacetylase and have 
attracted much interest due to their anti-cancer properties. Although many HDACi 
have been described in the literature, most of them have many disadvantages in 
the clinical setting, namely toxicity. Thus, research is now focused on finding 
more effective and less toxic HDACi that can be used as anti-tumour drugs in 
cancer patients. HDACi, such as TSA, have very toxic side effects at high doses 
and therefore are of limited therapeutic use. For example, depsipeptide was 
withdrawn from clinical trials due to its cardiovascular toxicity (Lin et al., 2006). 
In the present study, in collaboration with Prof. Marson at UCL, we have 
synthesised and characterised novel HDACi that are more potent than SAHA 
(figure 5.1). We used the SRB assay to screen drug candidates for potential anti- 
tumour activity. Screening was performed using the MCF-7 breast cancer cell 
line. A number of compounds only slightly inhibited the proliferation of MCF-7 
cells, but were not as good as SAHA and therefore were not analysed further. 
However, four of them, compounds 214,215,220 and 221 were able to inhibit the 
proliferation of MCF-7 cells. Compounds 214,215 and 221 had similar IC50 of 
around 2.3µM, slightly less than SAHA. The complete structures of these 
compounds are not shown in this thesis as patents are being sought to cover the 
intellectual properties arising from these findings. Also, compounds 214,215 and 
221 caused a G2/M arrest at higher concentrations, and were able to induce the 
expression of Ac-H3, Bim and p21C'pl. The induction of Bim suggests that cells 
die by apoptosis rather than necrosis, since this Bc12- family member is a well 
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known pro-apoptotic protein. Furthermore, the induction of acetylated-H3 further 
confirms that these compounds are actually HDAC inhibitors and their effects in 
cells are not due to non-specific cytotoxic events. The induction of the cell cycle 
inhibitor p21C'pl agrees with other studies performed with similar compounds, 
such as TSA, that have shown that p21C'p' is an important target of HDACi. Also, 
it suggests that the G1/S arrest caused by the compounds could be due to the 
induction of p2lc'Pl. These characteristics make these HDACi good anti-cancer 
drug candidates. Although there are seemingly small differences in the chemical 
structures of compounds 214,215 and 221, it was found that these structural 
changes had a significant effect on biological activity. 
As judged by the results presented in this chapther, compound 220 is a more 
potent inhibitor than SAHA but less potent than TSA. Compound 220 caused cell 
cycle arrest with apoptosis occuring after 48h of treatment. An extra group ("G") 
attached to the SAHA molecule therefore appears to increase the potency of the 
drug and is thought to be responsible for the increased inhibition of proliferation 
of MCF-7 cells. Variation of the groups fused to this key carbon atom in the 
SAHA molecule, where the "G" group binds, results in a marked difference in 
potency. Cell cycle analysis revealed that compound 220 induces G1/S arrest at 
low concentrations (0.1µM) and G2/M arrest at higher and more cytotoxic 
concentrations (0.5µM). This is consistent with other findings were HDACi, such 
as TSA, induce similar cell cycle profiles in many cancer cell types (Kim et al., 
1999; Li et al., 2006; Rokhlin et al., 2006; Sowa et al., 1999; Yamashita et al., 
2003). Interestingly, the SRB assay and the HDAC assay gave consistent results. 
Compound 220 gave an in vitro and in vivo IC50 of approximately 0.3µM 
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compared to the 2.5µM of SAHA. Also, compound 220 was able to induce the 
expression of BimEL, p2lcºp1 and acetylated-H3, proving that this compound has 
HDAC inhibitory activity and probably induces apoptosis in MCF-7 cells. 
Compound 220 was chosen for further studies in order to validate its potential 
properties as an anti-cancer drug. 
Besides cancer, HDACi can be used for the treatment of other diseases also. 
HDACi such as valproic acid have also been used for the treatment of 
neurodegenerative diseases like epilepsy. This is partly due to the fact that 
HDACi induce the expression of various neuroprotective proteins (Nau et al., 
1991). Moreover, some HDACi have been shown to reduce graft-versus-host 
disease in patients that have had bone marrow transplantation by suppressing pro- 
inflammatory cytokines (Leng et al., 2006). 
Future work 
Further studies on the effects of these HDACi on other types of transformed 
cancer cells will need to be done. Also, the effect of these HDACi on non- 
transformed cells has to be examined. TSA has been shown to have a much 
greater effect on transformed rather than non-transformed cells. It will be very 
interesting to see if the same happens with the novel HDACi discussed in this 
work. In addition, it will be important to see if there is a difference on the effect of 
HDACi between low grade and more aggressive tumour types. 
Clearly other factors will have to be considered before this drug can be used in 
clinical trials. Studies will be done to test the solubility and perhaps improve it so 
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that it potentially improves the efficacy of the HDACi. Accordingly, efforts are 
currently under way to more thoroughly evaluate the efficacy and toxicity profiles 
of these and other HDACi and to optimize their potency through synthesis of 
further derivatives. Moreover, the metabolism of compounds has to be examined 
before further studies can be done. TSA and other known HDACi compounds 
such as butyrate and phenylbutyrate show high biotransformation; therefore 
patients require high dose administration (Warrell et al., 1998). Studies have 
shown that TSA converts to its corresponding metabolites after only 20min of 
exposure therefore causing a very short exposure to the pharmacologically active 
parent compound. This is a limiting factor for use as a therapeutic agent (Elaut et 
al., 2002). 
This study was mainly performed in MCF-7 cells so it has to be extended in other 
breast cancer cell lines and other cancer types to verify it. Furthermore, studies 
would need to be done in primary patient samples as results from cell lines may 
not apply to primary cells. Another factor that could be addressed in further 
studies is the specificity of each compound. Most HDACi are known to target 
more than one HDAC. Very few HDACi are known to be able to specifically 
target one HDAC. For example, tubacin selectivity inhibits HDAC6 and causes 
accumulation of acetylated a-tubulin but fails to inhibit proliferation of cells 
(Haggarty et al., 2003; Kim et al., 2003a). 
Compound 220 was selected for further study to determine its in vivo efficacy in 
xenograft mouse models because of its favorable toxicity profile. Based on further 
examination of this compound to evaluate its solubility, toxicity, metabolic 
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properties and its ability to decrease tumour growth in mouse models, the 
compound could lead to a phase I clinical trial in humans. 
All the data accumulated thus far are consistent with an epigenetic effect of these 
HDAC inhibitors. The precise mechanism of induction of cell death remains 
unknown and needs to be addressed in future studies. 
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CHAPTER VI 
DISCUSSION 
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Research performed over the last decade has highlighted the role of HDACi as a 
potential new class of therapeutic agents. One of the best-studied HDAC 
inhibitors, called TSA, has been shown to exhibit potent anti-proliferative 
properties, therefore studying its mechanism of action allows us to determine a 
role for its use in the future as a cancer therapeutic agent (Johnstone et al., 2002; 
Narlikar et al., 2002). HDAC inhibitors inhibit HDACs, leading to a less 
condensed chromatin structure by increasing acetylation. The first HDACi 
approved by the FDA was SAHA. SAHA is used for the treatment of cutaneous 
T-cell lymphoma and is well tolerated by humans (Kelly et al., 2005). However, 
most HDACi are very toxic to humans and cannot be used in the clinical setting. 
Research is now focused on studying the biology and structure of HDACi in order 
to identify novel HDACi that can be used as drugs in humans with diseases such 
as cancer. 
One way to study the mechanism of action of various anti-cancer drugs is to study 
their effects on their targets. Studies have shown that the expression of 7-10% of 
genes is altered in response to treatment with various HDACi (Chambers et al., 
2003; Glaser et al., 2003; Mitsiades et al., 2004; Peart et al., 2005; Sasakawa et 
al., 2005). Therefore, despite the fact that HDACi are non-specific and toxic, they 
actually affect only a small number of genes. The targets of most HDACi still 
remain unknown. The best characterised target of TSA is the cell cycle inhibitor 
p2lc'pl (Kim et al., 1999). In chapter III, the F-Box protein FBXL20 was 
identified as an important TSA target. The identification of this novel F-Box 
protein stemmed from previous work in our laboratory in finding Skp2 
homologues that could be involved in the regulation of cyclin D I. FBXL20 was 
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not shown to regulate cyclin D1. In chapter IV, FBXL20 was shown to be a direct 
target of TSA, as induction of its mRNA levels by TSA was not blocked by the 
protein synthesis inhibitor CHX and therefore de novo protein synthesis is not 
required. Since there are no known data characterising the role and function of 
FBXL20 in human cells, this work initially focused on characterising FBXL20 
and subsequently examining its role in the TSA-induced effects in MCF-7 cells. 
Previous research performed on the FBXL20 homologue FBL2 in rat cells 
showed that FBL2 is ubiquitously expressed, able to bind Skp1, localised in the 
perinuclear compartment of cells and overexpressed in growth arrested 
hepatocytes (Ilyin et al., 1999). Similar results were obtained for FBXL20 in 
human MCF-7 breast cancer cells. PCR analysis showed that it is expressed in 
many cancer cell lines. Interestingly, the rat expresses only part of the protein 
found in humans. This is likely to be due to a mutation that leads to the formation 
of a translational stop codon, which subsequently leads to a truncated protein in 
rats. This suggests that the human FBXL20 may bind different proteins and have 
different functions than its rat homologue i. e the C-terminal region which is not 
expressed in rat cells may have additional functions in the human. Consistent with 
other studies, where a number of FBL2 splice variants were shown in the rat cells 
(Ilyin et al., 1999), FBXL20 was shown to have a splice variant in MCF-7 cells 
that lacks exon 7. 
Subcellular localisation studies in human cells, similar to the rats, showed that 
FBXL20 localises in the cytoplasm, concentrated mainly around the nucleus. In 
addition, in agreement with other classical SCF E3 ligases, where F-Box proteins 
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such as Skp2 are able to bind Skpl, ROC-1 and CUL-1 (Zhang et al., 1995), 
FBXL20 was shown to bind all three proteins, suggesting that FBXL20 is a novel 
E3 ligase that leads to the degradation of yet unknown proteins. 
Due to its similarity to Skp2, FBL2 has been compared to Skp2 in rat cells in 
other studies (Ilyin et al., 1999). In agreement with these studies, this work has 
shown that, despite the similarities between Skp2 and FBXL20, they have distinct 
functions. The reason for this remains unclear. Skp2 expression is mainly 
increased during S-phase, leading to the degradation of the G1/S phase inhibitor 
p27K'p'(Carrano et al., 1999). This allows progression of cells through the cell 
cycle. However, this study showed that FBXL20 is mainly expressed in growth 
arrested cells, which suggests that it may play a role in the Go/G1 transition. 
Moreover, when FBXL20 is silenced, the expression of Skp2 protein is increased 
and vice versa. This inverse relationship between Skp2 and FBXL20 expression 
could be cell cycle phase mediated. Silencing Skp2 expression leads to a G1/S 
arrest, which may indirectly lead to the upregulation of FBXL20. Conversely, 
when FBXL20 is silenced, Skp2 levels increase, which suggests that since Skp2 
levels are high in cycling cells, silencing FBXL20 gives cells a growth advantage 
and Skp2 levels increase in order to mediate cell cycle progression. The 
relationship between these two proteins remains unclear. Furthermore, the 
transcription of Skp2 has been shown to be regulated by the FoxM 1 transcription 
factor but this is not the case with FBXL20, as silencing FoxM1 had no effect on 
the mRNA levels of FBXL20. These data together show that FBXL20 is a novel 
E3 ligase that is ubiquitously expressed, localised in the cytoplasm and its 
expression is induced during cell death and growth arrest. 
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The work in chapter IV also demonstrated that TSA caused Gl/S arrest at low 
concentrations and G2/M arrest at higher concentrations (Li et al., 2006; Rokhlin 
et al., 2006; Yamashita et al., 2003). Knockdown of FBXL20 gave a growth 
advantage to MCF-7 cells in response to TSA. Cell cycle analysis showed that 
knockdown ofFBXL20 and subsequent treatment with TSA leads to a reduction in 
the number of cells in the G2/M phase of the cell cycle compared to the NSC 
transfected cells. This implies that FBXL20 may cause the degradation of a 
protein or proteins involved in the G2/M transition. Furthermore, overexpression 
of FBXL20 in TSA treated cells led to an induction in apoptotic cell death 
compared to non-transfected cells. My data indicates that the novel FBXL20 F- 
Box protein plays an important role in TSA-induced Gz/M arrest and apoptosis in 
MCF-7 cells. Similar results were also obtained when cells were treated with 
SAHA and SBHA. This is very important as it suggests that FBXL20 is a target of 
all HDACi and not only TSA. 
TSA 
1 
Skp2 
1 
FBXL20 
1 
p27' P' Cell cycle arrest f_ Bim 
Apoptosis 
Figure 6.1 Schematic to represent the role of FBXL20 and Skp2 in TSA- 
induced cell cycle arrest and apoptosis. 
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It is still unclear exactly how TSA regulates FBXL20. It is possible that TSA 
affects FBXL20 through HDAC2, since silencing HDAC2 caused an increase in 
the mRNA levels of FBXL20. Research in our laboratory has suggested that 
HDAC2 is the predominant HDAC in MCF-7 cells and that is why I decided to 
examine its possible role in regulating FBXL20. In contrast, HDACI did not seem 
to regulate the expression of FBXL20 as its knockdown in MCF-7 cells did not 
affect the levels of FBXL20 mRNA. Other HDACs could also potentially regulate 
FBXL20 but have not been tested in this study. Future studies could focus on 
finding which HDACs could regulate FBXL20 using techniques such as RNAi in 
order to silence the expression of all HDACs and then test the expression of 
FBXL20. 
Also, it is uncertain if TSA regulates FBXL20 only at the transcriptional level, 
since TSA induced the expression of the recombinant protein Flag-FBXL20 
which is regulated by a different promoter than the endogenous FBXL20. TSA 
probably regulates FBXL20 in two different ways, at the transcriptional and 
translational level. However, the induction of the protein levels of Flag-FBXL20 
could de due to decreased degradation of the protein. If this is the case, then TSA 
regulates FBXL20 only at the transcriptional level. The promoter and the stability 
of FBXL20 have to be examined further in order to understand how TSA 
regulates FBXL20. 
In chapter IV the function of FBXL20 was explored through identifying one of its 
downstream targets. FBXL20 was shown to function by regulating the pro- 
apoptotic protein Bim. The induction of Bim expression by TSA is abrogated 
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when FBXL20 is silenced. Also, knockdown of FBXL20 leads to a decrease in the 
protein expression of Bim. This is unlikely to be mediated at the transcriptional 
level since silencing of FBXL20 did not significantly alter Bim mRNA levels. 
Cell cycle analysis also showed that when FBXL20 is silenced, Bim is required for 
the abrogation of TSA-induced G2/M arrest. As discussed in chapter IV, FBXL20 
was able to bind Bim and its overexpression led to the overexpression of Bim 
protein levels. It is unlikely that FBXL20 is responsible for the degradation of 
Bim as silencing FBXL20 should lead to an increase in the protein levels of Bim. 
This is not the case and thus it is possible that FBXL20 binds Bim and prevents it 
from binding another E3 ligase that is responsible for its degradation. More work 
has to be done to understand how FBXL20 regulates Bim. Mutations in FBXL20 
and further GST-pulldowns of the constructs could lead to the identification of the 
site that is responsible for binding Bim. Other binding partners of FBXL20 also 
have to be identified. Moreover, FBXL20 could be tested for its potential binding 
of BimL and Bims. 
Current research focuses on the design of drugs that specifically target molecular 
alterations found only in transformed cells and not in normal cells. HDACi have 
been shown to be very promising in this respect and therefore there has been a lot 
of effort to market HDACi as treatment for all major solid and haematologic 
cancers, either as a single therapy or in combination. Researchers are trying to 
associate specific tumour types with specific gene expression profiles and thus 
identify the changes that occur in normal cells that lead them to become 
cancerous. 
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In chapter V, a series of compounds showed promising anti-tumour properties. 
Compounds 214,215,220 and 221 inhibited proliferation of MCF-7 cells. The 
most potent so far, compound 220, when used at a dose of 500nM, caused 
accumulation of acetylated histone H3, inhibition of cell proliferation and G2/M 
cell cycle arrest. This was accompanied by an increase of p21C'pl and Bim in 
MCF-7 cells. This compound does indeed target HDACs, as an HDAC assay 
revealed that there is a decrease in HDAC activity upon treatment with compound 
220. This is a very promising anti-tumour agent and shows greater potency than 
SAHA. The relationship of the antitumour effects of this compound to its 
pharmacodynamic and pharmacokinetic properties in vivo is yet unknown but will 
be examined in future studies. However the IC50 of 220 is still high and could 
cause side effects when used in humans. It is possible that compounds like 220 
would have a better therapeutic effect when used in combination with 
chemotherapy as has been shown with the combination of other HDACi with 
DNA topoisomerase II inhibitors (Marchion et al., 2004), doxorubicin (Catalano et 
al., 2006), taxanes (Dowdy et al., 2006) and imatinib (Nimmanapalli et al., 2003). 
Using these combination treatments, HDACi increase the efficacy of 
chemotherapeutic drugs in treating many cancer types, possibly by offering 
improved access for these agents to target DNA/protein complexes. 
A number of HDACi are now in clinical trials for the treatment of many types of 
cancer including breast, lung, renal, pancreatic and bladder cancer (Paris et al., 
2008). Development of novel HDACi is an extensive area of research. However, 
most HDACi developed have shown significant levels of toxicity. For some 
inhibitors, it is possible that their increased binding time is responsible for this 
178 
increased in vivo toxicity, which is why less potent inhibitors such as SAHA may 
have better therapeutic properties. Also, HDACi are non-specific and thus can 
target a number of different cell death pathways, making them very effective anti- 
tumour agents. A number of studies are now being carried out to develop HDACi 
that have more selective inhibitory properties. HDACi that target a specific 
HDAC are not yet available due to the fact that there is a high degree of homology 
between their catalytic sites. Also, HDACs function by being part of large protein 
complexes and this makes the discovery of an isotype specific drug an even 
harder task. However it is not clear how efficient these drugs will be in killing 
cancer cells. Efficacy may decrease considerably as these HDACi will only target 
a single HDAC. More selective inhibitors may however be beneficial in lowering 
the tendency of tumours to become HDACi resistant and thus increase their 
efficacy. Isotype specific HDACi would certainly be very useful in understanding 
better the biology and pharmacology of HDACs. Up to now, the RNAi technique 
has been used as a tool to study the functions of a specific HDAC. 
An important factor that has to be considered when using these drugs in clinical 
trials is that cardiac toxicity has sometimes been observed as a side effect of 
treatment (Paris et al., 2008). This includes conduction problems and also cardiac 
muscle hypertrophy. Some studies suggest that these toxicities may be HDAC 
class specific, while others think that it is due to the chemical structure of the 
compound under study. This of course should not stop the development of these 
drugs. The exact mechanism of action of these drugs remains unknown and the 
mode of action of one inhibitor may differ considerably from another due to their 
chemical structure or pharmacokinetic profile. Therefore, there is a strong need 
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for identifying more targets that are common for all compounds, shedding some 
light on the general mechanism of action of these drugs. 
HDACi could not only be used for the treatment of cancer but also for other 
diseases such as epilepsy, as has been shown with the HDACi valproic acid (Nau 
et al., 1991). Moreover, some HDACi have been shown to reduce graft-versus- 
host disease in patients that have had bone marrow transplantation by suppressing 
pro-inflammatory cytokines (Leng et al., 2006). Also, HDACi have shown a 
promising therapeutic role in the treatment of Huntington's disease (Sadri-Vakili 
and Cha, 2006). They have also emerged as potent alternatives to anti- 
inflammatory drugs, offering a novel approach for the treatment of rheumatoid 
arthritis or lupus erythematosus (Blanchard and Chipoy, 2005). Furthermore, a 
novel HDACi inhibitor named MGDO 103 has shown potential for the treatment of 
high-risk myelodysplastic syndrome (MDS)(Garcia-Manero et al., 2008). The 
variety of diseases that HDACi can target highlights even more how important it 
is to discover novel HDACi that can be more potent, less toxic and cause less side 
effects than already known ones. 
The characterisation of the role and function of FBXL20 is important as it appears 
to be a target of all HDACi. This will allow a greater understanding of how 
HDACi work. Moreover, FBXL20 may be considered a tumour suppressor and 
therefore its overexpression may be used for potential therapeutic benefit. The 
function of a single gene is insufficient to explain how HDACi work but, along 
with other targets, it helps in elucidating the mechanism of action of HDACi in 
different cells. 
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In summary, this work has shed some light on how HDACi exert their effects on 
cells by identifying the FBXL20 protein as an important target of the HDAC 
inhibitor TSA. FBXL20 was shown to be a novel E3 ligase that mediates its 
functions through regulating the pro-apoptotic BCL-2 member Bim. This novel 
finding could have therapeutic implications as HDACi such as SAHA have been 
used in clinical trials and targeting FBXL20 could synergise with conventional 
chemotherapeutic drugs or HDACi to promote cell cycle arrest and/or cell death 
in breast cancer cells. Lastly, this study has set the parameters for testing novel 
HDAC inhibitors by examining their effect on the cell cycle, proliferation and 
their effect on deacetylation. 
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